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General introduction 
Vaccination is the most effective tool to fight against infectious diseases [1]. With vaccination 
smallpox was eradicated in 1979, which had killed millions of people in 20th century and 
before [2]. The incidence of other devastating diseases such as polio, tuberculosis and tetanus 
has substantially declined owing to the routine vaccination programs [3]. However, there is 
still a need for new and better vaccines against infectious diseases [4]. Nowadays, in addition 
vaccination gains increasing attention for therapeutic use against established diseases, such as 
cancer and chronic auto-immune disorders [5].  
Traditional vaccines are derived from attenuated organisms or inactivated pathogens. These 
vaccines can induce potent immune responses, but safety issues including the administration 
of potentially harmful components and reversion to virulent forms have restricted their 
application. Nowadays, subunit antigens containing o ly antigenic parts of a pathogen are 
being extensively investigated because of their better safety. However, they are generally less 
immunogenic than traditional vaccines. In order to improve their immunogenicity, immune 
modulators and nanoparticle delivery systems can be used [6-9].  
Microneedle technology for vaccine delivery  
Most vaccines are administered by intramuscular or subcutaneous injection, but these 
methods can cause pain and stress due to the fear of injection [10]. Furthermore, there is a risk 
of infection due to the reuse of needles especially n developing countries [11]. Lastly, the 
delivery of vaccines to antigen presenting cells may be inefficient as these delivery sites are 
not rich of antigen presenting cells.  
As an alternative, intradermal delivery has gained attention because of its potential for needle-
free administration. Additionally, the skin is easy to access and contains a large number of 
antigen presenting cells, such as Langerhans cells in epidermis and dendritic cells in dermis, 
making the skin an attractive site for vaccination [12]. However, the stratum corneum, the 
uppermost layer of the skin, forms the main barrier and prevents most foreign substances from 
entering our body. To effectively overcome the skin barrier, microneedles have been 
developed [13]. Microneedles are micro-sized needle structures which can be used to 
penetrate the skin in a non-invasive and pain-free way, as they only pierce the upper layers of 
skin without touching the deeper nerves and blood vessels [14].  
Microneedles were first used for pretreatment of the skin [15]. After the conduits were made 
and the microneedles were removed, the vaccine-loaded patch or formulation was applied 
onto the microneedle-penetrated skin. However, the diffusion of vaccines through the 
microneedle-made conduits is slow due to the small di meter of the conduits and small 
surface area of the pretreated skin. As a result, only a small fraction of the antigen is delivered 
into the skin. Furthermore, the conduits may close soon after the removal of the microneedles, 
limiting the time available for diffusion [16]. To increase the delivery efficiency of vaccines 
and avoid the separate application of vaccines after the removal of the microneedles, several 
types of new microneedle systems have been developed in the past twenty years, including 
coated, hollow and dissolvable microneedles [13, 14, 17, 18].  
In case of coated microneedles, antigens are coated onto the surface of microneedles. After 
the microneedles are inserted into the skin, the antige  should be quickly released. One 
disadvantage of using coated microneedles is that the coating amount of antigen is limited due 
to the small surface area of microneedles. At the same time, there could be a waste of antigen 
during the coating process, as the coating efficiency is normally much lower than 100%. 
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Several methods have been reported for the coating of antigen on microneedles. Gill et al. 
described a dip coating method and found that the surface tension and viscosity of the coating 
solution had a major influence on the uniformity and thickness of the coating, respectively 
[19, 20]. Chen et al. proposed a gas jet drying approach to reduce vaccine wastage and 
produce a thinner coating of antigen [21]. In our group, we developed pH-sensitive 
microneedles by modifying their silicon surface with pyridine groups. The microneedles can 
adsorb negatively charged antigens at slightly acidic onditions and release them at neutral pH 
[22]. Finally, in some studies a layer-by-layer coating approach was used, in which the 
amount of coated antigen can be tailored by adjusting the number of coating layers [23, 24].  
Dissolvable microneedles are made of water soluble polymers or low-molecular-weight 
sugars and the antigen is loaded inside the solid microneedle matrix [25]. When the 
microneedles are inserted into the skin, they start to dissolve, thereby releasing the antigen 
[17, 25]. The advantage of using dissolvable microneedles is that there is no sharp waste after 
the application of the microneedles. The mostly used method for fabrication of dissolvable 
microneedles is micromolding [25]. The micromolds are first filled with an aqueous 
polymer/sugar solution, and through evaporation of the solvent the polymer/sugar will be 
solidified to form the microneedles [26]. Recently, efforts have been made to load vaccines 
only in the tips of dissolvable microneedles, aiming to maximize the delivery/release of the 
loaded antigen during the application of microneedls [27, 28].  
Hollow microneedles contain conduits through which the liquid formulation of vaccines can 
be injected into the skin. The advantage of using hollow microneedles, compared to coated 
and dissolvable microneedles, is that the injection v lume, rate and depth can be precisely 
controlled [14, 29]. Furthermore, there is no need to optimize the loading process of vaccines 
in the microneedles and in case of liquid vaccine formulations the formulation buffer does not 
have to be developed. A disadvantage is that dry vaccine formulations need to be 
reconstituted in water or buffer before injection [13]. Hollow microneedles can be made from 
metal, polymer or silicon [13]. Davis et al. reported a laser micromachining method in which 
nickel was coated onto a polymer mold made by laser drilling. The prepared hollow 
microneedles were released by etching the polymer mold [30]. In our group a method was 
developed to prepare hollow microneedles by etching fused silica capillaries with 
hydrofluoric acid [31].  
Microneedles can be penetrated into skin manually or by using an applicator. As the elastic 
skin will stretch and deform when being pressed, the manual application may result in a low 
and variable penetration efficiency of microneedles [32]. By using an applicator, the 
microneedles can be applied with a fast, controlled rate with the penetration force precisely 
controlled. However, the disadvantage is that a sophi ticated and expensive applicator needs 
to be developed.  
Nanoparticles for vaccine delivery 
Nanoparticle delivery systems have been extensively studied for vaccination, as they are able 
to enhance the immunogenicity of antigens by protecting them from degradation, increasing 
their uptake by antigen presenting cells and co-delivering them with adjuvants [8]. 
Furthermore, the immune responses can be potentially modified by tuning the properties of 
nanoparticles such as size, surface charge, loading and release of antigens [33]. Different 
types of nanoparticles have been studied for vaccintio , such as polymeric nanoparticles, 
liposomes, inorganic nanoparticles and emulsions [7, 8, 33-38].  
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Polymeric nanoparticles are prepared from synthetic or natural polymers such as poly(lactic-
co-glycolic) (PLG), poly(lactic-co-glycolic acid) PLGA, chitosan and gelatin [39]. The most 
often studied polymeric nanoparticles are PLGA nanop rticles and the antigens are normally 
encapsulated inside the PLGA matrix. The antigens will be released from the nanoparticles 
during the PLGA degradation process. Liposomes are made of lipids and the antigens can be 
adsorbed on the surface of liposomes, loaded in the cor  or incorporated in between the lipid 
bilayers. Polymeric nanoparticles and liposomes have been extensively investigated for 
vaccine delivery because of their excellent biocompatibility and biodegradability. Inorganic 
nanoparticles have been studied for the delivery of vaccines because of their rigid structure 
and excellent thermo stability. Recently, mesoporous silica nanoparticles (MSNs) have gained 
increasing attention for vaccine delivery because of their excellent biocompatibility and 
multiple options for surface functionalization. Additionally, the large pores and surface area 
of MSNs allow for efficient loading of relatively large amounts of antigens [40, 41].  
Studies have shown that the physicochemical characteristics of nanoparticles such as size, 
surface charge and release property of antigens have an important influence on the 
immunogenicity of the encapsulated antigens. Nanoparticles with a size below 200 nm have 
been shown to be more efficiently taken up by dendritic cells [33, 42]. Nanoparticulate 
vaccines with a positive zeta potential have been rported to enhance the activation of antigen 
presenting cells and the subsequent immune responses [43]. Besides, the sustained release of 
antigen together with the depot effect of nanoparticles on cell surface could allow longer 
interaction of antigen with the antigen presenting cells [6, 44].  
An increasing number of studies focuses on the use of nanoparticles for co-delivery of antigen 
and Toll-like receptor (TLR) ligands [46-54]. These ligands can function as pathogen-
associated molecular patterns and selectively bind to the TLRs of antigen-presenting cells, 
thereby enhancing the immune responses. Among different types of TLR ligands, poly(I:C) 
and CpG, which are ligands for TLR3 and TLR9 respectiv ly, have been extensively 
investigated. Both of these adjuvants are capable of enhancing Th1/CD8+ T cell responses [9]. 
Recent reported studies have shown that antigen and poly(I:C)/CpG co-encapsulated 
nanoparticles elicited superior Th1/CD8+ T cell responses compared to mixture of antigen and 
adjuvant solution [46, 48-54]. The co-delivery of antigen and immune modulator to the same 
antigen presenting cells is likely responsible for this [47, 52].  
Combination of microneedles and nanoparticles for intradermal delivery of vaccines 
The intradermal delivery of nanoparticulate vaccines was first studied by using traditional 
hypodermic needles [46, 48, 50, 53-56]. Some studies have shown that the intradermal 
injection of these vaccines induce stronger IgG2a [54] or CD8+ T cell responses than 
subcutaneous injection [56]. Other studies further ave shown that the antigen and adjuvant 
co-encapsulated nanoparticles induce higher IgG2a titers [46, 53] and CD8+ T cell responses 
[50] compared to antigen and adjuvant solution after th  intradermal delivery by hypodermic 
needles. 
Nowadays, researchers are trying to combine the utilization of microneedles and nanoparticles 
for intradermal delivery of vaccines. Initially, microneedles were used for pretreatment of 
skin and the nanoparticles were applied onto the pretreated skin after removal of the 
microneedles. Microneedle-assisted administration of anoparticle vaccines has been shown 
to induce stronger immune responses than antigen solution [57, 58]. However, the reported 
results were conflicting. Another study showed thatantigen-loaded liposomes did not enhance 
immune responses compared to antigen solution in microneedle pretreated mice, most likely 
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because the transport of the nanoparticles in the conduits made by microneedles was limited 
[59].  
To improve the delivery efficiency of nanoparticulate vaccines, coated, hollow and 
dissolvable microneedles were used [24, 49, 60, 61]. For coated microneedles, the processes 
of the encapsulation of antigen into nanoparticles and the coating process of nanoparticles 
onto microneedles need to be optimized, in order to reach a sufficient antigen dose coated on 
the microneedles. Demuth et al. described the coating of antigen-loaded lipid nanocapsules 
onto PLGA based microneedles by using a layer-by-layer coating approach [24]. The coated 
multilayers were rapidly released into the skin after the application of microneedles into the 
skin, resulting in a balanced response of multiple IgG isotypes, whereas the immunization 
with soluble antigen only induced a weak IgG1-biased immune response. In case of 
dissolvable microneedles, it is important to study whether the loading of nanoparticles in the 
microneedles does not affect the properties of dissolvable microneedles, such as the 
mechanical strength or dissolution rate of microneedl s in the skin. It has been reported that 
antigen-loaded PLGA nanoparticles were successfully encapsulated into methylvinylether and 
maleic anhydride (PMVE/MA) based dissolvable microneedles [60, 61]. The prepared 
microneedles were able to penetrate the skin and dissolve quickly within 15 min. The 
dissolvable microneedles loaded with antigen encapsul ted PLGA nanoparticles induced 
higher Th1/CD8+ responses than antigen solution [60, 61]. In case of hollow microneedles, a 
suspension of nanoparticulate vaccine can be directly injected into the skin. Siddhapura et al. 
reported the use of hollow microneedles for intrademal injection of tetanus toxoid -loaded 
chitosan nanoparticles into mice. This was found to induce a higher IgG2a response and 
stronger expression of Th1 cytokines than a commercial vaccine delivered intradermally [62].  
From the above it can be concluded that microneedle-mediated intradermal delivery of 
nanoparticulate vaccines is a promising approach for e fective intradermal vaccination. 
However, there are no systematic studies reported yet focusing on 1) optimization of 
microneedle-based systems for the delivery of nanoprticulate vaccines, 2) the effect of 
physicochemical characteristics of nanoparticles on the immunogenicity of encapsulated 
antigens after microneedle-mediated intradermal vaccin tion.   
As described above, coated microneedle arrays with pyridine modified pH-sensitive surface 
and hollow microneedles prepared from fused silica capillaries have been developed in our 
lab and used successfully for intradermal delivery of various protein antigens [14]. The results 
of the immunization studies have shown that the microneedle mediated immunization groups 
induced comparable immune responses as compared to subcutaneous or intramuscular group 
[22-23, 31, 63-65]. Therefore it is attractive to cmbine these microneedle approach with 
nanoparticles  to improve ithe immunogenicity of the antigens. 
Aim and outline of this thesis 
The aim of this thesis is to determine whether a combination of microneedles and 
nanoparticles can be used to elicit potent immune responses after intradermal administration 
and whether the immune response can be tailored by the choice of the nanoparticles. For these 
purposes, two types of microneedles, namely coated nd hollow microneedles, and several 
types of nanoparticles, covering a broad range of physicochemical parameters, were used. 
In Chapter 2, the development of a new type of MSNs for the encapsulation of ovalbumin 
(OVA) is described. Additionally, the coating of OVA-loaded MSNs onto pH-sensitive 
microneedle arrays was investigated. In Chapter 3, another type of nanoparticles, namely 
PLGA nanoparticles, are used for the encapsulation of OVA and an adjuvant (poly(I:C)). T 
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cell responses induced by these nanoparticles after hollow microneedle-mediated intradermal 
immunization in mice were studied. In Chapter 4, hollow microneedles are used to study the 
effect of nano-encapsulation of OVA and poly(I:C) on humoral and cellular immune 
responses. In this study, four types of nanoparticles, namely MSNs, PLGA nanoparticles, 
liposomes and gelatin nanoparticles, were compared. In Chapter 5, hollow microneedles are 
used to examine the effect of encapsulation manner of diphtheria toxoid (DT) and poly(I:C) in 
liposomes on the antibody responses in mice. In Chapter 6, the antibody responses of DT-
loaded MSNs after coated and hollow microneedle-mediat  intradermal vaccination are 
compared. In Chapter 7, the main findings of the studies described in this thesis are 
summarized and discussed. The future prospects of using microneedles for intradermal 
delivery of nanoparticulate vaccines are briefly discussed. 
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ABSTRACT 
Purpose To develop a new intradermal antigen delivery system by coating microneedle arrays with 
lipid bilayer-coated, antigen-loaded mesoporous silica nanoparticles (LB-MSN-OVA).   
Methods Synthesis of MSNs with 10-nm pores was performed an  the nanoparticles were 
loaded with the model antigen ovalbumin (OVA), and coated with a lipid bilayer (LB-MSN-
OVA). The uptake of LB-MSN-OVA by bone marrow-derived dendritic cells (BDMCs) was 
studied by flow cytometry. The designed LB-MSN-OVA were coated onto pH-sensitive 
pyridine-modified microneedle arrays and the delivery of LB-MSN-OVA into ex vivo human 
skin was studied. 
Results The synthesized MSNs demonstrated efficient loading of OVA with a maximum 
loading capacity of about 34% and the lipid bilayer enhanced the colloidal stability of the 
MSNs. Uptake of OVA loaded in LB-MSN-OVA by BMDCs was higher than that of free 
OVA, suggesting effective targeting of LB-MSN-OVA to antigen-presenting cells. 
Microneedles were readily coated with LB-MSN-OVA atpH 5.8, yielding 1.5 µg of 
encapsulated OVA per microneedle array. Finally, as a result of the pyridine modification, 
LB-MSN-OVA were effectively released from the microneedles upon piercing the skin. 
Conclusion Microneedle arrays coated with LB-MSN-OVA were successfully developed and 
shown to be suitable for intradermal delivery of the encapsulated protein antigen. 
Keywords  Intradermal antigen delivery ∙ lipid bilayer ∙ mesoporous silica nanoparticles ∙ pH-
sensitive microneedle arrays 
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INTRODUCTION 
Vaccination is regarded as one of the most promising trategies for reducing mortality and 
improving human health [1, 2]. Most of the current vaccines are delivered by intramuscular or 
subcutaneous injection, which have inherent limitations, such as the risk of infections induced 
by reusing needles and syringes and the needle fear o  children and patients. Therefore, new 
needle-free, easy to use and effective vaccination methods are urgently needed. One of these 
potential methods is microneedle-mediated intradermal vaccination [3]. 
Intradermal vaccination is attractive because the skin i  easily accessible and harbors a large 
number of immune cells, such as dendritic cells (DCs) [1, 4]. Microneedles are micron-sized 
structures with a length of less than 1 mm which can be used to overcome the skin barrier 
located in the top layer of the skin. As these needles o not penetrate to the depths where 
nerve endings reside, coating of antigens on microneedles enables minimally-invasive and 
pain-free delivery of vaccines into skin [5-7]. A major challenge however, is the limited dose 
that can be delivered with coated microneedles. In an effort to improve coating efficiency, our 
lab designed pH-sensitive pyridine-modified microneedl s with a surface pKa below 
physiological pH, which allows the adsorption of negatively-charged proteins at slightly 
acidic conditions (pH 5.8) and their release at neutral pH (pH 7.4). In our previous study, 
intradermal immunization using pH-sensitive microneedl s coated with 5.7 µg OVA were 
compared to conventional subcutaneous or intradermal i munization [8, 9]. Microneedle-
mediated immunization led to comparable T-cell respon es but 10-fold lower IgG responses 
when compared to conventional subcutaneous or intradermal immunization. Possible 
strategies to further improve the immunogenicity of vaccines by the intradermal route could 
be adding an adjuvant or using nanoparticles to deliver the antigens [2, 6, 10-13]. 
The adjuvanticity of nanoparticles is attributed to their capability of protecting antigens from 
degradation, forming a depot at the site of injection, and facilitating antigen uptake by DCs 
[14]. A variety of nanosized vaccine delivery systems have been developed, such as 
polymeric nanoparticles [15], emulsions [16], and lipid-based nanoparticles [15, 17]. Recently 
mesoporous silica nanoparticles (MSNs) have gained significant attention as drug delivery 
vehicles because of their controlled size and mesostructure, excellent in vivo biocompatibility, 
and their large surface area and pore volume, enabling the efficient loading of active small 
molecules or proteins [2, 18-21]. 
Herein, we report a new intradermal delivery system, which synergistically integrates the 
advantages of nanoparticles and microneedles by coating pH-sensitive microneedles with 
antigen-loaded, lipid bilayer-covered MSNs. As a model antigen, OVA was used. This protein 
is negatively charged (pI of 4.9) [22] at pH 7.4. For the delivery of OVA, a novel type of 
ultrafine MSNs with large pores (~10 nm in diameter) was synthesized with a positive surface 
charge (AEP-MSNs), resulting in efficient loading of OVA in the AEP-MSN pores. To 
enhance the colloidal stability of OVA-loaded AEP-MSNs and generate a negative surface 
charge, a negatively charged lipid bilayer (LB) was as embled at the AEP-MSN surface and 
the lipid-coated and OVA-loaded AEP-MSNs are referred to as LB-MSN-OVA [23-25]. This 
method synergistically combines features of liposomes and MSNs and has been reported to 
address the multiple challenges including stability, targeting and multicomponent delivery [24, 
25]. The designed LB-MSN-OVA were coated onto pH-sensitive pyridine-modified silicon 
microneedles by electrostatic interactions between the pyridine groups and the LB-MSN-
OVA at low ionic strength. Piercing the LB-MSN-OVA coated microneedles into ex vivo 
human skin resulted in the successful release of the nanoparticles due to a shift in pH from 5.8 
to 7.4 (Scheme 1).  
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Scheme 1. Preparation and application of pH-sensitive microneedl  arrays coated with LB-
MSN-OVA. (a) Encapsulation of OVA into AEP-MSNs, followed byfusion of liposomes 
(composed of DOPC/DOPS/cholesterol), resulting in LB-MSN-OVA. (b) Adsorption of LB-
MSN-OVA onto pH-sensitive microneedles and penetration of microneedles into human skin, 
resulting in a pH shift and delivery of LB-MSN-OVA into the viable epidermis and dermis. 
MATERIALS AND METHODS 
Materials 
Tetraethyl orthosilicate (TEOS, 98%), sulfuric acid (96-98%), hydrochloric acid (36%-38%), 
(3-aminopropyl)triethoxysilane (APTES, 99%), 4-pyridinecarboxaldehyde (97%), sodium 
cyanoborohydride (95%), 3-[2-(2-aminoethylamino)ethylamino] propyltrimethoxysilane 
(AEPTMS, technical grade), Ovalbumin (OVA, ≥98%), 1,3,5-trimethylbenzene (TMB, 97%), 
Pluronic P123 (EO20PO70EO20, Mn ∼ 5800 g/mol), and cholesterol (≥99%) were purchased 
from Sigma-Aldrich (Zwijndrecht, the Netherlands). Fluorocarbon surfactant FC-4 was 
purchased from Yick-Vic Chemicals & Pharmaceuticals (HK) Ltd. 1,2-dioleoyl-sn-glycero-3-
phosphocholine (DOPC), 1,2-dioleoyl-sn-glycero-3-[phospho-L-serine](sodium salt) (DOPS), 
and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) 
(ammonium salt) (DOPE-LR) were purchased from Avanti Polar Lipids Inc (Alabaster, AL). 
Hydrogen peroxide (30%) and ethylenediaminetetraacetic acid (EDTA) were purchased from 
Fluka (Steinheim, Germany). Toluene (≥99.7%) was purchased from Biosolve (Valkenswaard, 
the Netherlands). Alexa Fluor®488 ovalbumin conjugates (OVA-AF488), anti-CD40-FITC, 
anti-CD80-PE and anti-CD86-APC were purchased from Thermo Fisher Scientific (Waltham, 
MA). Sterile phosphate buffered saline (PBS, 163.9 mM Na+, 140.3 mM Cl-, 8.7 mM HPO4
2-, 
1.8 mM H2PO4
-, pH 7.4) was obtained from Braun (Oss, the Netherlands). All the other 
chemicals used are of analytical grade and used without further purification. Milli-Q water 
(18.2 MΩ/cm, Millipore Co., USA) was used for the preparation of solutions. 1 mM 
phosphate buffer (PB) with a pH of 7.4 was prepared in the lab. Silicon microneedle arrays 
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with 576 microneedles per array on a back plate of 5 × 5 mm2 and a length of 200 µm per 
microneedle were kindly provided by Robert Bosch GmbH (Stuttgart, Germany).  
Synthesis of MSNs and Amino-functionalized MSNs (AEP-MSNs) 
Mesoporous silica nanoparticles were synthesized according to a published procedure with 
modifications [26]. Briefly, surfactant Pluronic P123 (0.5 g) and FC-4 (1.4 g) were dissolved 
in HCl (80 mL, 0.02 M), followed by the introduction of TMB (0.48 mL). After stirring for 6 
h, TEOS (2.14 mL) was added dropwise. The resulting mixture was stirred at 30 °C for 24 h 
and transferred to an autoclave at 120 °C for 2 days. Finally, the solid product was isolated by 
centrifugation, and washed with ethanol and Milli-Q water. The organic template was 
completely removed by calcination at 550 °C for 5 h. 
To prepare cationic MSNs, AEPTMS in absolute ethanol (4 mL, 20 wt%) was incubated with 
MSNs (100 mg) overnight at room temperature. The desired AEP-MSNs were collected by 
centrifugation and washed with ethanol to remove unr acted AEPTMS.  
Characterization of MSNs and AEP-MSNs 
Morphology of MSNs and AEP-MSNs was visualized by transmission electron microscopy 
(TEM) using a JEOL 1010 instrument (JEOL Ltd, Peabody, MA) with an accelerating voltage 
of 70 kV. To prepare the samples, several droplets of nanoparticle suspension (1 mg/ml) were 
put on a copper grid, dried overnight and coated with carbon.   
Nitrogen adsorption-desorption isotherms of samples w re obtained with a TriStar II 3020 
surface area analyzer (Micromeritics, Norcross, GA). Before each measurement, MSNs were 
outgassed in the vacuum (below 0.15 mbar) at 300 °C for 16 h, while AEP-MSNs were 
outgassed at room temperature. The specific surface areas were calculated from the adsorption 
data in the low pressure range using the Brunauer-Emmett-Teller (BET) model [27]. The pore 
size distribution was determined following the Barrett-Joyner-Halenda (BJH) model. 
Thermogravimetric analysis (TGA) with a Perkin Elmer TGA7 (Waltham, MA) was used to 
measure the amount of amine-containing groups on the surface of AEP-MSNs. All the 
samples were tested under an air atmosphere from 25 °C to 800 °C at a heating rate of 
10 °C/min.  
Encapsulation of OVA in AEP-MSNs 
For loading of OVA into AEP-MSNs, OVA (0.5 mL, 0.5 mg/mL 1mM PB) and AEP-MSNs 
(0.5 mL, 2 mg/mL, 1mM PB) were mixed and incubated in Eppendorf mixer (400 rpm, 25 °C, 
Nijmegen, the Netherlands) for different time periods (0, 0.5, 1, 2, 4, 8 and 24 h). After 
incubation, the suspensions were centrifuged and the encapsulation efficiency (EE%) of OVA 
was determined by measuring the difference in its intrinsic fluorescence intensity with a plate 
reader (Tecan M1000, Männedorf, Switzerland) (excitation wavelength = 280 nm and 
emission wavelength = 320 nm) in the supernatant before and after the encapsulation.  
To determine the maximum loading capacity (LC%) of OVA in AEP-MSNs, the AEP-MSNs 
(2 mg/mL) were mixed with different initial concentrations of OVA (ranging from 0.25, 0.5, 1, 
1.5, 2 to 3 mg/mL) and incubated in an Eppendorf mixer (400 rpm, 25 °C) for 0.5 h. Next, the 
suspensions were centrifuged at 9000 g for 5 min. The EE% of OVA was determined by 
measuring the difference in their intrinsic fluoresc nce intensity in the supernatant before and 
after the encapsulation with a plate reader (Tecan M1000). 
The EE% and LC% were calculated as below:  
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Where tova represents the total content of OVA, and fova is the content of free OVA (OVA in 
the supernatant).  
Preparation of Liposomes  
Liposomes were prepared by dispensing stock solutions of DOPC, DOPS and cholesterol in a 
molar ratio of 7/1/2 into scintillation vials. All ipids were dissolved in chloroform. A lipid 
film was generated by slow evaporation of chloroform in the vial under a nitrogen flow and 
dried under vacuum overnight. The lipid film was rehydrated by the addition of PB (1 mL, 1 
mM, pH 7.4) and the mixture was vortexed for 10 s to form a cloudy lipid suspension. The 
obtained suspension was sonicated in a water bath for 10 min. The resulting clear liposomes 
dispersions were stored at 4 °C. To obtain fluorescent liposomes, a fluorescently labeled lipid 
(DOPE-LR) was incorporated into the liposomes by adding the lipids at 1 wt% DOPE-LR to 
the lipid solution prior to liposome formation. 
Preparation of LB-MSN-OVA 
To prepare LB-MSN-OVA, OVA (0.5 mL, 0.25 mg/mL) solution in PB (1 mM, pH 7.4) was 
first transferred into a 2-mL Eppendorf tube, followed by the addition of AEP-MSNs (0.5 mL, 
1 mg/mL) in PB (1 mM, pH 7.4) and liposome (0.5 mL, 2 mg/mL) in PB (1 mM, pH 7.4). 
The resulting mixture was incubated in the Eppendorf mixer for 1.5 h (400 rpm, 25 °C). The 
particles were collected and excess liposomes and OVA were removed by centrifugation 
(9000 g, 5 min). The encapsulation efficiency of OVA was determined by measuring the 
difference in their intrinsic fluorescence intensity n the supernatant before and after the 
encapsulation on a Tecan M1000 plate reader. All experiments were performed in triplicate. 
For the uptake study of LB-MSN-OVA in dendritic cells, OVA-AF488 was used to prepare 
LB-MSN-OVA. 
Characterization of LB-MSN-OVA  
The hydrodynamic size distribution was measured with dynamic light scattering (DLS) using 
a Malvern Nano-zs instrument (Worcestershire, UK). Samples were diluted with 1 mM PB 
(pH 7.4) and measured 3 times each with 10 runs at 25 °C. The zeta potential was measured 
by laser Doppler velocimetry using the same instrument. Samples were diluted with 1 mM PB 
(pH 7.4) and measured 3 times with 20 runs.  
The size distribution was also measured by NanoSight LM20 (NanoSight Ltd., Amesbury, 
UK). Samples were injected into chamber by an automa ic pump (Harvard Apparatus, catalog 
no. 98-4362, Holliston MA). The samples were diluted o 5 μg/ml with 1 mM PB (pH 7.4) 
and measured at 25 °C. A 90-s video was captured with the shutter set at 1495 and the gain at 
680. The data was analyzed by NTA 2.0 Build 127 software. 
Imaging of LB-MSN-OVA was performed by using a CryoTitan (FEI Corp, Hillsboro, OR) 
operating at 300 kV and equipped with a field emission gun (FEG). Cryo-samples were 
prepared from a 3 µL droplet of sample solution placed on the grid inside the Vitrobot™ 
chamber at 100% relative humidity and 20 °C. Prior to use the TEM grids were glow 
discharged by a Cressington 208 carbon coater to rende  them hydrophilic. The samples were 
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blotted to remove excess solution and vitrified by using an automated vitrification robot 
(Vitrobot™ Mark III, FEI Corp).  
OVA Release Studies from AEP-MSNs and LB-MSN-OVA 
To study the influence of ionic strength on the release of OVA from AEP-MSNs, phosphate 
buffer (PB, 1 mM Na2HPO4 and 1 mM NaH2PO4 were mixed at molar ratio of 5:2, pH 7.4) 
with various concentrations of NaCl (0, 0.9, 1.8, 3.6, 7.2, 14.4 and 28.8%, m/v) were prepared. 
AEP-MSNs loaded with OVA (1 mg, based on the mass of AEP-MSNs) were dispersed in 
one of the buffers (1 mL) mentioned above. The suspen ions were kept in the Eppendorf 
mixer for 0.5 h (400 rpm, 37 °C), followed by centrifugation (9000 g, 5 min) to collect the 
supernatant. The amount of released OVA in the buffer was quantified by measuring the 
intrinsic fluorescence intensity of OVA with a Tecan M1000 plate reader. The released OVA 
in PB with 0.9, 1.8 and 3.6% NaCl was also tested by high pressure size-exclusion 
chromatography (HP-SEC). Far-UV circular dichroism (CD) spectra of OVA before and after 
release were measured by using a Jasco J-815 spectropolarimeter (Tokyo, Japan). Spectra 
were collected from 260–190 nm, at 25 °C.  
To compare the in vitro release of OVA from AEP-MSNs and LB-MSN-OVA, OVA-loaded 
AEP-MSNs and LB-MSN-OVA were dispersed in PBS (pH 7.4) and incubated in the 
Eppendorf mixer (400 rpm, 37 °C). At various time points, the suspensions were centrifuged 
and the supernatants were replaced with fresh PBS. The amount of OVA released into the 
supernatant was determined by measuring the intrinsic fluorescence intensity of OVA on a 
Tecan M1000 plate reader.  
Interaction of LB-MSN-OVA with Bone marrow-derived dendritic cells (BMDCs) 
Dendritic cells were cultured from BALB/c donor mice as previously described [28]. The 
study was carried out under the guidelines compiled by the animal ethic committee of the 
Netherlands, and approved by the ethical committee on animal experiments of Leiden 
University. Briefly, cell suspensions of bone marrow were obtained by flushing the femurs 
and tibia of adult BALB/c mice with culture medium. The cells (6 × 106 cells/well) were 
cultured for 10 days in Iscove’s Modified Dulbecco’s Medium (IMDM) supplemented with 
10% (v/v) fetal bovine serum, penicillin and streptomycin (100 units/ml), 20 μM beta-
mercaptoethanol and 20 ng/ml GM-CSF. The cells were cultured at 37 °C with 5% CO2. The 
medium was refreshed every 2 days. 
To study the uptake of nanoparticles, BMDCs (2.5 × 105 cells/ml) were cultured with LB-
MSN-OVA containing 6 μg/ml, 0.6 μg/ml or 0 μg/ml (culture medium) OVA-AF488 for 4 h 
at either 4°C or 37 °C. Free OVA-AF488 solution with the same concentrations was used as a 
control. After 4 h, the uptake of OVA-AF488 was measured using flow cytometry 
(FACSCanto II, Becton Dickinson, NJ). To quench the external AF488 signal, 0.02% trypan 
blue was added 5 min before FACS analysis. The uptake of OVA-AF488 was expressed as 
the mean fluorescence intensity (MFI, fluorescence i t nsity of each cell in average) in the 
AF488 channel. 
To study the activation of BMDCs by the nanoparticles, BMDCs (5 × 105 cells/ml) were 
cultured with LB-MSN-OVA containing 6 μg/ml, 0.6 μg/ml or 0 μg/ml (culture medium) 
OVA-AF488 for 4 h at 37 °C. OVA-AF488 solution with e same concentrations and LPS (1 
μg/ml) were used as controls. The cells were stained for 30 min with a mixture of 300 × 
diluted anti-CD40-FITC, anti-CD80-PE, and anti-CD86-APC. The cells were washed and the 
expression of CD40, CD80 and CD86 were quantified by flow cytometry. 
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Modification of Silicon Microneedle Arrays to Obtain a pH-sensitive Surface  
To coat negatively charged particles onto silicon microneedle arrays, the microneedles were 
chemically modified to obtain a pH-sensitive surface (positively charged at pH 5.8) by using 
pyridine groups, as described previously [6]. The surface of silicon was first cleaned by 
acetone and methanol. Next the surfaces were hydroxlated by a fresh piranha mixture 
consisting of 30% (v/v) H2O2 and 70 % (v/v) H2SO4. Then the surface was incubated with 2% 
(v/v) APTES in toluene overnight at room temperature to obtain the amine-modified silicon 
surface. 
The amine-modified surface was modified with 4-pyridinecarboxaldehyde (100 mM) in 
anhydrous isopropanol with acetic acid (1%, v/v) at room temperature. The obtained imine 
bonds on pyridine-modified surface were reduced to a secondary amine by incubating in 
NaBH3CN (50 mM) in isopropanol for 2 h. Finally the modified surface was cleaned with 
isopropanol and methanol and dried in a vacuum ovenat 50 °C for 0.5 h.  
Coating of LB-MSN-OVA  on pH-sensitive Microneedle Arrays  
To determine the level of binding of LB-MSN-OVA on the microneedle arrays, DOPE-LR 
was added to the lipids when the LB-MSN-OVA were prpared. The top of the microneedle 
arrays was incubated with LB-MSN-OVA (50 µl) with a concentration of 0.1, 0.5 and 1 
mg/mL in EDTA buffer (1 mM, pH 5.8) for 2 h at room temperature. The microneedles were 
then washed with coating buffer (450 µl) and the solution was kept for measurement. The 
binding efficiency of LB-MSN-OVA was determined by comparing the DOPE-LR 
concentration in the coating solution before and after coating by using a Tecan M1000 plate 
reader (Excitation wavelength = 575 nm and Emission wavelength = 590 nm). The structure, 
geometry and the surface morphology of the LB-MSN-OVA coated pH-sensitive microneedle 
arrays were examined by scanning electron microscopy (SEM) in a FEI NOVA nanoSEM 
200 (Hillsboro, OR). The LB-MSN-OVA coated on microneedle arrays were also visualized 
by Nikon D-Eclipse C1 confocal laser scanning micros ope (CLSM, Tokyo, Japan) with a 
depth resolution of 5 µm/step, equipped with a 10 × Plan Apo objective. The x and y 
resolution was 2.5 µm. An argon laser (488 nm) was used to visualize OVA-AF488 with a 
530/55 emission filter and a diode-pumped solid-state l ser (561 nm) with a 590/55 emission 
filter was used to visualize DOPE-LR.  
Delivery of LB-MSN-OVA from Microneedles into ex vivo Human Skin  
After coated with LB-MSN-OVA, the pH-sensitive microneedles were pierced into human 
skin from the abdomen, which was used within 24 h after cosmetic surgery from a local 
hospital. The study was conducted in accordance to Helsinki principles and written informed 
patient consent was obtained. The microneedles wereapplied into the skin by an impact-
insertion applicator with a velocity of 54.8 cm/s a described previously [6]. After 1 s, the 
applicator was removed and the microneedles were kept inside the skin for 30 min. Then the 
microneedles were removed and visualized by scanning electron microscopy (SEM) in a FEI 
NOVA nanoSEM 200 (Hillsboro, OR). The skin was visualized by Nikon D-Eclipse C1 
CLSM (Tokyo, Japan) with a depth resolution of 5 µm/step, equipped with a 4 × Plan Apo 
objective. The x and y resolution was 6.3 µm. An argon laser (488 nm) was used to visualize 
OVA-AF488 with a 530/55 emission filter and a diode-pumped solid-state laser (561 nm) 
with a 590/55 emission filter was used to visualize DOPE-LR. 
Statistical Analysis  
Mesoporous  silica nanoparticle-coated microneedle arrays for intradermal antigen delivery 
21 
 
All data shown are mean corrected values ± SD of at least three experiments. The results of 
cell experiments are analyzed by Two-way ANOVA with Bonferroni posttests.  
RESULTS  
Characterization of MSNs and AEP-MSNs 
The MSNs were synthesized from the silica precursor tetraethoxy silane (TEOS) by using a 
mixture of a nonionic triblock copolymer (Pluronic P-123) and the cationic fluorocarbon 
surfactant (FC-4) as organic templates. Furthermore the swelling agent TMB was added to 
induce the formation of large-pore MSNs [29]. The obtained pristine MSNs were modified 
with AEPTMS in order to generate a positively charged surface (AEP-MSNs). Inspection 
with TEM revealed that the negatively charged MSNs were rectangular in shape with 
mesochannels along the short axis (Fig. 1a). Modificat on with AEPTMS did not alter the 
morphology or mesostructure (Fig. 1b), as compared to pristine MSNs. Furthermore, 
characterization with N2 adsorption-desorption isotherms of both MSNs and AEP-MSNs 
showed that these nanoparticles have typical IV isotherms according to International Union of 
Pure and Applied Chemistry (IUPAC) classification (Fig. 1c) [30]. The existence of channel-
type mesopores was confirmed by the existence of a type-H1 hysteresis loop (Fig. 1c) [31]. 
The values for BET specific surface area (SBET), the total pore volume (Vt), BJH pore 
diameter (WBJH) and surface charge of MSNs and AEP-MSNs are summarized in Table 1. It 
can be seen that after modification with AEPTMS, SBET, Vt and WBJH were slightly reduced 
because of the attachment of the functionalized silanes on the pore surface. The pore diameter 
of the AEP-MSNs was 1-2 nm smaller than that of MSNs (Fig. 1d), but still sufficiently large 
to accommodate OVA (4 × 5 × 7 nm) [78]. Dynamic light scattering (DLS) measurements 
showed that the hydrodynamic diameter of MSNs and AEP-MSNs was 146.3 ± 0.3 nm and 
213.7 ± 0.8 nm, respectively. The observed increase in Z-average size for AEP-MSNs may be 
attributed to some particle aggregation, which is probably due to the decreased charge 
repulsion among AEP-MSNs compared to MSNs (Table 1). 
 
Table 1 Physical characteristics of nanoparticles (n=3)  
Sample 
BET 
surface area 
(m2/g) 
Pore 
volume 
(cm3/g) 
Pore 
diameter 
(nm)a 
Size (nm) PDI 
Zeta-potential 
(mV)b 
MSNs 506 1.01 10 ± 1 146.3 ± 0.3 0.154 ± 0.035 -27.8 ± 0.4 
AEP-MSNs 318 0.71 9 ± 1 213.7 ± 0.8 0.170 ± 0.062 10.9 ± 0.5 
AEP-MSN-
OVA 
- - - 1842 ± 126 0.373 ± 0.056 -8.1 ± 1.3 
LB-MSN-
OVA 
- - - 190.7 ± 2.7 0.125 ± 0.029 -24.0 ± 0.7 
aCalculated from desorption branch of the N2 sorption isotherms based on the BJH method. 
bZeta-potential was measured in 1 mM PB at pH 7.4. 
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Fig. 1 Characterization of the MSNs and AEP-MSNs. TEM images of (a) MSNs and (b) 
AEP-MSNs. Scale bar = 200 nm. (c) Nitrogen adsorptin-desorption isotherms and (d) plots 
of pore diameter vs. pore volume (inset), calculated from the desorption isotherms using BJH 
model, show that the MSNs and AEP-MSNs have an average pore diameter of 10 nm and 9 
nm, respectively.  
 
Encapsulation and Release of OVA from AEP-MSNs 
The percentage of grafted amine-containing groups on the surface of AEP-MSNs was 6.9%, 
as determined by thermogravimetric analysis (TGA, see Fig. 2a). The encapsulation 
efficiency (EE%), defined as the percentage of OVA which is adsorbed in the MSNs or AEP-
MSNs was determined as a function of incubation time (Fig. 2b). The calibration curve used 
to calculate the concentration of OVA is shown in supplementary Fig. 1a. This study revealed 
that the OVA encapsulation within AEP-MSNs was very fficient, as 95 ± 0.4% (mean ± SD, 
n = 3) of the protein was encapsulated in the AEP-MSNs. Furthermore, equilibrium of OVA 
encapsulation was reached in less than 5 min. In comparison, only 12 ± 2% (mean ± SD, n = 
3) of OVA was encapsulated in negatively charged MSNs after 24 h. The loading capacity 
(LC%) of OVA was calculated from the amount of OVA encapsulated in AEP-MSNs and 
expressed as the percentage of the total weight of OVA-loaded AEP-MSNs. The LC% of 
OVA in AEP-MSNs was dependent on the initial concentration of OVA (Fig. 2c). The 
maximum LC% was 34 ± 4% (mean ± SD, n = 3) and was achieved by increasing the initial 
concentration of OVA, indicating a diffusion-driven capsulation process [32].  
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To examine the influence of ionic strength of the mdium on the release profile of OVA from 
the AEP-MSNs, the concentration of NaCl in the buffer was varied. The calibration curve 
used to calculate the concentration of OVA is shown in supplementary Fig. 1b. The release 
percentage of OVA (defined as the percentage of OVA released from total encapsulated OVA 
in AEP-MSNs) increased from 0.6 ± 0.2% (mean ± SD, n=3) in NaCl-free buffer to 82 ± 2% 
(mean ± SD, n = 3) in buffer containing 7.2% NaCl (Fig. 2d). These results demonstrate that 
the ionic strength of the medium plays an important role in the release of OVA, indicating that 
the interaction between OVA and AEP-MSNs is mainly electrostatic in nature. The structural 
integrity of the released OVA was examined by HP-SEC, showing that the released OVA was 
mainly monomeric (Fig. 2e), and far-UV CD spectroscopy, indicating that the secondary 
structure of released protein was similar to that of native OVA (supplementary Fig. 2). These 
results strongly indicate that encapsulation and release have no adverse effect on the protein 
structure. 
Preparation and Characterization of LB-MSN-OVA 
The OVA-loaded AEP-MSNs had the tendency to precipitate and form large aggregates 
(Table 1), probably due to the decreased surface charge upon protein encapsulation (-8.1 ± 1.3 
mV, mean ± SD, n = 3). In order to increase the colloidal stability, the OVA-loaded AEP-
MSNs were stabilized with a lipid bilayer composed of DOPC, DOPS and cholesterol. For 
this, liposomes and OVA-loaded AEP-MSNs were mixed and equilibrated for 1.5 h and 
afterwards the excess lipids were removed by centrifugation. The encapsulation efficiency of 
OVA in the resulting lipid-coated AEP-MSNs (LB-MSN-OVA) was determined to be 74 ± 
1%, as compared to 99 ± 1% without lipid (mean ± SD, n = 3). The obtained LB-MSN-OVA 
were characterized by DLS, NTA and TEM. The mean number-based hydrodynamic diameter 
(176 ± 11 nm, mean ± SD, n = 3) measured by NTA (supplementary Fig. 3) was close to the 
Z-average hydrodynamic diameter (190.7 ± 2.7 nm; PDI = 0.125 ± 0.029; mean ± SD, n = 3) 
found by DLS (Fig. 3a). The existence of a lipid bilayer surrounding the AEP-MSNs was 
confirmed by cryoTEM (Fig. 3b and 3c). The colloidal stability of the formulation was 
examined by measuring the hydrodynamic diameter and zeta-potential of LB-MSN-OVA for 
one week (Fig. 3d-f). It showed that LB-MSN-OVA slightly changed in diameter and zeta-
potential, revealing that the lipid bilayer strongly enhanced the colloidal stability. The release 
of OVA from AEP-MSNs and LB-MSN-OVA was examined in PBS (pH 7.4) for 32 h (Fig. 
2f). The burst release of OVA from LB-MSN-OVA was less in comparison to AEP-MSNs, 
indicating that the lipid bilayer acts as a barrier etaining the OVA for longer inside the AEP-
MSNs. 
Interaction of LB-MSN-OVA with BMDCs  
As proteins in serum may interact with the particles, the colloidal stability of LB-MSN-OVA 
in cell culture medium was studied. Only limited aggregation of the nanoparticles was 
observed and a modest amount of OVA (15%) was releas d fter 4 h (supplementary Table 1). 
To examine whether LB-MSN-OVA facilitate the uptake by BMDCs, the uptake of LB-
MSN-OVA was assessed by flow cytometry and compared to that of free OVA solution. As 
shown in Fig. 4, at 4ºC there was almost no uptake (no significance compared to culture 
medium only) of LB-MSN-OVA or OVA in BMDCs (Fig. 4a), indicating that the uptake of 
LB-MSN-OVA and OVA is mediated by an active process. At 37 ºC the fluorescent level of 
LB-MSN-OVA treated cells was significantly higher (p＜0.001) than that for free OVA-
AF488 with the OVA concentration of 6 μg/ml (Fig. 4b). There was no significant difference 
found between LB-MSN-OVA and free OVA at lower conce tration. These results indicate 
that LB-MSN-OVA are capable of promoting antigen uptake by antigen-presenting cells  
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Fig. 2 (a) Thermogravimetric analysis (TGA) curves of MSNs and AEP-MSNs. (b) 
Encapsulation kinetics of OVA into MSNs and AEP-MSNs (mean ± SD, n = 3), concentration 
of OVA is 0.5 mg/mL and MSNs (AEP-MSNs) is 2 mg/mL. (c) Loading capacity (LC%) of 
OVA into AEP-MSNs (mean ± SD, n = 3) at different iitial concentration of OVA. (d) 
Influence of ionic strength on OVA release from AEP-MSNs (mean ± SD, n = 3). (e) HP-SEC 
chromatograms of the released OVA from AEP-MSNs. (f) Release profiles of OVA from 
AEP-MSNs and LB-MSN-OVA in PBS (pH 7.4) (mean ± SD, n = 3). 
 
 
 
Fig. 3 Characterization of LB-MSN-OVA. (a) Hydrodynamic diameter of LB-MSN-OVA 
determined by DLS. (b) CryoTEM image of AEP-MSNs, and (c) LB-MSN-OVA, revealing a 
lipid bilayer thickness of ~4 nm (indicated by white arrows), scale bar = 100 nm. (d-f) 
colloidal stability of OVA-loaded AEP-MSNs and LB-MSN-OVA over one week (d: 
hydrodynamic diameter, e: polydispersity index and f: zeta potential). 
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(BMDCs). In order to study the activation of BMDCs by the nanoparticles, BMDCs were 
incubated with different formulations for 4 h and the expression of CD40, CD80 and CD86 
was measured. Whereas exposure to LPS led to a significant upregulation of these activation 
markers, LB-MSN-OVA did not induce increased expression of CD40, CD80 or CD86 on 
dendritic cells compared to free OVA or cell culture medium (Fig. 4c). 
 
Fig. 4 The uptake of LB-MSN-OVA in BMDCs at 4 ºC (a) and 37 ºC (b), and the activation 
of BMDCs by LB-MSN-OVA (c). Bars represent mean ± SD, n=3. The uptake of OVA-
AF488 and expression of CD40, CD80 and CD86 were expressed as the mean fluorescence 
intensity (MFI). *** P＜0.001. 
Table 2 Coating amount of LB-MSN-OVA and OVA on microneedl arrays 
Amount of LB-MSN-OVAa 
(µg) 
Coated LB-MSN-OVA 
(µg) 
Coated OVAb 
(µg) 
Coating 
efficienc
y (%) 
5 1.3 ± 0.2 0.24 ± 0.03 27 ± 3 
25 5.4 ± 1.7 1.0 ± 0.3 22 ± 7 
50 7.9 ± 1.3 1.5 ± 0.2 16 ± 3 
aThe amount of LB-MSN-OVA in coating solution; bThe amount of coated OVA was 
calculated from the loading capacity of OVA and thecoating amount of LB-MSN-OVA. All 
the coating amounts are expressed as the amount of AEP-MSNs and are based on one 
microneedle array which contains 576 needles per array. All the results are based on 3 
independent microneedle arrays.  
Coating of LB-MSN-OVA on Microneedles 
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Next, we investigated whether the LB-MSN-OVA could be adsorbed onto a silicon 
microneedle array via physical adsorption. First, the pH-sensitive pyridine-modified 
microneedle arrays were prepared as described previously [6]. The microneedle arrays were 
coated with LB-MSN-OVA at pH 5.8 in an EDTA buffer (1 mM). To determine the optimal 
concentration of LB-MSN-OVA for the coating process, the nanoparticle concentration was 
varied in the buffered coating solution. Increasing the LB-MSN-OVA concentration resulted 
in increased amounts of LB-MSN-OVA coated onto the microneedle array surfaces. However, 
the coating efficiency is reduced (Table 2). The lowest coating efficiency obtained was 16 ± 
2.7% (mean ± SD, n = 3), corresponding to 7.9 ± 1.3 μg (mean ± SD, n = 3) and 1.5 ± 0.24 μg 
(mean ± SD, n = 3) of LB-MSN-OVA and OVA, respectively coated on the microneedle 
array. Considering the surface area of the microneedles accounts for 40% of the total surface 
area of microneedle arrays, 3.2 ± 0.5 μg (mean ± SD, n = 3) of nanoparticles and 0.58 ± 0.10 
μg (mean ± SD, n = 3) of OVA were coated onto the microneedle surface of one array. 
 
 
Fig. 5 SEM images of pyridine-modified microneedle arrays before the adsorption of LB-
MSN-OVA with different magnifications (a: 80 ×; b: 2000 ×; c: 5000 ×), after the adsorption 
of LB-MSN-OVA with different magnifications (d: 80 ×; e: 2000 ×; f: 5000 ×) and after the 
penetration of human skin (g: 80 ×; h: 2000 ×; i: 5000 ×).  
Scanning electron microscopy imaging was used to visualize the presence of the LB-MSN-
OVA on the pyridine-modified microneedle arrays (Fig. 5a-f). Compared to untreated 
pyridine-modified arrays (Fig. 5a-c), a high number of nanoparticles were observed on the 
surface of the microneedles (Fig. 5d-f) after coating with LB-MSN-OVA. To determine 
whether the OVA and nanoparticles colocalized on the microneedles, the LB-MSN-OVA 
coated microneedles were visualized by CLSM. For this experiment, we used OVA-AF488 
and DOPE-LR enabling the visualization of both the protein and lipids. Imaging revealed that 
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the fluorescent labels were both located at the microneedle surfaces indicative of the integrity 
of the LB-MSN-OVA upon physical adsorption (Fig. 6a-c). This showed us that LB-MSN-
OVA could be immobilized onto microneedles via electrostatic interaction. 
 
Fig. 6 CLSM images of LB-MSN-OVA coated microneedles (a-c). Red: DOPE-LR (a); 
Green: OVA-AF488 (b); Merged (c). The x and y arrows show that the scanning area is 1200 
μm × 1200 μm large. The z arrow indicates the scanning depth of 200 μm. CLSM images of 
human skin after removal of the LB-MSN-OVA coated microneedle arrays (d-f). Red: DOPE-
LR (d); Green: OVA-AF488 (e); Merged (f). The x and y arrows show that the scanning area 
is 3180 μm × 3180 μm large. The z arrow indicates the scanning depth of 280 μm. 
Delivery of LB-MSN-OVA into Human Skin 
Next, the delivery of LB-MSN-OVA from the surface of microneedles into the skin was 
studied. For this, the nanoparticle-coated microneedle arrays were applied onto human skin ex 
vivo for 30 min and subsequently withdrawn. Next the intradermal delivery was studied by 
both SEM and CLSM. Less particles were observed on surface of microneedles after the 
penetration and withdrawal from human skin (Fig. 5g-i). Colocalization of the fluorescence 
from both OVA-AF488 and DOPE-LR was observed inside th  skin (Fig. 6d-f), illustrating 
that the microneedles penetrated into the skin and successfully delivered the LB-MSN-OVA.  
DISCUSSION  
An alarming trend towards decreased vaccine compliance in the western world emphasizes 
the need to develop effective, but also safe and easily dministrable vaccines. In this respect 
dermal vaccination is interesting as the skin provides an easily accessible (and potentially 
painless) route of administration and also provides an environment which is very conductive 
for the initiation of immunological memory. Topical dministration of vaccines is often not 
effective as bulky vaccines do not permeate the skin. Recently, we and other groups have 
shown that antigens can effectively be delivered into the epidermis and dermis by means of 
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coated microneedles [3, 4, 10, 33]. However, some major challenges remain, which include 
the effective dose that can be delivered with coated microneedles and the immunogenicity of 
the subunit vaccines [4, 6].  
Here we introduce a novel carrier system for subunit vaccines with a high loading efficiency 
that effectively delivers a model antigen into the skin using a complementary charged 
microneedle array. To our best knowledge, the current study is the first example of a 
microneedle-mediated intradermal delivery system for mesoporous nanoparticles, which 
could be a promising tool to deliver a wide range of compounds into the skin. High loading 
efficiency was achieved by encapsulating the model antigen OVA into surface-modified 
MSNs with large pores (>10 nm). We chose MSNs because of their advantageous properties, 
including large surface area, controlled particle size and pore structure as well as ease of 
surface modification. Moreover, a previous study showed that subcutaneous immunization 
with 2 μg of OVA-loaded MSNs induced comparable antibody responses as 50 μg OVA 
adjuvanted with Quil-A [18], demonstrating that antigen-loaded MSNs can elicit an immune 
response at reduced antigen doses compared to a conventional delivery system. Our results 
indicate that one of the reasons for the immune enhancing effect on MSNs may be the 
increased uptake by dendritic cells when OVA is associated with MSNs (Fig. 4). LB-MSN-
OVA do not increase the activation of dendritic cells compared to free OVA, which is in line 
with previous findings [34]. Similar results were reported with OVA-loaded PLGA 
nanoparticles [35] as OVA-loaded PLGA nanoparticles w re found not to increase activation 
of human monocyte-derived dendritic cells (MHC II, CD83 and CD86). This suggests that the 
addition of adjuvants capable of inducing DC maturation, may further increase the 
immunogenicity of LB-MSN-OVA.  
For an efficient dermal delivery of nanoparticulate vaccines, MSNs are required that are small 
in size. In addition, they should have large pores (inner diameter > 5 nm) in order to 
encapsulate large amounts of proteins. Most nanosized MSNs do not fit these criteria, 
although recently some examples have emerged, mainly for the delivery of DNA/RNA [24, 
36-39]. MSNs with a large pore size of about 10 nm,recently developed in our lab [26], were 
used in the current study to accommodate the relativ y large OVA molecules (4 × 5 × 7 nm). 
The encapsulation study showed that the synthesized MSNs can accommodate a large amount 
of OVA within 5 min after mixing AEP-MSNs with OVA. It has been reported that MSNs 
with a pore size of 3.6 and 2.3 nm had a maximum OVA LC% of 21.8% [1] and 7.2% [18], 
respectively. The even higher maximum LC% of OVA in our study of 33.9% may be due to 
the larger pore size.  
To coat nanoparticles onto the pyridine-modified microneedles, the nanoparticles should have 
a negative surface charge allowing for adsorption based on electrostatic interactions, and a 
good colloidal stability allowing uniform and reproducible coating. In our study, negative 
liposomes were used to fuse to the surface of the positively charged AEP-MSNs, to achieve a 
negative surface charge. This fusion method was previously used for coating fluorophore [40], 
photosensitizers [41] and DNA loaded MSNs [23] and was reported to be based on the 
electrostatic interaction between the lipids and surface of MSNs [23]. The fusion of lipid 
bilayer on MSN surface has been shown to be able to modify the charge, improve the stability 
of MSNs and contain the drug inside the pores of MSNs. In order to prepare the liposomes, 
DOPC and cholesterol were used because in a previous study liposomes containing DOPC 
and cholesterol were shown to be able to stabilize drug-, small interfering RNA- and toxin-
loaded MSNs [25]. DOPS was used to give the liposomes a negative charge, which is needed 
to coat the nanoparticles onto the positively charged microneedles. Our results show that the 
colloidal stability of OVA-loaded MSNs was improved after liposome fusion and the lipid 
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bilayer generated a negatively charged surface on LB-MSN-OVA. The LB-MSN-OVA were 
coated onto microneedles at pH 5.8 where more than 90% of the pyridine groups are 
positively charged [6]. Combined with the low ionic strength of the buffer, this allows for the 
binding of the negatively charged LB-MSN-OVA via electrostatic interactions. The presence 
of the lipid bilayer on the surface of MSNs was confirmed by cryoTEM and indicated by the 
change of surface charge (from +11 mV to -24.0 mV at pH7.4). The encapsulation efficiency 
of OVA was decreased by about 25% after the fusion of liposomes, which may be because the 
negatively charged lipid bilayer and OVA were competing with each other for the binding on 
the MSN surface and some of the OVA coated on the AEP-MSN surface may be replaced by 
the lipid bilayer. The release study showed that the coated lipid bilayer functioned as a gate 
and prolonged the release of the antigen, which could be important for the nanoparticles to 
remain their adjuvant effect [35].   
The binding of LB-MSN-OVA on microneedles was visualized by both SEM and CLSM. The 
SEM images showed that after coating the microneedles with LB-MSN-OVA, the surface of 
the microneedles became rougher, but the sharpness of the microneedles was not affected. 
One major disadvantage of coated microneedles is the limited amount of materials that can be 
coated on microneedles because of the small surface area. The amount of LB-MSN-OVA 
coated on one microneedle array was 7.9 µg and was higher than that of inactivated polio 
virus (IPV) in a previous study (100 ng) [33]. Thus next to improving the immunogenicity of 
antigens, LB-MSN-OVA could also provide an effective way of increasing the antigen dose 
coated on microneedles. This may be because LB-MSN-OVA have a lower zeta potential than 
IPV under similar conditions (-16.8 mV vs -7.8 mV in 1 mM EDTA at pH 5.8). In our study 
the coated OVA loaded in LB-MSN-OVA is 1.5 µg on one microneedle array and is much 
higher than the amount of coated IPV [33] in a previous study. Other possibilities to increase 
the delivered amount of antigen are increasing the number of microneedle arrays used or 
increasing the number of needles on one array. 
To effectively deliver antigens into the skin, next to efficient coating of the antigen on the 
microneedles, rapid dissolution from the microneedls once inserted into the skin, is critical. 
The pH-sensitive microneedles used in the present study were developed in our lab for the 
intradermal delivery of vaccines by coating antigens at slightly acidic pH and releasing them 
at physiological pH. CLSM images showed that the LB-MSN-OVA were successfully 
released into the holes made by the microneedles. The fluorescence from lipids and OVA was 
found to still co-localize with each other in the holes made by microneedles, indicating that 
the LB-MSN-OVA may be still intact after the releas. This would be important for LB-
MSN-OVA to remain their adjuvant effect [25].  
Thus, the developed system combines the advantages of microneedles and nanoparticles. 
Microneedles allow non-invasive delivery of vaccines into skin and antigen-loaded 
nanoparticles have the potential to increase and moify the immune response against the 
antigen. In addition, by coating the nanoparticles onto the pH-sensitive pyridine-modified 
microneedles, the separate application of antigen aft r microneedle penetration is avoided. An 
important concern is the bio-distribution of MSNs after intradermal delivery. Studies have 
shown that intravenously injected MSNs were mainly excreted out of mice through urine and 
feces, indicating that MSNs are biodegradable [42] and other studies showed that MSNs can 
undergo hydrolysis to form non-toxic silica acid [43]. However, as deposition in the skin may 
alter the biodistribution and clearance of the MSNs, systematic studies need to be performed 
in order to assess the safety of these nanoparticles in animals and humans. 
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CONCLUSION 
In conclusion, the LB-MSN-OVA coated microneedle arrays represent a novel intradermal 
antigen delivery system. The large pores of MSNs enabled the rapid encapsulation of OVA 
with a high loading capacity. The introduction of lipid bilayers significantly improved the 
colloidal stability of OVA-loaded AEP-MSNs and concomitantly reduced the premature 
release of OVA. In addition, it enabled the coating of the nanoparticles on the surface of pH-
sensitive microneedle arrays. Application of LB-MSN-OVA coated microneedle arrays into 
human skin (ex vivo) resulted in the successful delivery of the OVA-loaded nanoparticles into 
the skin. The method is not restricted to the delivery of antigens, but may also be useful to 
deliver any compound that can be encapsulated in MSNs like (low-molecular-weight) drugs, 
RNA, DNA and proteins. 
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Supplementary Information
 
Supplementary Fig. 1 Calibration curves for quantification of OVA  in 1 mM PB with a pH 
of 7.4 (a) and PBS with a pH of 7.4 (b). The intrinsic fluorescence intensity (FI) of OVA was 
measured with an excitation wavelength of 280 nm and an emission wavelength of 320 nm.
 
Supplementary Fig. 2 Far-UV CD spectra of free OVA and OVA released from AEP
in PBS, pH 7.4, 25 °C. 
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Supplementary Fig. 3 Size distribution of the LB-MSN-OVA determined by nanoparticle 
tracking analysis (NTA). 
 
 
Supplementary Table 1. Stability of LB-MSN-OVA in cell culture medium (n=3). 
Time (h) Size (nm) PDI 
Zeta Potential 
(mv) 
Released OVA 
(%) 
0 632.5 ± 13.9 0.528 ± 0.031 -10.8 ± 0.6  
1 575.0 ± 18.3 0.535 ± 0.051 -11.7 ± 0.4  
2 536.5 ± 19.6 0.584 ± 0.057 -12.8 ± 0.5  
4 566.1 ± 64.5 0.485 ± 0.158 -13.3 ± 0.2 15.2 ± 0.6 
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Abstract 
The skin is an attractive organ for immunization due to the presence of a large number of 
epidermal and dermal antigen-presenting cells. Hollow microneedles allow for precise and 
non-invasive intradermal delivery of vaccines. In this study, ovalbumin (OVA)-loaded 
poly(lactic-co-glycolic acid) (PLGA) nanoparticles with and without TLR3 agonist poly(I:C) 
were prepared and administered intradermally by hollow microneedles. The capacity of the 
PLGA nanoparticles to induce a cytotoxic T cell response, contributing to protection against 
intracellular pathogens, was examined. We show that a single injection of OVA-loaded PLGA 
nanoparticles, compared to soluble OVA, primed both adoptively transferred antigen-specific 
naïve transgenic CD8+ and CD4+ T cells with markedly high efficiency. Applying a triple 
immunization protocol, PLGA nanoparticles primed also endogenous OVA-specific CD8+ T 
cells. Immune response, following immunization with in particular anionic PLGA 
nanoparticles co-encapsulated with OVA and poly(I:C), provided protection against a 
recombinant strain of the intracellular bacterium Listeria monocytogenes, secreting OVA. 
Taken together, we show that PLGA nanoparticle formulation is an excellent delivery system 
for protein antigen into the skin and that protective cellular immune responses can be induced 
using hollow microneedles for intradermal immunizations. 
Keywords: protein vaccine, hollow microneedles, intradermal immunization, PLGA 
nanoparticles, cytotoxic T cell response 
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1. Introduction 
The skin is an organ with many immune cells and is considered a potent organ for 
immunizations [1]. However, the challenge is to deliver high-molecular-weight antigens 
across the stratum corneum, which is the outermost layer of the skin and acts as an effective 
natural barrier for penetration of pathogens and allergens into the skin. One of the methods to 
circumvent the skin barrier is the use of microneedl s. Microneedles are miniaturized needles 
that provide the possibility of minimally invasive accination in the dermis and epidermis of 
the skin. There are other benefits in using microneedles compared to traditional hypodermic 
needles, like possible painless vaccination, the requi ment of less trained personnel and 
reduced contamination risk [2]. Nowadays a wide variety of these microneedles exist, 
including solid, coated, dissolving and hollow microneedles [3, 4]. 
Hollow microneedles have multiple benefits, for instance they can be used to inject a wide 
variety of fluids into the skin at different pressure-driven flow rates [3, 5, 6] and offer the 
highest precision in dose delivery among all microneedle types. Furthermore, they offer the 
possibility to screen formulations without time-consuming design and preparation of 
microneedles, as in case of coated and dissolving microneedles. Recently, hollow 
microneedles and an applicator for them were developed in our laboratory to inject 
formulations in precise manner into the skin. These microneedles were successfully used for 
formulations with inactivated polio virus vaccine in rats resulting in effective humoral 
immune responses [7-9]. However, whether hollow microneedle-mediated delivery may also 
induce T cell responses towards vaccine antigens is presently unclear.  
Cytotoxic CD8+ T cells play an important role in cellular immune protection against 
intracellular pathogens or tumor growth. To induce such CD8+ T cell responses, an antigen 
needs to be processed in the cell and presented by MHC-I molecules on professional antigen-
presenting cells (pAPC) to the immune system. Delivery of vaccine protein antigens over the 
cellular membrane can be achieved using delivery systems and over the past decades different 
types of them, such as polymeric nanoparticles, emulsions and lipid-based nanoparticles have 
been developed [10-12]. Nano-encapsulation of antige s has several advantages, such as 
stabilization of antigens in vivo, enhancement of the uptake by pAPC and also reduction of 
antigen release into systemic circulation [4, 13]. The immune outcome can be potentially 
shaped by using nanoparticles with difference size [14] and surface charge [15], and by co-
encapsulating antigen and adjuvant into the nanoparticles [16, 17]. 
For the production of polymeric nanoparticles, poly(lactic-co-glycolic acid) (PLGA) is the 
most commonly used polymer, because of its superior biocompatibility and biodegradability 
[18-20]. Previous studies have shown that model antige - and adjuvant-loaded PLGA 
nanoparticles used for vaccination were able to improve the induction of cell-mediated 
immune response in mice [17, 21-23]. However, relatively little is known about how 
encapsulation in PLGA nanoparticles modifies T cell responses to antigen/adjuvant 
combinations that are delivered intradermally by microneedles. One recent study reported that 
PLGA nanoparticles, delivered intradermally using dissolving microneedles arrays [24], 
induced cellular immune responses and protection against viral infection and tumor growth.  
In this study, nanoparticles were prepared and chara terized in terms of size, surface charge 
and antigen/adjuvant release profiles. We investigated the ability of hollow microneedle-
delivered protein antigens, encapsulated in either anionic or cationic PLGA nanoparticles with 
and without co-encapsulated TLR3 agonist poly(I:C) to induce a protective cellular immune 
response towards an intracellular pathogen in a mouse model. 
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2. Materials and Methods 
2.1. Materials  
PLGA (acid terminated, lactide glycolide 50:50, Mw 24.000 - 38.000), polyethylenimine (PEI, 
linear, average Mn 10,000), Roswell Park Memorial Institute medium (RPMI) and Fetal 
bovine serum (FBS) were purchased from Sigma-Aldrich (Zwijndrecht, The Netherlands). 
PVA 4-88 (31 kDa) was obtained from Fluka (Steinheim, Germany). Endotoxin-free 
ovalbumin (OVA), polyinosinic-polycytidylic acid (poly(I:C)) (low molecular weight) and its 
rhodamine-labelled version were obtained from Invivogen (Toulouse, France). Alexa647 
labelled OVA (OVA-Alexa647) was ordered from Thermo-Fischer Scientific (Waltham, 
MA). Dimethylsulfoxide (DMSO) was obtained from Bios lve BV (Valkenswaard, The 
Netherlands). Sodium dodecyl sulfate (SDS) was obtained from Merck Millipore 
(Hohenbrunn, Germany). Ammonium-Chloride-Potassium (ACK) lysis buffer (150 mM 
NH4CL, 1 mM NaHCO3; pH 7.40) and 1 mM phosphate buffer (PB;  pH 7.4) were prepared 
in the lab. Milli-Q water (18.2 MΩ/cm, Millipore Co., USA) was used for the preparation of 
solutions. Sterile phosphate buffered saline (PBS) was obtained from Braun (Oss, The 
Netherlands). All other chemicals used are of analytical grade.  
Purification antibodies used for DynaBeads® selection were all made in house and included 
the following antibody clones: αCD11b (clone M1/70), αMHC-II (M5/114), αB220 (RA3-
6B2), αCD4 (GK1.4), αCD8 (YTS169) and αCD25 (PC61). Purification antibodies for sorting 
via flow cytometry were αCD8-APC (53-6.7; eBioscience), CD44-FITC (IM7; eBioscience) 
and CD62L-PE (MEL-14; BD Bioscience) using a BD influx (BD Biosciences). For the 
detection of the adoptively transferred T cells theantibodies αCD45.2-PerCPCy5.5 (104; 
eBioscience), αCD4-PE (GK1.5; eBioscience) and αCD8-APC (53-6.7; BD Bioscience) were 
used. Detection of the endogenous T cells was measur d using the antibodies αCD8-APC (53-
6.7; eBioscience), αCD4-eFluor450 (GK1.5; eBioscience), αCD62L-Horizon B510, αCD44-
FITC (IM7; eBioscience), αCD16/CD32-unstained (2.4G2; made in house) and αIFN-γ-PE 
(XMG1.2; eBioscience). 
2.2. Preparation of PLGA nanoparticles 
OVA-loaded PLGA nanoparticles were prepared by double emulsion with solvent 
evaporation method as previously reported with modificat ons [25]. Briefly, 75 µl OVA (20 
mg/ml) in PBS was dispersed in 1 ml PLGA (25 mg/ml) in ethyl acetate by a Branson sonifier 
250 (Danbury, USA) for 15 s with a power of 20 W. To prepare anionic OVA-loaded PLGA 
nanoparticles (anPLGA-OVA), the obtained water-in-oil emulsion was emulsified with 2 ml 2% 
(w/v) PVA with the sonifier (15 s, 20 W) to get a water-in-oil-in-water double emulsion. In 
case of cationic OVA-loaded PLGA nanoparticles (catPLGA-OVA), the single emulsion was 
emulsified with 2 ml 2% (w/v) PVA and 4% (w/v) PEI solution. The double emulsion was 
added dropwise into 25 ml 0.3% (w/v) PVA (40 °C) under stirring. The ethyl acetate was 
evaporated by a rotary evaporator (Buchi rotavapor R210, Switzerland) for 3 h (150 mbar, 
40 °C). The nanoparticle suspension was centrifugated (AvantiTM J-20XP centrifuge, 
Beckman Coulter, Brea, CA) at 35000 g for 10 min, washed twice with 1 mM PB to remove 
the excess OVA and PVA, and dried in a Alpha1-2 freeze dryer (Osterode, Germany, -49 °C, 
90 mbar) overnight. To prepare OVA and poly(I:C) co-encapsulated PLGA nanoparticles 
(anPLGA-OVA-PIC), 18.75 μl OVA (40 mg/ml) and 75 μl poly(I:C) (46.7 mg/ml, including 
0.03% fluorescently labelled equivalent) were emulsified with 1 ml PLGA (25 mg/ml) in 
ethyl acetate to obtain the water-in-oil emulsion. The remaining of the procedure was 
identical to that of anPLGA-OVA. The obtained nanoparticles were stored at 4 ℃ for analysis 
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and further use. To prepare the PLGA nanoparticles for release study, 10% OVA-Alexa647 
was used during the preparation. 
2.3. Characterization of PLGA nanoparticles 
The size and polydispersity index (PDI) of nanoparticles were measured by dynamic light 
scattering and the zeta potential of nanoparticles wa measured by laser doppler velocimetry 
using a Nano ZS® zetasizer (Malvern Instruments, Worcestershire, U.K.). The samples were 
diluted with 1 mM PB buffer to a nanoparticle concetration of 25 μg/ml before each 
measurement. To determine the loading efficiency of OVA and poly(I:C) in PLGA 
nanoparticles, approximately 1 mg of nanoparticles w re dissolved in a mixture of  15%  (v/v) 
DMSO and 85% (v/v) 0.05 M NaOH and 0.5% SDS. The amount of OVA was determined by 
MicroBCA method following the manufacturer’s instructions. The amount of poly(I:C) was 
quantified by the fluorescence intensity of rhodamine labelled poly(I:C) (λex 545 nm/ λem 576 
nm). The encapsulation efficiency (EE) and loading capacity (LC) of OVA and poly(I:C) in 
the nanoparticles were calculated as below: 
EE % =  
 	!"! #$% /' ((*:,)
..	  	 /' ((*:,)
 × 100 %       (1) 
LC % =  
 	!"! #$% / ' ((*:,)
/	/'	0.12 "3
 × 100 %    (2) 
Where Mloaded OVA/poly(I:C) represents the mass of loaded OVA or poly(I:C), Mtotal OVA/poly (I:C)  is 
the total amount of OVA or poly(I:C) added to the formulation and Mnanoparticles is the weight 
of nanoparticles. 
2.4. Release of OVA and poly(I:C) from PLGA nanoparticles 
Nanoparticles were prepared in triplicate as described above. To study the release of OVA 
and poly(I:C) from PLGA nanoparticles, 3 mg anPLGA-OVA, catPLGA-OVA or anPLGA-
OVA-PIC were dispered into 1 ml RPMI supplemented with 10% FBS and incubated at 37 °C 
with a shaking speed of 350 rpm. At different time points, the suspensions were centrifugated 
(9000 g, 5 min) with Sigma 1-15 centrifuge (Osterode, Germany). A release sample of 600 μl 
of the supernatant was collected and replaced by fresh medium. The released amount of OVA 
and poly(I:C) was determined by fluoresence intensity of OVA-Alexa647 (λex 647 nm/λem 671 
nm) and rhodamine labelled poly(I:C) (λex 545 nm/λem 576 nm), respectively.  
2.5. Mice and intradermal immunizations 
8-18 week old male B6.SJL/ptprcaPep3b/BoyCrl (B6.SJL) wild type mice and 8-30 week old 
transgenic (tg) mice that express pOVA323-339-specific T cell receptor (OT-II mice) or 
pOVA257-264-specific T cell receptor (OT-I mice) were initially obtained from Charles River 
and were bred in house. Abdomen of mice were shaved prior to immunization on both flanks 
and intradermal immunization was done using a single hollow microneedle as reported 
previously [8, 9]. The hollow microneedle was inserted into the abdomen of mice using an 
applicator controlling precisely the depth, volume and rate of the injections. The injections 
were performed at a depth of 120 µm, a volume of 40 µl in 3 injections (2 on right flank, 1 on 
left flank) and with a rate of 10 µl/min. In several mice, the depth was increased up to 200 µm 
if leakage was observed in the beginning of injection. In all experiments a total of 5 µg OVA 
or 50 µg OVA peptides was injected per immunization. In case of anPLGA-OVA-PIC, the 
dose of poly(I:C) was also 5 µg. Ethical approval ws given by the Animal Ethics Committee 
from Utrecht University, The Netherlands.  
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2.6. Adoptive transfer of OVA specific tg T Cells 
OVA-specific T cell transferred mice were obtained by injecting OT-I CD8+ and OT-II CD4+ 
T cells into wildtype B6.SJL mice. In order to obtain OT-I and OT-II cells, spleens were 
isolated from OT-I and OT-II mice and erythrocyte-dpleted splenocytes were obtained as 
follows. Single cell suspensions were prepared by passage over a 70 µM cell strainer after 
homogenizing the spleens with a syringe plunger, in RPMI 1640 GlutaMAX supplemented 
with 8.5% fetal calf serum (Bodinco), 30 μM 2-mercaptoethanol and penicillin/streptomycin 
(complete RPMI medium). The erythrocytes were deplet d by lysis with ACK lysis buffer. 
Transgenic naïve CD4+ (OT-II) cells and transgenic CD8+ (OT-I) cells were isolated from 
splenocytes by negative selection using Magnetic DynaBeads® (Thermo Fisher Scientific, 
Waltham, MA). Antibodies used were αCD11b, αMHC-II, αB220 and either αCD4 for CD8 
(OT-I) T cell purification or αCD8 and αCD25 for naïve CD4+ (OT-II) T cell purification. 
After negative selection by magnetic beads, a purity around 70% was achieved for naïve tg 
CD4+ (OT-II) T cells. An additional sorting was necessary to separate naïve from non-naïve 
tg CD8+ (OT-I) T cells. After selection on CD8+, CD44low and CD62Lhigh using a BD influx, 
100% purity of naïve tg CD8+ (OT-I) T cells was obtained. Naïve tg CD4+ (OT-II) T cells 
were stained with carboxy-fluorescein succinimidyl ester (CFSE; 0.5 µM, Invitrogen) and 
naïve tg CD8+ (OT-I) T cells were stained with Cell trace violet (CTV; 5 µM, Invitrogen) for 
10 min at 37°C. A total of 2 × 106 CFSE-labelled naïve tg CD4+ T cells  and 1 × 106 CTV-
labelled naïve tg CD8+ cells were injected into the tail vein of recipient mice, one day before 
immunization to obtain OVA-specific T cell transferr d mice.  
2.7. In vivo proliferation of adoptively transferred T cells  
OVA-specific T cell transferred mice were immunized with OVA, anPLGA-OVA and 
catPLGA-OVA at day 0. PBS and OVA peptide immunizations were used as negative and 
positive control, respectively. Proliferation of tg T cells was studied at day 3, 5 and 7. 2.5 × 
106 erythrocyte depleted splenocytes or draining (ingui al) lymph node cells were stained 
with αCD45.2, αCD4 and αCD8 and transferred cells were measured as a percentage of 
CD45.2+ and either CD8+ or CD4+ cells of total cells using a FACSCanto II (BD Biosciences) 
and FlowJo (TriStar) analysis software. Percentages of fully proliferated (> 6 division) 
transferred cells were measured by similar antibody staining, but as CD45.2+ and either CTV-
CD4+ and  CFSElow or as CFSE-CD8+ and CTVlow, all after gating on live cells on FSC-
A/SSC-A and single cells in FSC-A/FSC-H.  
2.8. Endogenous CD4+ and CD8+ T cell responses 
B6.SJL mice were immunized with OVA, OVA+poly(I:C) (OVA+PIC), anPLGA-OVA, 
catPLGA-OVA or anPLGA-OVA-PIC at day 0, 3, 6 and T cell responses were analyzed at 
day 13. The endogenous CD4+ T cell response was measured by 3H thymidine incorporation. 
For this 0.2 × 106 erythrocyte-depleted splenocytes or inguinal lymph node cells were plated 
in complete RPMI medium in a 96 well round bottom plate for 72 h with or without 10 µg/mL 
OVA Endo-Fit (Worthigton) or ConA, at 37 °C in a humidified incubator. After 72 h, 3H-
Thymidine (0.4 µCi/well; Amersham Biosciences Europe GmbH) was added for an additional 
18 h and incorporation into DNA was measured by liquid scintillation counting (Microbeta, 
Perkin-Elmer Inc.).  
CD8+ T cell activation was measured using intracellular IFN-γ staining as described 
previously [26]. In short, 2.5 × 106 erythrocyte-depleted splenocytes were incubated in 
complete RPMI medium with 1 µg/ml pOVA257-264 (Genscript) or complete RPMI medium 
with 10 μM monensin (eBioscience) for 6 h at 37 °C in 6% humidified incubator. Cells were 
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stained with either αCD8, αCD4, αCD62L or αCD44 in the presence of αCD16/CD32 to 
block Fc-receptors. Next they were fixed with 2% paraformaldehyde and stained with αIFN-γ 
antibody in the presence of 0.05% saponin. Samples were measured on a FACSCanto II (BD 
Biosciences) and analyzed using FlowJo software (Tre Star). 
2.9. CFU counts in bacterial challenge study 
B6.SJL mice were immunized with OVA, OVA+PIC, anPLGA-OVA, catPLGA-OVA or 
anPLGA-OVA-PIC at day 0, 3 and 6. Mice were challeng d with recombinant Listeria 
monocytogenes secreting OVA (rLM-OVA) 21 days after final immunization. rLM-OVA [27, 
28] were cultured in Brain Hart Infusion broth (BHI; Sigma-Aldrich) with 5 µg/mL 
erythromycin and to challenge the mice 100.000 CFU bacteria from a LOG-phase culture 
were injected in 200 µl/mouse in the tail vein. Mice mmunized with 10.000 CFU rLM-OVA 
at day 6 were used as positive control and unimmunized mice served as negative control. To 
study the elimination of bacteria, three days after challenge spleens were isolated and single 
cell suspensions were made in RPMI medium. Serial dilutions were plated on BHI agar plates 
and CFU counts were determined after approximately 36 h in a 37 °C incubator. The 
remaining mice were sacrificed 5 days after the challenge to study the CD4+ and CD8+ T cell 
responses. The specific T cell response was determin d in spleen using intracellular IFN-γ 
staining method as described in section 2.8.. To determine the memory phenotype of the 
CD8+ T cells, CD62L and CD44 antibodies were used. Firstly, in the gate of the total CD8+ T 
cells, three different populations were gated (Supplement Figure 1B; solid lines). CD44- 
were considered naïve T cells, CD44+CD62L+ are T central memory cells and CD44+CD62L- 
are T effector and T effector  memory cells. Secondly, in order to determine the antigen 
specific memory phenotype, the gates that were set on all CD8+ T cells were copied in the 
CD8+IFN-γ+ population.  
2.10. Statistics  
Statistical significance was determined using Krukis-Wallis and multiple comparison/post hoc 
analysis was done with Dunns correction, *=p<0.05, **=p<0.01, ***=p<0.001. 
3. Results 
3.1. Preparation and characterization of PLGA nanoparticles  
The physicochemical characteristics of PLGA nanoparticles are shown in Table 1. All types 
of PLGA nanoparticles had a size of approximately 150 nm with a low PDI ranging from 
0.032 to 0.100. AnPLGA-OVA had a negative surface charge with a zeta potential of 
approximately -18 mV and catPLGA-OVA possessed a positive surface charge with an 
opposite zeta potential around +10 mV. The EE% of OVA was around 50% in both anPLGA-
OVA and anPLGA-OVA-PIC, and catPLGA-OVA showed a significantly higher EE% of 
87%. CatPLGA-OVA had also a higher LC% (10.4%) of OVA than anPLGA-OVA (6.6%) 
and anPLGA-OVA-PIC (2.8%). The ratio between the initial amount of OVA and poly(I:C) 
in the formulations during the preparation procedur was adjusted in order to prepare 
anPLGA-OVA-PIC with similar LC% of OVA (2.8%) and poly(I:C) (2.7%).  
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Table 1: Physicochemical characteristics of PLGA nanoparticles 
Nanoparticles Size (nm) PDI ZP (mV) 
EE% LC% 
OVA Poly(I:C)  OVA Poly(I:C)  
anPLGA-
OVA 
155.0±6.2 0.064±0.010 
-
18.2±1.7 
54.8±1.0 - 6.6±0.1 - 
catPLGA-
OVA 
147.3±2.1 0.100±0.029 9.9±0.5 87.0±4.8 - 10.4±0.6 - 
anPLGA-
OVA-PIC 
148.4±8.4 0.032±0.007 
-
17.4±0.8 
47.2±16.2 9.6±2.8 2.8±1.0 2.7±0.8 
The formulations are characterized in terms of size(diameter) and polydisperse index (PDI), 
zeta potential (ZP), encapsulation efficiency (EE) and loading capacity (LC) of OVA and 
poly(I:C). The EE% of OVA or poly(I:C) was defined as the percentage of encapsulated 
amount of OVA or poly(I:C) compared to the added amount of OVA or poly(I:C). The LC% 
of OVA or poly(I:C) was defined as the percentage of encapsulated amount of OVA or 
poly(I:C) compared to the amount of nanoparticles. AnPLGA-OVA: anionic OVA-loaded 
PLGA nanoparticles. CatPLGA-OVA: catonic OVA-loaded PLGA nanoparticles. AnPLGA-
OVA-PIC: OVA and poly(I:C) co-encapsulated anionic PLGA nanoparticles. 
3.2. Release of OVA and poly(I:C) from PLGA nanoparticles 
Release of OVA and poly(I:C) from PLGA nanoparticles was measured in vitro in culture 
medium containing serum (Fig. 1). The developed nanoparticles showed a burst release of 
OVA within the first day, followed by a slow release. At day 30 around 49%, 22% and 26% 
OVA were released from anPLGA-OVA, catPLGA-OVA and anPLGA-OVA-PIC, 
respectively. The release of poly(I:C) followed the tr nd of OVA in anPLGA-OVA-PIC. At 
day 30, around 42% poly(I:C) was released. Thus, all of the PLGA nanoparticles released at 
most half of their content within one month. 
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Figure 1. Release of OVA and poly(I:C) from PLGA nanoparticles. PLGA nanoparticles 
were dispersed into culture medium containing serum and incubated at 37 ºC. At different 
time points, the release sample was collected to deermine the release amount of OVA (A) 
and poly(I:C) (B). Per time point 3 independent measurements were performed (mean ± SEM, 
n=3) 
3.3. OVA-loaded PLGA nanoparticles enhanced antigen-induced activation of tg T 
helper cells and enabled priming of tg cytotoxic T cells after intradermal immunization 
using a hollow microneedle  
To determine the induction of a cellular immune response towards a protein antigen that is 
delivered via hollow microneedles, we first examined the ability of a protein antigen to 
activate transgenic (tg) T cells that were adoptively transferred (Fig. 2A). Naïve OVA specific 
CD4+ and CD8+ T cells were isolated from spleens of OT-II and OT-I mice, expressing a tg T 
Cell Receptor specific for the CD4+ and CD8+ T cell epitopes (OVA323-339 and OVA257-264) of 
the model antigen OVA, respectively [29, 30]. After staining with cell trace dyes, these cells 
were mixed and transferred into congenic recipient mice, allowing the distinction between 
host and donor T cells in flow cytometry, based on expression of the congenic marker (Fig. 
2A). One day later the recipient mice were immunized intradermally, using a hollow 
microneedle, with full length OVA protein or with te OVA epitopes (pOVA). These epitopes 
do not require any antigen processing in order to ac iv te tg T cells and served as a positive 
control. We first determined if CD4+ T helper cells were activated in the present study. Tg 
CD4+ T cells were detected in flow cytometry as CD4+ CD45.2+ T cells within the 
lymphocyte gate in either draining inguinal lymph nodes (dLN) or in the spleens. In OVA 
protein-immunized mice, a small increase in numbers of tg CD4+ T cells compared to PBS 
group was found in the dLN after immunization (Fig. 2B). Minimal systemic responses were 
measured in the spleen (Fig. 2C). Besides, minimal numbers of transferred CD4+ T cells 
activated by OVA protein were fully proliferated (Fig. 2D-F; depicted by more than 6 
dilutions of cell trace dye). Numbers of tg CD4+ T cells were higher than PBS group in both 
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dLN and spleen in mice immunized with peptides (Fig. 2B). OVA peptides showed a high 
proliferation rate of the tg CD4+ T cells at day 5, while at day 7 the numbers of fully 
proliferated cells dropped (Fig. 2E-F).  
 
Figure 2. Encapsulation of OVA by PLGA nanoparticles enhances activation of tg CD4+ 
T cells after intradermal immunization using hollow microneedle.  
(A) Experimental design; naïve CD8+ tg T cells specific for OVA257-264 were isolated from 
spleens of OT-I mice and stained with Cell Trace Violet. CD4+ tg T cells specific for OVA323-
339 were isolated from spleens of OT-II mice and stained with Carboxyfluorescein 
succinimidyl ester (CFSE). From both cell types 1 × 06 cells were injected in tail vein of 
B6.SJL mice 1 or 2 days before intradermal immunization. T cell responses were analyzed on 
day 3, 5 and 7. (B-F) CD4+ T cell response of tg transferred T cells.  (B-C) Amount of 
transferred tg T cells as a percentage of CD45.2+CD4+ cells in either dLN cells (B) or 
lymphocyte gate of splenocytes (C). (D) Indication of fully proliferated (>6 dilutions) cells in 
the CFSE window of CTV- / CD45.2+CD4+ / lymphocyte gate. (E-F) Percentage of cells that 
are CD45.2+CD4+ and divided more than 6 times as measured by CFSE intensity on day 5 or 
7 in either dLN (E) or spleen (F) after intradermal immunization via hollow microneedles 
with the formulations indicated on X-axes. Graphs are representative for 1 of total 2 
independent experiments. Per experiment the number of mice used is n=4 for OVA, anPLGA-
OVA and catPLGA immunization groups, n=3 for pOVA immunization groups, and n=2 for 
PBS immunization group (as depicted by the amount of dots in the graph). Statistical 
significance was determined using Krukis-Wallis and multiple comparison/post hoc analysis 
was done comparing immunization strategies versus PBS or OVA immunization with Dunns 
correction, *=p<0.05. 
We then determined whether OVA encapsulation in PLGA nanoparticles could enhance 
OVA-specific tg CD4+ T cell responses. When mice were immunized with OVA-loaded 
anPLGA-OVA and catPLGA-OVA, we detected higher numbers of OVA-specific tg CD4+ T 
cells than OVA group in dLN and spleen, both at day5 and 7 post-immunization (Fig. 2B-C). 
Total numbers of tg CD4+ T cells retrieved from PLGA-OVA nanoparticle immunized mice 
were also much higher than that in mice immunized with OVA peptides (Fig. 2B-C). Over 
95% of these cells were fully proliferated in anPLGA-OVA and catPLGA-OVA groups, while 
OVA induced only slightly more fully proliferated cells than PBS locally on day 5 (Fig. 2E) 
Hollow microneedle-mediated intradermal delivery of model vaccine antigen-loaded PLGA 
nanoparticles elicits protective T cell-mediated immunity to an intracellular bacterium 
47 
 
and systemically (Fig. 2F) on day 7. No differences were observed between responses 
detected against anPLGA-OVA and catPLGA-OVA. Taken together, we show that 
encapsulation in PLGA nanoparticles enhanced the activation of tg T helper cells by OVA 
after intradermal immunization using hollow microneedles. 
Next, it was determined if the followed immunization strategy also induced a cytotoxic 
cellular immune response. Activation and proliferation of CD8+ tg T cells was measured in 
the experimental setup as shown in Fig. 2A. As expected, no increase in the numbers of tg 
CD8+ T cells was detected in either dLN or spleen at day 3, 5 or 7 after immunization with 
soluble OVA protein (Fig. 3A-B). On day 3, immunization with OVA had induced some T 
cell proliferation, as shown by dilution of cell trace dye (Fig. 3C-D), although this 
proliferation did not lead to a significant increas in tg CD8+ T cell numbers (Fig. 3A-B) as 
compared to PBS group. In contrast, immunization with OVA-loaded PLGA nanoparticles 
induced a marked increase in tg CD8+ T cell numbers in both dLN and spleen, as detected a  
both days 5 and 7 (Fig. 3A-B). Most of these cells were fully proliferated and there was no 
difference observed between responses induced by anPLGA-OVA and catPLGA-OVA (Fig. 
3C-D). Immunization with OVA peptides induced a strong systemic tg CD8+ T cell response 
at day 5, but in contrast to nanoparticle-immunization, this response decreased significantly at 
day 7 (Fig. 3A-B). This was probably due to differing kinetics of T cell responses triggered 
by precise T cell epitopes, compared to full length OVA, which requires prior antigen 
processing. In conclusion, our data indicate that encapsulation of OVA in PLGA 
nanoparticles enables OVA to trigger CD8+ tg T cell responses upon hollow microneedle-
mediated intradermal delivery. 
 
 
Figure 3.  Encapsulation of OVA by PLGA nanoparticles enabled activation of tg CD8+ 
T cells after intradermal immunization using hollow microneedle. CD8+ T cell response 
of tg transferred T cells. (A-B) Amount of transferred tg T cells as a percentage of 
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CD45.2+CD8+ cells in either dLN cells (A) or lymphocyte gate of splenocytes (B). (C-D) 
Percentage of cells that are CD45.2+CD8+ and divided more than 6 times as measured by Cell 
Trace Violet intensity on day 3, 5 or 7 in either dLN (C) or spleen (D) after intradermal 
immunization via hollow microneedles with the formulations indicated on X-axes. Graphs are 
representative for 1 of total 2 independent experimnts. Per experiment the number of mice 
used is n=4 for OVA, anPLGA-OVA and catPLGA immunizat on groups, n=3 for pOVA 
immunization groups and n=2 for PBS immunization group (as depicted by the amount of 
dots in the graph). Statistical significance was determined using Krukis-Wallis and multiple 
comparison/post hoc analysis was done comparing immunization strategies versus PBS 
immunization with Dunns correction, *=p<0.05. 
3.4. OVA primed both endogenous CD4+ and CD8+ T cell responses in immunized hosts 
when particulated in PLGA nanoparticles or adjuvanted with TLR3 agonist 
Having shown that hollow microneedle-mediated immunization with OVA-loaded PLGA 
nanoparticles activates adoptively transferred tg Tcells (Fig. 2-3), we next examined whether 
this strategy also primes endogenous T cell responses in immunized hosts. To this end, wild 
type mice were immunized at day 0, 3 and 6 with OVA, OVA+PIC, anPLGA-OVA, 
catPLGA-OVA or anPLGA-OVA-PIC (Table 1; Fig. 4A).  
 
Figure 4. Specific endogenous T cell responses induced by OVA when particulated in 
anionic, cationic PLGA nanoparticles or when adjuvanted with TLR3 agonist. 
(A) Schematic overview of immunization strategy of measuring wild type T cell responses. 
Intradermal immunization on day 0, 3 and 6 and respon es measured 7 days after final 
immunization (day 13). (B-C) Percentage of IFN-y+ cells in CD8+ gate within the lymphocyte 
gate on FSC/SSC of dLN (B) or spleen (C). IFN-γ+ cells upon stimulation with medium is 
considered background and shown in gray. Results were pooled of 2 experiments with a total 
of 6-9 mice/group. (D) CD4+ T cell response was measured by proliferation of splenocytes 
upon stimulation of OVA protein. Each data point represents the results of one animal. 
Incorporation of 3H-thymdine in DNA was measured liquid scintillation counting as CCTM. 
Statistical significance was determined using Krukis-Wallis and multiple comparison/post hoc 
analysis was done comparing all immunization groups with Dunns correction, *=p<0.05, 
**=p<0.01, ***=p<0.001. 
At day 13, antigen-specific CD8+ T cell responses were detected by intracellular IFN-γ 
cytokine staining (Supplement Fig. 1A). Background levels of IFN-γ produced by CD8+ T 
cells was low in all mice, as depicted by restimulation of cells with medium (Fig. 4B-C). As 
expected, no OVA257-264-specific CD8
+ T cell response was detected in mice immunized with
Hollow microneedle-mediated intradermal delivery of model vaccine antigen-loaded PLGA 
nanoparticles elicits protective T cell-mediated immunity to an intracellular bacterium 
49 
 
soluble OVA (Fig. 4B-C). In contrast, responses to this epitope were clearly detectable in 
dLN (Fig. 4B) and the spleen (Fig. 4C) of mice immunized with OVA+PIC, anPLGA-OVA 
or catPLGA-OVA. Responses in the anPLGA-OVA group tended to be lower than that in the 
catPLGA-OVA group. The addition of poly(I:C) enhanced the CD8+ response, either when 
mixed with OVA solution or co-encapsulated with OVA in PLGA nanoparticles (anPLGA-
OVA-PIC) (Fig. 4B-C). Thus, following hollow microneedle-mediated delivery, a specific 
recipient CD8+ T cell response is induced by OVA when encapsulated in PLGA nanoparticles 
or when adjuvanted with TLR3 agonist (either mixed or co-encapsulated with OVA in PLGA 
nanoparticles). Furthermore, induction of OVA-specific CD4+ T cell responses in the 
immunized mice was determined by measuring 3H-thymidine incorporation in 72 h 
splenocyte cultures incubated with OVA protein. Some OVA-specific proliferation was 
detected in mice immunized with OVA+PIC, catPLGA-OVA, and anPLGA-OVA-PIC (Fig. 
4D), although no significant differences between groups were observed.  
Thus, hollow microneedle-mediated intradermal immunization with OVA loaded PLGA 
nanoparticle with or without poly(I:C) induces clearly detectable OVA257-264-specific CD8
+ T 
cell responses and minor OVA-specific CD4+ T cell responses in mice.   
3.5. Protective immune response towards recombinant rLM-OVA after intradermal 
immunization using hollow microneedles  
CD8+ T cells play an essential role in clearance of the intracellular bacterium Listeria 
monocytogenes [31]. Next, we determined whether hollow microneedl -mediated vaccination 
with PLGA nanoparticles induces protective immunity against rLM-OVA. Mice were 
immunized with OVA, OVA+PIC, anPLGA-OVA, catPLGA-OVA or anPLGA-OVA-PIC at 
day 0, 3 and 6 and challenged with the bacterium 21 days after final immunizations (Fig. 5A). 
Unimmunized mice served as a negative control and mice immunized with rLM-OVA at day 
6 served as a positive control, as these mice are typically able to completely clear the 
bacterium within 3 days after challenge. Determination of CFU counts in the spleens at day 
30 showed that mice immunized with rLM-OVA indeed completely cleared the challenge 
dose, while spleens of non-immunized mice contained i  average approximately 100.000 
bacteria (Fig. 5B). While immunization with soluble OVA, OVA+PIC and anPLGA-OVA 
failed to protect (Fig. 5B), protection was observed in at least one mouse immunized with 
catPLGA-OVA. Moreover, anPLGA-OVA-PIC induced full protection, resulting in zero 
bacteria count in the spleen, similar to mice immunized with rLM-OVA (Fig. 5B). This 
indicates that immunization with anPLGA-OVA-PIC, and to some degree catPLGA-OVA, 
via the intradermal route using hollow microneedles, licited a protective cellular immune 
response.  
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Figure 5. Protective immune response towards rLM-OVA after hollow microneedle 
mediated intradermal immunization. (A) Schematic overview of challenge study in which 
the mice received an i.v. challenge of 100.000 recombinant Listeria monocytogenes-OVA 
(rLM-OVA) 21 days after 3 immunizations with different formulations. CFU count of rLM-
OVA in spleen was determined 3 days after challenge and T cell activation was measured 5 
days after challenge. (B) Spleens were isolated and serial dilutions were plated on BHI agar 
plates and CFU’s were counted 36 h after incubation at 37°C. (C-D) CD4+ T cell and CD8+ T 
cell responses were measured by using a procedure ientical to that used for T cell responses 
showed in Fig. 4B-D. Gentamycin was added to culture medium to prevent further growth of 
potential rLM-OVA. Per experiment n=4 for OVA, anPLGA-OVA and catPLGA-OVA 
immunization groups, n=3 for pOVA immunization groups and n=2 for PBS immunization 
group (as depicted by the amount of dots in the graph). Statistical significance was determined 
using Krukis-Wallis and multiple comparison/post hoc analysis was done with Dunns 
correction, *=p<0.05. 
To study the possible relation between T cell respon e and the capacity to clear the pathogen, 
the T cell response in the spleen of the challenged mice was measured. Results of T cell 
responses 5 days after challenge with rLM-OVA showed that all immunization regimens 
triggered OVA-specific CD4+ T cell responses, and that the addition of poly(I:C) did not 
further increase these responses (Fig. 5C). In all immunized groups except OVA-immunized 
mice a particularly robust activation of antigen-specific CD8+ T cells was detected (Fig. 5D). 
Remarkably, the activated CD8+ T cells in OVA-immunized mice consisted of 40% central 
memory T cells (Tcm; CD62L+CD44+) and 60% effector T cells and effector memory T cells 
(Teff/Tem ;CD62L-CD44+). In contrast, in the other immunization groups the Tcm 
populations were much smaller and the Teff/Tem cell population much larger (Sup Fig. 1B-
D; solid line). While Tcm:Teff/Tem cell ratio failed to correlate with immune protection, 
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cells within the CD62L-CD44+gate were further analyzed (Sup. Fig. 1B-D; dotted line). We 
found higher CD44int:CD44hi cell ratios in mice that had received anPLGA-OVA-PIC, 
catPLGA-OVA and rLM-OVA, i.e. the immunization regimens that led to reduced CFU 
counts following bacterial challenge (Fig. 5E). Thus, the presence of antigen-specific CD44int 
CD8+ T cells seems favorable for immune protection to rLM-OVA infection.   
4. Discussion 
Nowadays, most of the vaccines under investigation are based on recombinant proteins or 
subunits of pathogens, because of improved safety and lower production cost compared to 
live or attenuated vaccines [32]. However, in general such vaccines are poorly immunogenic 
and fail to elicit robust cell-mediated immunity against intracellular pathogens. In this respect, 
nanoparticle-based delivery of antigens may be an attractive tool, because it can improve 
immune response induction to encapsulated antigens [33]. In this study, OVA was used as a 
model antigen and encapsulated into PLGA nanoparticles with or without the adjuvant 
poly(I:C). The capacity of the nanoparticle formulations to stimulate cell-mediated immunity 
was investigated by intradermal immunization using hollow microneedles. We show that 
intradermal delivery using hollow microneedles can elicit a protective cellular immune 
response when the antigen is encapsulated in cationic PLGA nanoparticles or when the 
antigen and adjuvant are co-encapsulated in anionic PLGA nanoparticles. These data expand 
on previous studies using hollow microneedles where humoral immune responses were 
detected [7-9], which illustrate the attractiveness of the intradermal route for the delivery of 
vaccines.  
Nanocarriers used for delivery of proteins or subunit vaccines enhance antigen uptake by 
antigen presenting cells and contribute to a prolonged presentation of the vaccine antigen at 
the cell surface [34, 35]. This leads to activation of a cellular immune response, which was 
exemplified in previous studies showing that PLGA nanoparticle-encapsulated antigens, with 
or without adjuvant, may induce strong T helper type 1 and cytotoxic T cell immune response 
(Th1/CTL) when delivered systemically or subcutaneously [15, 17, 36]. However, relatively 
little is known about the immune responses elicited by nanoparticle vaccines when 
administered intradermally using microneedles. Some previous studies showed that coated 
and dissolvable microneedle delivered protein antige  induced CD8+ T cell responses [39-41]. 
In these studies none of the vaccine antigens were encapsulated in nanoparticles. Our results 
showed that the encapsulation of antigen in nanoparticles with and without adjuvant can 
enhance the T cell responses. These results are in line with a previous study, in which 
dissolving microneedles loaded with PLGA nanoparticle encapsulated antigens were used for 
intradermal vaccination, and shown to induce a robust antigen-specific protective cellular 
immune response in mice [24].  
Our data show that hollow microneedle-delivered particulated OVA not only activated 
transferred tg T cells, but also primed endogenous protective CD8+ T cell responses in 
immunized mice. In mice adoptively transferred with tg T cells, an endogenous T cell 
response could not be detected (data not shown). This may be explained by the single 
injection immunization regimen in  these studies, which may be sufficient to prime adoptively 
transferred tg CD8+ T cells, but not the naïve antigen-specific T cellr pertoire. Alternatively, 
interference of the relatively easily activated tg T cells with priming of naïve T cells of 
recipient mice, for example by cytotoxicity towards antigen presenting pAPC as part of an 
immune homeostasis feedback loop, may explain this observation. For this reason, to examine 
whether hollow microneedle-mediated immunization with PLGA nanoparticles encapsulated 
OVA may prime OVA-specific endogenous CD8+ T cells in mice, a priming procedure 
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consisting of three immunizations delivered over a time period of 6 days was used. This 
protocol had been shown to induce cellular immune responses following dermal DNA tattoo 
immunization [26, 42], but not yet when using hollow microneedles [7]. We report here that 
this prime boost protocol indeed elicits vigorous CD8+ T cell responses in mice immunized 
with PLGA nanoparticles encapsulated with antigen, when using hollow microneedles as 
delivery method. 
A variety of dendritic cells in the dermis and epidermis have been shown to contribute to 
immune activation following dermal immunization [43, 44], and they all express diverse 
pathogen recognition receptors, such as Toll-like receptors (TLRs). In agreement with this 
observation, multiple intradermal immunization studies have shown added effects of different 
Toll-like receptor (TLR) agonists based adjuvants [16, 45]. In our study, co-delivery of OVA 
and the TLR3 agonist poly(I:C) in PLGA nanoparticles, led to protective cellular immune 
responses to rLM-OVA. Possibly, the nanoparticles act as a depot system and stimulate the 
immune system by controlling the release of OVA andpoly(I:C), resulting in prolonged OVA 
presentation and enhanced immunogenicity [23].  
Cationic PLGA nanoparticles are considered to be more immunogenic than anionic PLGA 
nanoparticle, as their positive surface charge facilit te the interaction with anionic cell 
membranes, enhancing uptake of these nanoparticles by phagocytic cells [46]. However, this 
enhanced interaction can also lead to increased cell cytotoxicity [10], contributing to the 
challenges faced for therapeutic use in humans. In our adoptive transfer studies anPLGA-
OVA and catPLGA-OVA seemed to perform equally well. However, catPLGA-OVA primed 
the endogenous cellular immune responses efficiently, while anPLGA-OVA did not show 
significant increase of response compared to OVA solution. Besides, although one mouse 
showed full protection from subsequent infection with rLM-OVA after immunization with 
catPLGA-OVA, no statistical difference in degree of immune protection induced by plain 
cationic compared to anPLGA-OVA was detected. Our results show that inclusion of 
poly(I:C) in the anionic nanoparticles was needed to fully protect immunized mice from 
infection. 
Remarkably, although immune protection differed between mice immunized with OVA 
particulated in cationic or anionic PLGA without or with poly(I:C), vigorous OVA-specific 
CD8+ T cell responses were detected in all groups except for mice immunized with soluble 
OVA. Further analysis of CD8+ T cell phenotype showed that there was no difference within 
percentage of Tcm and Tem/Teff cells between the diff rent PLGA nanoparticle immunized 
groups, but an enhanced ratio of CD8+ T cells with CD44int phenotype was detected in mice 
immune to rLM-OVA challenge. Difference in antigen release can have a role in shaping the 
memory phenotype [47], however we found similar release profiles of OVA in the different 
nanoparticle formulations. Thus, although no clear definition of CD44intCD62Lneg is available 
[48-50], we show a correlation between their presence and intradermal immunization-induced 
protective immunity to challenge with rLM-OVA. 
Taken together, we show that hollow microneedles are an excellent tool for intradermal 
vaccination, leading to the induction of minor CD4+ T cell and vigorous CD8+ T cell 
responses to PLGA nanoparticle encapsulated with antigens. Evoked CD8+ T cell responses 
provided full protection against an intracellular bacterium if poly(I:C) was co-encapsulated 
with the OVA antigen in PLGA nanoparticles. Future studies may show whether other 
adjuvants have similar effects or whether specific adjuvants may induce protection to specific 
categories of intracellular pathogens. 
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Supplementary information 
 
Supplementary Figure 1. 
(A) Gating strategy used for determination of CD8+ T cell response. After live gate on 
forward/sideward scatter, double or adhering cells are excluded on FSC-A/FSC-H gate. IFN- 
γ
 + cells were determined after gating on CD8+ cells. (B) All CD8+ cells were used to 
determine different population on CD62L and CD44 surface markers. Memory phenotype 
was next determined on CD8+IFN- γ + population only. (C+D) Percentage of Tcm (CD62L+ 
CD44int/hi) and Teff/Tem (CD62L-CD44int/hi) in the specific T cell population. Statistical 
significance was determined using Kruskal-Wallis, and multiple comparison/post hoc analysis 
was done with Dunn’s correction, *=p<0.05. 
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Abstract 
In this study, we investigated the potential of intradermal delivery of nanoparticulate vaccines 
to modulate the immune response of protein antigen usi g hollow microneedles. Four types of 
nanoparticles covering a broad range of physiochemical parameters, namely poly (lactic-co-
glycolic) (PLGA) nanoparticles, liposomes, mesoporous silica nanoparticles (MSNs) and 
gelatin nanoparticles (GNPs) were compared. The devloped nanoparticles were loaded with 
a model antigen (ovalbumin (OVA)) with and without an adjuvant (poly(I:C)), followed by 
the characterization of size, zeta potential, morphlogy, and loading and release of antigen 
and adjuvant. An in-house developed hollow-microneedle applicator was used to inject 
nanoparticle suspensions precisely into murine skin at a depth of about 120 µm. 
OVA/poly(I:C)-loaded nanoparticles and OVA/poly(I:C) solution elicited similarly strong 
total IgG and IgG1 responses. However, the co-encapsul tion of OVA and poly(I:C) in 
nanoparticles significantly increased the IgG2a respon e compared to OVA/poly(I:C) solution. 
PLGA nanoparticles and liposomes induced stronger IG2a responses than MSNs and GNPs, 
correlating with sustained release of the antigen and adjuvant and a smaller nanoparticle size. 
When examining cellular responses, the highest CD8+ and CD4+ T cell responses were 
induced by OVA/poly(I:C)-loaded liposomes. In conclusion, the applicator controlled hollow 
microneedle delivery is an excellent method for intadermal injection of nanoparticle vaccines, 
allowing selection of optimal nanoparticle formulations for humoral and cellular immune 
responses. 
Key words: Intradermal vaccination, hollow microneedles, nanoparticles, antigen, adjuvant 
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1. Introduction 
Skin is an attractive administration site for immunization and may act as an excellent 
alternative for traditional intramuscular or subcutaneous vaccination. Furthermore, 
intradermal vaccination may enable dose sparing, sice the skin has a rich network of immune 
cells compared to muscle or subcutaneous tissue [1]. However, the uppermost layer of the 
skin, the stratum corneum, is the main barrier thatprevents the transport of vaccines (>500 
Da) across the skin. Therefore, novel delivery methods need to be developed. Among various 
methods developed for antigen delivery via the skin, especially microneedle-based approaches 
have recently attracted increasing attention [2]. The major advantage of microneedles is their 
ability to pierce the skin in a minimally invasive manner and subsequently deliver their 
payload in the superficial skin layers potentially without pain, owing to the limited 
penetration depth of microneedles (typically <500 µm) [3].  
Several microneedle types have been developed for vaccine delivery, such as coated or 
dissolving microneedles which can release the dry antigen into the epidermis and dermis after 
the piercing of the skin [2]. In contrast, hollow microneedles can be used to deliver antigens 
or particulate formulations as solutions or suspensions into the skin. To this end, in our group 
a hollow microneedle device has been developed that allows precise and controlled injections 
into the epidermis and dermis by using etched fused-silica capillary-based microneedles [4-6]. 
The advantage of the hollow microneedles compared to dissolving or coated microneedles is 
that little time is required for modifying the dose, formulation or administration depth. This is 
particularly advantageous when studying optimization of formulations or parameters for the 
immunization (e.g. penetration depth or vaccine dose). Furthermore, if required a higher dose 
can be injected into the skin compared to dissolving a d coated microneedles. 
Subunit antigens are based on purified antigens and are regarded safer than traditional whole 
bacterium- or virus-based vaccines [7]. However, these antigens have often lower 
immunogenicity and therefore adjuvants, such as toll-like receptor (TLR) ligands or toxoids, 
are needed to increase the immune response [8]. Recently, nanoparticles have gained growing 
attention for the delivery of subunit vaccines because of their capability of protecting antigens 
from degradation, forming a depot at the site of injection, and facilitating antigen uptake by 
dendritic cells (DCs) [9-11]. Studies have additionally shown that co-formulation of antigen 
and adjuvant into a nanoparticle might be crucial to improve immune responses against 
subunit vaccines [12-15]. However, it is not well understood how the physicochemical 
properties such as size, material, surface charge o release behavior of antigen/adjuvant 
influence the immune response. Previously, it has been proposed that positively charged 
nanoparticles with a size smaller than about 200 nm might be optimal for the interaction with 
antigen-presenting cells [9, 16-18]. Moreover, sustained release of antigen and adjuvant from 
nanoparticles and a depot effect of nanoparticles on the cell surface could allow the co-
delivery of antigen and adjuvant to antigen-presenting cells [17, 19]. However, most 
vaccination studies have been performed by intramuscular or subcutaneous injection and no 
studies have directly compared different nanoparticles for intradermal vaccine delivery.  
The aim of this study was to assess the potential of ntigen loaded nanoparticles, with or 
without co-encapsulated adjuvant, to induce humoral and cellular immune responses after 
hollow microneedle-mediated intradermal immunization. To this end, we prepared four 
different nanoparticulate delivery systems with varying physicochemical properties, namely 
poly (lactic-co-glycolic) acid (PLGA) nanoparticles, liposomes, mesoporous silica 
nanoparticles (MSNs) and gelatin nanoparticles (GNPs). LGA nanoparticles [10, 20-24] and 
liposomes [12, 18, 22, 25] have been extensively investigated as biocompatible and 
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biodegradable nanoparticle vaccine delivery systems. MSNs gain increasing attention for 
vaccine delivery because of their controlled size and mesostructure, excellent in vivo 
biocompatibility and high loading capacity [26, 27]. Gelatin based nanoparticles have been 
studied as promising vaccine carriers because of their excellent biocompatibility, stability and 
aptness for surface modification [28-30].  
A model antigen, ovalbumin (OVA), with and without a TLR3 agonist, poly(I:C), was 
encapsulated into the nanoparticles. First, the physicochemical properties and the in vitro 
release of antigen and adjuvant of the different nanop rticulate formulations were 
characterized. Next, mice were immunized with the formulations by using a hollow 
microneedle device followed by the analysis of humoral and cellular immune responses. The 
results reveal that the immune response depends on encapsulation of antigen/adjuvant and the 
characteristics of nanoparticles. Furthermore, we demonstrate that the hollow microneedles 
together with the applicator are excellent tools for intradermal vaccination and screening of 
nanoparticulate formulations.  
2. Materials and methods 
2.1. Materials 
PLGA (acid terminated, lactide glycolide 50:50, Mw 24 – 38 kDa), gelatin from porcine skin 
(bloom 300), OVA for in vitro studies (albumin from chicken egg white, lyophilized), bovine 
serum albumin (BSA) ≥96%, gluteraldehyde, glycine, cholamine chloride hydrochloride (2-
aminoethyl)-trimethylammoniumchloride hydrochloride, 1-ethyl-3-(3-dimethyl-aminopropyl) 
carbodiimide hydrochloride (EDC), cholesterol (≥99%) and hydrofluoric acid ≥48% were 
purchased from Sigma-Aldrich (Zwijndrecht, The Netherlands). Polyvinyl alcohol (PVA) 4-
88 (31 kDa) and ethylenediaminetetraacetic acid (EDTA) were purchased from Fluka 
(Steinheim, Germany). 1-stepTM ultra 3,3',5,5'-tetramethylbenzidine (TMB) was obtained from 
Thermo-Fisher Scientific (Waltham, MA). Endotoxin-free OVA, polyinosinic-polycytidylic 
acid (poly(I:C)) (low molecular weight) and its rhodamine-labeled version were purchased 
from Invivogen (Toulouse, France). Egg phosphatidylcho ine (EggPC), 1,2-dioleoyl-sn-
glycero-3-phosphocholine (DOPC), 1,2-dioleoyl-sn-glycero-3-[phosphor-L-serine](sodium 
salt) (DOPS), 1,2-dioleoyl-3-trimethylammonium-propane chloride salt (DOTAP) and 1,2-
dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) were ordered from Avanti Polar Lipids 
(Alabaster, AL). HRP-conjugated goat anti-mouse total IgG, IgG1 and IgG2a were purchased 
from Southern Biotech (Birmingham, AL). Fluorescently labeled antibodies specific for CD4, 
CD8 and CD45.1 were ordered from eBioscience (San Diego, The Netherlands). Sulfuric acid 
(95-98%) was obtained from JT Baker (Deventer, The Netherlands). Ethyl acetate and 
silicone oil (AK350) were ordered from Boom Chemicals (Meppel, The Netherlands). 
Dimethylsulfoxide (DMSO) was ordered from Biosolve BV (Valkenswaard, The 
Netherlands). Sodium dodecyl sulfate (SDS) was purchased from Merck Millipore 
(Hohenbrunn, Germany). Vivaspin 2 centrifugal concentrators (PES membrane, MWCO 
1000 kDa) were obtained from Sartorius Stedim (Nieuw gein, The Netherlands). Sterile 
phosphate buffered saline (PBS, 163.9 mM Na+, 140.3 mM Cl-, 8.7 mM HPO4
2-, 1.8 mM 
H2PO
4-, pH 7.4) was obtained from Braun (Oss, The Netherlands). Cell culture medium was 
prepared by mixing Roswell Park Memorial Institute m dium (RPMI) with 10% Fetal bovine 
serum (FBS), 1% L-glutamine and 1% Penicillin-streptamycin. 1 mM phosphate buffer (PB, 
0.77 mM Na2HPO4, 0.23 mM NaH2PO4, pH 7.4), 10 mM PB (7.7 mM Na2HPO4, 2.3 mM 
NaH2PO4, pH 7.4), 5 mM 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES, pH 
7.4) buffer, lysis buffer (150 mM ammonium chloride, 10 mM KHCO3, 0.1 mM EDTA, pH 
7.2), and FACS buffer (2% FBS in PBS, pH7.4) were ppared in the lab. All the other 
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chemicals used are of analytical grade and Milli-Q water (18 MΩ/cm, Millipore Co.) was 
used for the preparation of all solutions. 
2.2. Preparation of nanoparticles 
2.2.1. Preparation of PLGA nanoparticles  
OVA loaded PLGA nanoparticles (PLGA-OVA) were prepared by double emulsion with 
solvent evaporation method as previously reported with modifications [31]. Briefly, 75 µl 
OVA (20 mg/ml) in PBS was dispersed in 1 ml ethyl acet te containing 25 mg/ml PLGA by 
using a Branson sonifier 250 (Danbury, CT) for 15 s with a power of 20 W. The obtained 
water-in oil-emulsion was emulsified with 2 ml aqueo s solution containing 2% (w/v) PVA 
with the sonifier (15 s, 20 W). The water-in-oil-in-water double emulsion was added 
dropwisely into 25 ml 0.3% (w/v) PVA (40 °C) under stirring. The ethyl acetate was 
evaporated by a rotary evaporator (Buchi rotavapor R210, Flawil, Switzerland) for 3 h (150 
mbar, 40 °C). The nanoparticles were collected by centrifugation (AvantiTM J-20XP 
centrifuge, Beckman Coulter, Brea, CA) at 35000 g for 10 min. Finally, they were washed 
twice with 1 mM PB to remove the excess OVA and PVA and dried in an ice condenser 
(Alpha 1-2, Osterode, Germany) in freeze vacuum (-49 °C, 90 mbar) overnight for further use 
and storage. 
To prepare OVA and poly(I:C) co-encapsulated PLGA nanoparticles (PLGA-OVA-PIC), 
18.75 μl OVA (40 mg/ml) and 75 μl poly(I:C) (46.7 mg/ml, including 0.03% fluorescently 
labeled equivalent) were emulsified with 1 ml PLGA (25 mg/ml) in ethyl acetate to obtain the 
water-in-oil emulsion. The rest of the procedure was identical to that of PLGA-OVA.  
2.2.2. Preparation of liposomes 
Liposomes were prepared by a film hydration method [32]. A thin lipid film of EggPC: 
DOPE: DOTAP in a molar ratio of 9:1:2.5 was created by evaporating chloroform of lipid 
stock solutions (25 mg/ml) using a rotary evaporator (Buchi rotavapor R210, Flawil, 
Switzerland). To prepare OVA loaded liposomes (Lipo-OVA), the lipid film was rehydrated 
in 10 mM PB (pH 7.4) containing 0.25 mg/ml OVA, and subsequently stabilized at room 
temperature for 1 h, resulting in final lipid concetration of 12.5 mg/ml. In the case of OVA 
and poly(I:C) co-encapsulated liposomes (Lipo-OVA-PIC), after lipid film hydration, 250 µl 
poly(I:C) solution (1.32 mg/ml, containing 0.5% rhodamine-labeled poly(I:C)) was added 
slowly (2 µl/min) by using a syringe pump to the liposome suspension under stirring. Finally, 
the liposomes were extruded (LIPEXTM extruder, Northern Lipids, Burnaby, Canada) four 
times through a carbonate filter with a pore size of 400 nm and another four times through a 
filter with a pore size of 200 nm (Nucleopore Millipore, Amsterdam, The Netherlands). The 
obtained suspensions were transferred into VivaSpin 2 centrifuge concentrators (1000 kDa 
MWCO) and centrifuged (Allegra X-12R, Beckman Coulter, Indianapolis, IN) twice for 7 - 8 
h (350 g, 22 °C) to remove the excess OVA and poly(I:C) [18]. The liposome suspensions 
were collected and stored at 4 °C until further use.  
2.2.3. Preparation of MSNs  
Large pore MSNs were synthesized and used for the loading of antigen and adjuvant as 
described earlier [33]. To improve the colloidal stability of antigen loaded MSNs, negatively 
charged liposomes were fused to the surface of MSNs, as reported previously [34, 35]. For 
this purpose liposomes were prepared by dispensing stock solutions of DOPC (70 µl, 25 
mg/ml), DOPS (20 µl, 12.5 mg/ml) and cholesterol (10 µl, 25 mg/ml) in chloroform into 
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scintillation vials. A lipid film was created by slow evaporation of chloroform in the vial 
under a nitrogen flow and dried in vacuum overnight. The lipid film was rehydrated by the 
addition of 1 ml of 1mM PB (pH 7.4) and the mixture was vortexed for 10 s to form a cloudy 
lipid suspension. The obtained suspension was sonicated in a water bath for 10 min. The 
resulting clear liposome dispersions were stored at 4 °C for further use. 
To prepare lipid bilayer coated and OVA encapsulated MSNs (LB-MSN-OVA), OVA (0.5 
ml, 0.25 mg/ml) in 1 mM PB (pH 7.4) was first transferred into a 2 ml micro-centrifuge tube, 
followed by the addition of MSNs (0.5 ml, 1 mg/ml) and liposomes (0.5 ml, 2 mg/ml). For 
OVA and poly(I:C) co-encapsulated and lipid coated MSNs (LB-MSN-OVA-PIC), 0.5 ml 
solution containing 0.25 mg/ml OVA and 0.094 mg/ml poly(I:C) (containing 1.2% 
rhodamine-labeled poly(I:C)) were mixed with MSNs and liposomes similarly to LB-MSN-
OVA. The resulting mixtures were incubated for 1.5 h under shaking (400 rpm, 25 °C). The 
nanoparticles were collected and excess liposomes, OVA and poly(I:C) were removed by 
centrifuging the sample (9000 g, 5 min) with a Sigma 1-15 centrifuge (Osterode, Germany). 
The obtained nanoparticles were stored at 4 °C before the use.  
2.2.4. Preparation of GNPs 
GNPs were prepared by using a two-step desolvation method as previously described [36]. 
First, 1.25 g gelatin (cationic, pI 7-9) was dissolved in 25 ml ultrapure water at 50 °C while 
stirring at 600 rpm for 30 min. The first desolvation step was carried out by addition of 25 ml 
acetone. The mixture was left for 1 h until the gelatin precipitated. The supernatant was 
discarded and the sediment was re-dissolved in 25 ml ultrapure water at 50 °C while stirring at 
250 rpm for 30 min. Subsequently, the pH of the soluti n was adjusted to 2.5 by using 
concentrated HCl and a second desolvation step was performed by drop-wise (0.1 ml/s) 
addition of 80 ml acetone at 50 °C while stirring at 1200 rpm. The crosslinking of the GNPs 
was accomplished by adding 25 (w/w)% glutaraldehyde (GA) solution. The amount of added 
GA was adjusted such that the molar ratio between the NH2 groups of gelatin and GA 
molecules was 1:1. Calculations were performed based on the assumptions that MWgelatin = 
100 kDa and 1 mol gelatin has 37 mol NH2 [36]. The resultant suspension was stirred at 600 
rpm for 16 h at room temperature. Next, an equal volume of 100 mM glycine solution was 
added to the suspension to block the unreacted GA and stop the cross-linking reaction. The 
suspension was stirred for 1 h at room temperature before being centrifuged at 7000 g for 1 h 
(AvantiTM J-20XP centrifuge, Beckman Coulter, Brea, CA) to separate the GNPs from the 
reaction mixture. The GNPs were rinsed with ultrapue water in three rounds of centrifugation 
and resuspension. The obtained GNPs were cationized to increase the positive surface charge 
and consequently enhance the loading of OVA and poly(I:C). Briefly, the pH of GNP 
suspension was adjusted to 4.5 and the quaternary amine cholamine (10% of the weight of 
GNPs) was added under constant stirring. After 5 min, EDC (10% of the weight of GNPs) 
was added to the suspension to activate the carboxylic groups of gelatin which would couple 
cholamine. The mixture was stirred for 3 h at room te perature. The cationized GNPs were 
purified by three successive centrifugation steps as described above. Finally, the nanoparticles 
were resuspended in ultrapure water by using vortexing and probe sonication [37], and stored 
at 4 °C for further experiments. 
To prepare OVA loaded GNPs (GNP-OVA) for the humoral response study, 100 µg OVA in 
water was added to 2000 µg GNPs in water (total volume 1 ml) and the samples were mixed 
for 1 h (400 rpm, 25ºC). For OVA and poly(I:C) co-loaded GNPs (GNP-OVA-PIC), after 
shaking OVA and GNPs for 1 h, 100 µg poly(I:C) (contai ing 1% rhodamine-labeled 
poly(I:C)) was added to the GNP suspension and the suspension was mixed for another 1 h. 
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Finally, the loaded nanoparticles were separated by centrifugation at 2800 g for 5 min, 
followed by re-suspension in de-ionized water. For the cellular response study, a modification 
of the method was required to allow administration of a higher dose. Instead of water, 4 mM 
HEPES buffer (pH 7.4) was used for loading to contrl the pH. For GNP-OVA the added 
amounts of GNPs and OVA were 6000 µg and 300 µg (in 1.5 ml), respectively, and for GNP-
OVA-PIC, the amounts of GNP, OVA and poly(I:C) were 7000 µg, 200 µg and 200 µg (in 
1.5 ml), respectively. The modification did not significantly change the characteristics of 
nanoparticles.  
2.3. Characterization of the nanoparticles 
2.3.1. Particle size and zeta potential determination 
The particle size and polydispersity index (PDI), and zeta potential for all formulations were 
determined by dynamic light scattering and laser doppler velocimetry, respectively, by using a 
Nano ZS® zetasizer (Malvern Instruments, Worcestershire, U.K.). Particle size measurements 
were performed in 10 mM PB (pH 7.4) (PLGA nanoparticles, liposomes and MSNs) or 
ultrapure water (GNPs), while for zeta potential measurements samples were diluted in 5 mM 
HEPES buffer (pH 7.4).  
2.3.2. Morphological characterization 
Morphology of PLGA nanoparticles and GNPs was visual zed by using scanning electron 
microscopy (SEM, Nova NanoSEM, FEI, Eindhoven, The Netherlands) with a voltage of 15 
kV. Nanoparticles were first freeze-dried and coated with a thin layer of carbon. MSNs were 
visualized by transmission electron microscopy (TEM) using a JEOL 1010 instrument (JEOL 
Ltd, Peabody, MA) with an accelerating voltage of 70 kV. To prepare the samples, several 
droplets of MSN suspension (1 mg/ml) were added on a copper grid, dried overnight and 
coated with carbon. Liposomes were visualized by Cro-EM. The samples were diluted to 5 
mg/ml and drops of 3 µl were applied to 300 mesh EM grids with lacey carbon (Ted Pella, 
USA). Grids were transferred into an electron micros opy grid plunger (EM GP, Leica, 
Germany) operated at room temperature and 100% humidity. The sample was vitrified by 
removing excess liquid immediately followed by plunging into liquid ethane and the plunge-
frozen grids were stored in liquid nitrogen until further use. Samples were inserted into a 
Gatan 626 cryo holder (Gatan, Pleasanton, CA). A Tecnai F20 microscope (Thermo-Fisher, 
Eindhoven, The Netherlands) was operated at 200 kV and the EM images were recorded at 
defocus values between 1 and 3 micron underfocus on a Gatan 4k x 4k CCD (Gatan, 
Germany). 
2.3.3. Determination of loading efficiency of OVA and poly(I:C) 
To determine the loading efficiency of OVA and poly(I:C) in PLGA nanoparticles, the 
nanoparticles were dissolved in a mixture of 15% (v/v) DMSO and 85% (v/v) 0.05 M NaOH 
and 0.5% SDS. The amount of OVA was quantified by the microBCA method following the 
manufacturer’s instructions. The amount of poly(I:C) was determined by the fluorescence 
intensity of rhodamine labeled poly(I:C) (λex 545 nm/λem 576 nm) with a plate reader (Tecan 
M1000, Männedorf, Switzerland). The loading efficiency of OVA in liposomes, MSNs and 
GNPs was determined by measuring its intrinsic fluorescence intensity (λex 280 nm/λem 320 
nm) with the Tecan M1000 plate reader in the supernatant before and after the encapsulation 
(MSNs and GNPs) or in the purification filtrates (liposomes). The loading efficiency of 
poly(I:C) in these nanoparticles was quantified similarly by measuring the fluorescence of its 
rhodamine labeled equivalent (λex 545 nm/λem 576 nm).  
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The encapsulation efficiency (EE) and loading capacity (LC) of OVA and poly(I:C) in the 
nanoparticles were calculated as below: 
EE % =
 	!"! #$%/' ((*:,) 
..	  #$%/' ((*:,)
 × 100 %                                                   (1) 
LC % =
 	!"! #$%/' ((*:,) 
/	/'	0.12 "34#$%4' ((*:,)
 × 100 %                                            (2) 
Where Mloaded OVA/poly(I:C) represents the mass of loaded OVA or poly(I:C), Mtotal OVA/poly(I:C) is 
the total amount of OVA or poly(I:C) added to the formulations and Mnanoparticles+OVA+poly(I:C) is 
the total weight of nanoparticles, OVA and poly(I:C).  
2.3.4. In vitro release studies 
To study the release of OVA and poly(I:C), the nanoparticles were dispersed in PBS and 
shaken by using an Eppendorf thermomixer (Nijmegen, The Netherlands) at 37 °C with a 
speed of 550 rpm. The concentration for PLGA nanoparticles, liposomes, MSNs and GNPs 
after the suspension was 3 mg/ml, 5 mg/ml (lipid concentration), 1 mg/ml and 1.3 mg/ml, 
respectively. At predetermined time intervals, the tubes were taken out of the shaker bath and 
centrifuged at 10000 g for 10 min (PLGA nanoparticles and MSNs) or at 2800 g for 5 min 
(GNPs). A release sample of 600 µl was taken from the supernatant and replaced by fresh 
release medium. In the case of liposomes, 300 µl sample was collected to Vivaspin 500 
concentrators. After the centrifuging (350 g, 30 min), the filtrate was collected and replaced 
with fresh medium. The amount of released OVA and poly(I:C) were determined by intrinsic 
fluorescence of OVA (λex 280 nm/λem 320 nm) and fluorescence of rhodamine labeled 
poly(I:C) (λex 545 nm/λem 576 nm), respectively, using a Tecan M1000 plate reader. The 
amount of released OVA in PLGA nanoparticles was determined by the MicroBCA method. 
2.4. Hollow microneedles and applicator 
Hollow microneedles were prepared as described earlier [38]. Briefly, 4-cm pieces of 
polyimide-coated fused silica capillaries (Polymicro, Phoenix AZ, 375 µm outer diameter, 50 
µm inner diameter) were first filled with silicone oil in a vacuum oven (100 °C) overnight and 
subsequently etched for 4 h in ≥48% hydrofluoric acid. The polyimide coating was removed 
from the etched ends of capillaries by dipping them into heated (250 °C) sulfuric acid for 5 
min.  
A hollow-microneedle applicator was used to control the injection depth and volume as 
previously reported [5]. A 100-μl syringe with an inner diameter of 1.46 mm was used in 
conjunction with a syringe pump (NE-300, Prosense, Oosterhout, The Netherlands) and silica 
capillaries. High-pressure resistant CapTiteTM connectors were used to connect the pump, 
syringe, capillaries and needles.  
2.5. Immunization studies 
Female BALB/c mice (H2d) and C57BL/6 mice (H2b) were used for the antibody response 
and T-cell response study, respectively. The mice were 7-8 weeks old at the beginning of the 
experiment. All the mice were purchased from Charles Rivers (Maastricht, The Netherlands) 
and were housed under standardized conditions in the animal facility of Leiden Academic 
Centre for Drug Research of Leiden University. Experim nts were approved by the ethical 
committee on animal experiments of Leiden University (Licence number 14176). 
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2.5.1. Antibody response study 
BALB/c mice were anesthetized by intraperitoneal injection of ketamine (60 mg/kg) and 
xylanize (4 mg/kg), which was followed by the shaving of the injection site. At the same day 
mice (n = 8/group) were immunized by an intradermal injection of 10 µl nanoparticles loaded 
with 0.31 µg OVA, with or without approximately 0.31 µg poly(I:C), on the flank of the 
mouse by using the applicator, as described above. Solutions of 0.31 µg OVA, with or 
without 0.31 µg poly(I:C), were used as controls. The injection depth was set to about 120 
µm. In addition, subcutaneous injection of 0.31 µg OVA (100 µl) was used as another control. 
Mice were immunized on day 0 (prime), day 21 (1st boost) and day 42 (2nd boost), and 
sacrificed on day 49. Before each immunization, on the same day, a venous blood sample was 
collected from the tail to measure the antibody respon es. Before the sacrifice, the blood 
sample was collected from the femoral artery. 
2.5.2. T cell response study 
OT-I (OVA-specific CD8+) and OT-II (OVA-specific CD4+) T cell transferred C57BL/6 mice 
were used for the T cell response study. To obtain OT-I and OT-II T cells, spleens of OT-I 
and OT-II transgenic mice (CD45.1) were isolated ansi gle cell suspensions were obtained 
by forcing the spleens through a 70 um strainer. After erythrocyte depletion with ammonium 
chloride, percentage of CD8+/Valpha2+ or CD4+/Valpha2+ cells was determined by flow 
cytometry (BD FACSCanto-II, San Jose, CA). An equivalent of 8000 OT-I and 56000 OT-II 
cells were intravenously transferred through the tail vein into C57BL/6 mice. Next day, the T 
cell transferred mice were immunized with nanoparticle formulations. OVA and poly(I:C) 
solutions were used as controls. Before the immunization, mice were anesthetized by 
isoflurane inhalation (induction 4-5% and maintenance 1%), which was followed by shaving 
of the injection site. On the same day, mice (n = 5/group) were immunized by three 
intradermal injections of 13.3 µl (totally 40 µl) formulation containing 5 µg OVA with or 
without approximately 5 µg poly(I:C) on the flank of the mouse (two injections on the right 
side, one injection on the left side) by using the hollow-microneedle applicator as described 
above. 7 days after the immunization, venous blood sample was collected from the tail to 
analyze the T cell response. 
2.6. Determination of OVA specific IgG antibodies 
OVA-specific antibodies were analyzed by a sandwich enzyme-linked immunosorbent assay 
(ELISA) as described earlier [39]. Briefly, wells of the 96 well-plates were first coated with 
500 ng OVA for 1.5 h at 37 °C. The plates were blocked by incubation with 1% (w/v) BSA 
for 1 h at 37 °C. After the blocking, appropriate three-fold serial dilutions of mouse sera were 
applied to the plates and incubated for 1.5 h at 37 °C. Then the plates were incubated with 
horseradish peroxidase-conjugated goat antibodies against IgG, IgG1 and IgG2a (1:5000 
dilution) for 1 h at 37 °C. Finally, specific antibodies were detected by TMB. The absorbance 
was measured at 450 nm (Tecan M1000) and the antibody titer was determined as a log10 
value of the mid-point dilution of S-shaped dilution-absorbance curve of the diluted serum 
level.  
2.7. CD4+ and CD8+ T cell responses 
The erythrocytes of the blood sample (100 µl) were first lysed by incubating samples with 3 
ml lysis buffer for 6 min in ice, followed by addition of 5 ml cell culture medium. After the 
centrifugation (5 min, 500 g), the supernatant was discarded and the samples were suspended 
in 5 ml FACS buffer. Next, samples were centrifuged and 200 µl of cell suspension was 
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added to the 96-well plate after discarding the supernatant. The cell surfaces were stained by 
incubating the cells with 100 µl diluted (1:800) fluorescently labeled antibodies specific for 
CD45.1 (eFluor450), CD4 (APC) and CD8α (PerCP) for 30 min (100 µl/well). After 30 min 
incubation at 4 °C, the excess antibodies were washed by using FACS buffer. The cells were 
incubated with fixation and permeabilization solution (BD Biosciences) for 10 min at 4 °C. 
Finally, the cells were washed with FACS buffer and analyzed by flow cytometry (BD 
FACSCanto-II, San Jose, CA). The data were analyzed by using FlowJo software. 
2.8. Statistical analysis 
All the data of immunization studies were analyzed by one way ANOVA with Bonferoni’s 
post-test by using GraphPad Prism software (version 5.02). The level of significance was set 
at p<0.05. 
3. Results 
3.1. Physicochemical characterization of nanoparticles 
Table 1. Physicochemical characteristics of OVA/poly(I:C) loaded nanoparticles. 
Nanoparticles Size
a 
(nm) PDI
b ZP
c 
(mV) 
EEd % LC e % 
OVA Poly(I:C) OVA Poly(I:C)  
PLGA-OVA 157±7 0.060±0.028 -18±1 64.7±4.8 - 6.9±0.5 - 
PLGA-OVA-
PIC 
160±1 0.052±0.019 -22±4 76.7±2.0 13.9±4.2 2.7±0.7 3.0±0.9 
Lipo-OVA 124±15 0.152±0.026 44±2 97.0±2.4 - 1.6±0.1 - 
Lipo-OVA-PIC 171±9 0.270±0.040 41±1 92.1±5.6 98.6±2.3 1.5±0.1 1.6±0.1 
LB-MSN-OVA 656±5 0.280±0.018 -33±3 73.8±5.7 - 15.6±1.2 - 
LB-MSN-OVA-
PIC 
603±17 0.318±0.040 -38±3 34.4±3.3 64.9±14.6 7.9±0.8 5.9±1.3 
GNP-OVA 507±31 0.131±0.116 21±2 90.9±14.2 - 4.3±0.7 - 
GNP-OVA-PIC 757±235 0.320±0.179 8±12 96.8±4.3 95.0±4.4 3.5±0.9 3.4±1.0 
Data are average ± SD of at least 3 independent batches.  
aSize: Z-average in diameter, bPDI: poly dispersity index, cZP: zeta potential, dEE: 
encapsulation efficiency, eLC: loading capacity. 
Four different nanoparticle formulations (PLGA nanoparticles, liposomes, MSNs and GNPs) 
were developed and characterized in terms of size, zeta potential, surface morphology, and 
loading and release properties of encapsulated antigen and adjuvant. Physicochemical 
characteristics of the nanoparticles are summarized in Table 1. According to DLS, PLGA 
nanoparticles and liposomes had an average diameter b tween 120 nm and 170 nm with a PDI 
value below 0.1 (PLGA nanoparticles) and 0.3 (liposomes). MSNs and GNPs had a larger 
diameter, ranging from 500 nm to 760 nm, and PDI values between 0.1 and 0.3. The electron 
microscopy images revealed a spherical shape of PLGA nanoparticles, liposomes and GNPs, 
whereas MSNs had a rectangular shape with mesochannels along the short axis (Fig. 1). The 
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estimated size based on electron microscopy images is consistent with the size in Table 1 for 
PLGA nanoparticles and liposomes. MSNs had a smaller particle size in TEM images than in 
DLS measurements, indicating the presence of aggregates in these nanoparticle suspensions. 
In the case of GNPs, particles are swelling in aqueous medium [40], which may explain the 
smaller particle size in SEM images as compared to DLS.  
PLGA nanoparticles and MSNs had a negative zeta potential, whereas liposomes and GNPs 
possessed a positive zeta potential. In general, co-en apsulation of poly(I:C) did not 
substantially affect the size, the PDI and zeta potential of the nanoparticles (Table 1). 
Moreover, both OVA and poly(I:C) were efficiently encapsulated into the nanoparticles. The 
EE% of OVA reached more than 60% for all nanoparticles except LB-MSN-OVA-PIC (34%) 
(Table 1). Similarly, poly(I:C) had a EE% higher than 60%, except for PLGA nanoparticles 
(13.9%). During the development of the preparation process of the nanoparticles, the 
introduced amounts of antigen and adjuvant were optimized to obtain similar loading 
capacities of OVA and poly(I:C) for each delivery system (Table 1). 
 
 
Figure 1. Electron microscope images of nanoparticles. A) Scanning electron microscopy 
(SEM) image of PLGA nanoparticles; B) Cryo-EM image of liposomes; C) Transmission 
electron microscopy (TEM) image of MSNs; D) SEM image of GNPs. 
3.2. In vitro release of OVA and poly(I:C) from nanoparticles 
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Figure 2. Release profiles of OVA (A) and poly(I:C) (B) from PLGA nanoparticles 
(blue/spheres), liposomes (purple/diamonds), MSNs (green/triangles) and GNPs 
(brown/squares) in PBS at 37 ˚C. Open and closed symbols correspond to poly(I:C)-
containing and poly(I:C)-free nanoparticles, respectiv ly. Data points represent mean ± SD, n 
= 3.  
To determine the release properties of OVA or poly(I:C) from the nanoparticles, the particles 
were dispersed in PBS and the released amount of OVA or poly(I:C) was measured at regular 
time intervals during one month (Fig. 2). PLGA nanoparticles slowly released OVA and on 
day 30, approximately 13% and 20% of the encapsulated OVA were released from PLGA-
OVA and PLGA-OVA-PIC, respectively. Poly(I:C) release followed the OVA release and 
approximately 20% of the encapsulated poly(I:C) wasreleased during one month. Liposomes 
released about 30% OVA on the first day, followed by a slow release to 40% during one 
month. Approximately 12% poly(I:C) was slowly releas d from liposomes during one month. 
MSNs showed a burst release of approximately 40% OVA within the first 6 h, followed by a 
slower and linear release phase from 40% to almost 100% in the subsequent two weeks. The 
release of poly(I:C) was slower and only 30% poly(I:C) was released from LB-MSN-OVA-
PIC within 15 days. GNPs showed a burst release of nearly all loaded OVA and poly(I:C) 
within 2 h, followed by a slow release until 4 days. 
3.3. Antibody responses after intradermal immunization 
 
Figure 3. OVA-specific total IgG antibody titers measured in BALB/c mice on day 21 (A), 
day 42 (B) and day 49 (C). Bars represent mean ± SEM, n = 8. *p < 0.05, **p < 0.01, *** p < 
0.001. All the formulations were injected intradermally, except the subcutaneous control of 
Intradermal vaccination with hollow microneedles: a comparative study of various protein 
antigen and adjuvant encapsulated nanoparticles 
71 
 
OVA solution (OVA S.C.). Groups without a bar showed titers below the detection limit of 
the ELISA. 
 
First, it was examined whether intradermal vaccinatio  with solutions or nanoparticles 
containing 0.31 µg OVA with or without poly(I:C) (~0.31 µg) (Table 1) can induce antigen 
specific antibodies. The dose of antigen was chosen based on a dose response study (data not 
shown). As shown in Fig. 3, all groups, except the subcutaneous control of OVA solution, 
showed a detectable total IgG response on day 21, and the highest response was detected for 
the PLGA-OVA-PIC group (Fig. 3A). The total IgG levels increased after the boost on day 21 
(Fig. 3B) and 42 (Fig. 3C). All studied nanoparticle formulations and OVA or OVA-poly(I:C) 
solutions gave similar total IgG responses, except for PLGA-OVA. These nanoparticles 
showed significant weaker total IgG responses on day 42 and 49, but co-encapsulation of 
poly(I:C) in PLGA nanoparticles increased significantly total IgG titers to similar levels 
observed with the other nanoparticle suspensions. In conclusion, the nano-encapsulation of 
OVA or co-encapsulation of OVA and poly(I:C) did not lead to enhanced total IgG titers.  
Next, the subtype IgG1 and IgG2a titers were determined (Fig. 4). The IgG1 titers followed 
the trend of total IgG titers (Fig. 4A, C, E) and similarly the encapsulation of OVA or co-
encapsulation of OVA and poly(I:C) did not increase th  IgG1 response. However, the 
encapsulation of OVA, and particularly co-encapsulation of OVA and poly(I:C), strikingly 
increased the IgG2a response compared to OVA and poly(I:C) solution (Fig. 4B, D, F) 
(except GNP-OVA-PIC). Furthermore, liposomes and PLGA nanoparticles showed higher 
IgG2a responses than MSNs and GNPs (Fig. 4F). Specifically, on day 21 only PLGA-OVA-
PIC induced an IgG2a response (Fig. 4B). After each boosting on day 21 (Fig. 4D) and 42 
(Fig. 4F), there were more groups having an IgG2a response. On day 42, after prime and one 
boost, all OVA and poly(I:C) co-encapsulated nanoparticles, except GNP-OVA-PIC, showed 
an IgG2a response (Fig. 4D). After the second boost, on day 49, all the groups, except OVA 
solution, induced a measurable IgG2a response (Fig. 4F). These results illustrate that 
encapsulation of OVA especially co-encapsulation of OVA and poly(I:C) in nanoparticles is 
critical for enhancement of IgG2a response but the magnitude of this effect depends on the 
type of nanoparticles. 
The higher IgG2a responses observed with liposomes and PLGA nanoparticles suggested that 
these formulations may be able to trigger cellular immune responses more effectively. To 
study the efficacy of the developed nanoparticle formulations to induce T cell mediated 
immunity in vivo, OT-I (OVA specific CD8+ T cells) and OT-II (OVA specific CD4+ T cells) 
cells were transferred into C57BL/6 mice before intradermal vaccination. Seven days after the 
immunization T cell responses in blood were analyzed by flow cytometry with gating strategy 
shown in Fig. 5A. Lipo-OVA-PIC evoked significant higher CD8+ T cell responses than OVA 
and poly(I:C) solution and the other nanoparticle formulations (Fig. 5B), suggesting efficient 
induction of CTL responses by liposomes. In general, n no-encapsulation of OVA or co-
encapsulation of OVA and poly(I:C) increased the CD8+ response compared to OVA or 
OVA-poly(I:C) solution. In the case of CD4+ T cell response, Lipo-OVA-PIC and LB-MSN-
OVA-PIC induced the strongest response (Fig. 5C). OVA loaded nanoparticles induced 
similar CD4+ response compared to OVA solution. Poly(I:C) co-encapsulation slightly 
increased CD4+ responses compared to OVA-loaded nanoparticles but only in the case of 
liposomes the improvement was significant. Furthermore, the Lipo-OVA-PIC formulation 
induced a significantly higher CD4+ response than OVA and poly(I:C) solution.  
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Figure 4. OVA-specific IgG1 (A, C, E) and IgG2a (B, D, F) antibody titers measured in 
BALB/c mice on day 21 (A, B), 42 (C, D) and 49 (E, F). Bars represent mean ± SEM, n = 8. 
*p < 0.05, **p < 0.01, *** p < 0.001. All the formulations were injected intradermally, except 
the subcutaneous control of OVA solution (OVA S.C). Groups without a bar showed titers 
below the detection limit of the ELISA. 
3.4. T cell responses after intradermal immunization 
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Figure 5. OVA-specific T cell responses. (A) An example of the flow cytometry gating 
strategy used to determine the T cell responses. Lymphocytes were gated on forward/sideward 
scatter, followed by the exclusion of double or adhering cells. After pregating on CD4+ or 
CD8+ T cells, the percentage of respectively OT-II and OT-I were measured by gating on 
CD45.1+ cells. OVA specific CD8+ (B) and CD4+ (C) responses of transferred OT-I and OT-
II cells in mouse blood 7 days after the immunization (mean ± SEM, n = 5). *p < 0.05, **p < 
0.01, *** p < 0.001. 
4. Discussion 
In recent years, nanoparticles have been intensively nvestigated as vaccine delivery systems 
because of their advantages, such as protection of a tigen from degradation, increased antigen 
uptake by dendritic cells and the ability to co-deliv r antigen and adjuvant [10, 22, 41]. 
Nanoparticles also offer the possibility to adjust the type of immune response by modifying 
the nanoparticle characteristics such as size, surface charge and antigen release profile [10]. 
Numerous studies have indicated that nanoparticles an be used to modulate the immune 
response [9, 10, 12, 15, 17, 18, 20, 22, 25, 39, 42]. Owing to its high density of antigen-
presenting cells, the skin could be an attractive sit of administration of nanoparticulate 
vaccines. However, relatively little is known about the effect of nanoparticulate vaccines after 
(microneedle-mediated) intradermal vaccination. Therefore, in this study, we used hollow 
microneedles together with an applicator to examine the effect of nano-encapsulation of 
antigen and adjuvant on both the humoral and cellular response in mice. Our results showed 
that antigen and adjuvant loaded nanoparticles were successfully delivered intradermally in 
mice by using hollow microneedles together with theapplicator, leading to an effective 
nanoparticle-dependent immune response. Furthermore, after co-encapsulation of OVA and 
poly(I:C) into nanoparticles, the immune response was modulated towards a Th1 direction.  
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Previously, the in-house developed hollow microneedle/applicator system has been used for 
immunization with inactivated virus [4-6]. In these tudies we used hollow microneedles with 
a bore diameter of 20 µm. However, the system has not been used with nanoparticles with 
larger size (>100 nm). Therefore, the injection of nanoparticles through the system was tested 
in vitro (data not shown) prior to the in vivo studies presented here. These pilot studies 
showed that the hollow microneedles could be blocked due to occasional nanoparticle 
aggregation if the bore diameter was 20 µm. By increasing the bore diameter to 50 µm, this 
problem could be circumvented since increase of the bore diameter decreases particle 
obstruction in the CapTiteTM connectors in the system. Consequently, there was no blockage 
or leakage of formulation during the immunization studies. The success of intradermal 
injection was confirmed by the formation of a bleb at the injection site after each injection. 
Furthermore, no adverse effects, such as erythema or skin induration, were observed at the 
injection site during the studies.  
Intradermally administered OVA/poly(I:C) loaded nanoparticles did not increase the total IgG 
response compared to administration of antigen/adjuv nt alone. These results indicate that the 
encapsulation of OVA or co-encapulation of OVA and poly(I:C) is not required for a strong 
IgG response following intradermal administration. This may be caused by the efficient 
uptake of the free antigen/adjuvant by antigen-presenting cells in epidermis and dermis 
(Langerhans cells and dendritic cells) and lymph nodes beneath the skin. Additionally, 
poly(I:C) has been shown to strongly improve CD8 responses rather than IgG responses [43-
45]. In case of PLGA nanoparticles, PLGA-OVA showed even a lower total IgG response 
than OVA alone. This may be due to a change in the tertiary structure of OVA, either during 
preparation or in the acidic environment of PLGA nanoparticles during the degradation of the 
polymer after administration [46, 47]. Furthermore, in the current study the OVA dose was 
much lower (0.31 µg) compared to the dose used in previous studies (e.g. > 5 µg) [27, 42, 48]. 
The low dose can magnify the detrimental effect of partial OVA degradation in PLGA 
nanoparticles. 
Our results clearly show that co-delivery of the antigen and adjuvant in nanoparticles, 
increased significantly the IgG2a antibody response compared to OVA/poly(I:C) solution. 
This indicates that the nanoparticles skewed the immune response of the antigen more 
towards a Th1 direction [39]. Interestingly, PLGA nanoparticles and liposomes induced 
higher IgG2a responses than GNPs and MSNs. There ar at least two possible underlying 
factors that may play a role. i) The higher IgG2a response is in line with the slower release of 
OVA and poly(I:C) from PLGA nanoparticles and liposomes. The sustained release can allow 
the co-processing of adjuvant and antigen within the same antigen-presenting cell, which is 
suggested to be crucial for a higher IgG2a response [15, 19, 22]. Differences in release 
behavior of OVA/poly(I:C) between the nanoparticles may stem from the differences in the 
location of the antigen and adjuvant in nanoparticles and in the strength of the interaction 
between antigen/adjuvant and the nanoparticle matrix. On the one hand, in PLGA 
nanoparticles and liposomes the antigen/adjuvant is mixed with nanoparticle precursors 
during synthesis, and the antigen/adjuvant is expected to be localized inside the matrix of 
PLGA nanoparticles or in the aqueous core layer of lip somes. Therefore, it is likely that the 
antigen/adjuvant is mostly released after the nanoprticles are taken up and processed by 
antigen-presenting cells or degraded. On the other hand, with GNPs and MSNs the loading of 
antigen/adjuvant is done post-synthesis through adsorption of the antigen/adjuvant onto the 
surface of nanoparticles, presumably based on electrosta ic interactions. In addition, in MSNs 
interactions are expected to occur also between OVA/poly(I:C) and the stabilizing lipid 
bilayer. Antigen and adjuvant loaded in MSNs and GNPs are sensitive to environmental 
conditions, such as salts and endogenous proteins present in the skin tissue, that can accelerate 
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the release. As a result, the release of antigen/adjuv nt from MSNs and GNPs can be faster 
than that from PLGA nanoparticles and liposomes, as suggested by the in vitro release data. 
Premature release can consequently lead to separate uptake and processing of antigen and 
adjuvant by different antigen-presenting cells. ii) The size of PLGA nanoparticles and 
liposomes (less than 200 nm) is substantially smaller than that of MSNs and GNPs (above 
500 nm). Although single MSNs had a size below 200 nm, as shown by TEM images [33], 
DLS showed a larger diameter, indicating the aggregation of MSNs. Smaller particles with a 
size below 200 nm are expected to be more efficiently taken up by dendritic cells than bigger 
particles [16]. Moreover, large nanoparticles (500-20 0 nm) have been shown to be mostly 
associated with dendritic cells at the injection site after intradermal delivery, while small (20-
200 nm) nanoparticles are able to drain to lymph nodes and target there the dendritic cells 
[49]. Therefore, the higher IgG2a response induced by the OVA/poly(I:C) loaded PLGA 
nanoparticles and liposomes could be due to their better uptake by dendritic cells and faster 
trafficking to the lymph nodes.  
As IgG2a levels merely give an indication of the extent of IFN-γ induced isotype switching, 
we also directly assessed the capacity of each type of nanoparticulate formulation to induce 
CD8+ and CD4+ T cell responses in OT cell transferred mice. The number of transferred OT 
cells were kept low as an excess of transgenic T-cells have previously been shown to alter the 
T-cell response [50]. Our results showed that the Lipo-OVA-PIC formulation showed an 
exceptional high capacity to induce both CD8+ and CD4+ T cell responses, in line with the 
data from previous studies [18, 48]. The DOTAP based cationic liposomes have been shown 
to be very effective for the induction of CTL responses [9, 12, 18], as the cationic lipids 
promote the activation and maturation of dendritic cells and subsequently the T cell priming. 
Moreover, EggPC, the main lipid component of the prsent liposomes, has been shown to 
facilitate antigen presentation by enhancing peptid binding to MHC class II molecules [51]. 
So, the superior immune responses of liposomes may be caused by the properties of the lipids. 
As explained above, MSNs and GNPs may not be able to nhance the immune response 
because of their fast release of OVA/poly(I:C) and large size. In case of PLGA-OVA-PIC 
group, our data showed that the co-encapsulation of OVA and poly(I:C) did not increase the T 
cell responses. This is in contrast to previous reports [12-14], which have shown that the co-
encapsulation of OVA and poly(I:C) in PLGA nanoparticles can induce a strong CTL 
response after intramuscular or subcutaneous vaccination. This indicates that vaccine 
formulations that provide potent immune responses after intramuscular or subcutaneous 
administration, may be less suitable for intradermal delivery, reemphasizing the need for 
route-specific optimization of vaccine formulations [12, 18, 42]. Furthermore, targeting of 
different skin layers may also affect immune responses, as shown in previous studies [52, 53]. 
Nowadays, there is an increasing need of efficient Th1/CTL immune response, for example, 
in therapeutic vaccinations for cancer [13, 17, 45] and intracellular pathogens [14, 21]. Our 
results indicate that cationic liposomes are very promising nano-carriers to induce a superior 
Th1/CTL immune response compared to the other nanoparticles following hollow 
microneedle-mediated intradermal administration.  
5. Conclusions 
OVA and poly(I:C) loaded PLGA nanoparticles, liposomes, MSNs and GNPs were 
successfully developed and compared for hollow microneedle-mediated intradermal 
immunization in mice. The encapsulation of OVA and co-encapsulation of OVA and poly(I:C) 
induced a strikingly higher IgG2a antibody response than OVA/poly(I:C) solution, but the 
type of nanoparticle has a major effect on response. PLGA nanoparticles and especially 
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cationic liposomes induced the highest IgG2a, CD8+ T cell and CD4+ T cell responses, 
suggesting their superiority for intradermal vaccination. Finally, our study demonstrated that 
the in house developed hollow microneedle/applicator system is an excellent tool for 
nanoparticle-based intradermal vaccination and to screen different intradermal vaccine 
formulations. 
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Abstract 
In this study, we aimed to investigate the immunogeicity of cationic liposomes loaded with 
diphtheria toxoid (DT) and poly(I:C) after hollow microneedle-mediated intradermal 
vaccination in mice. The following liposomal formulations were studied: DT loaded 
liposomes, a mixture of free DT and poly(I:C)-loaded liposomes, a mixture of DT-loaded 
liposomes and free poly(I:C), and liposomal formulations with DT and poly(I:C) either 
individually or co-encapsulated in the liposomes. Reference groups were DT solution 
adjuvanted with or without poly(I:C) (DT/poly(I:C)). The liposomal formulations were 
characterized in terms of particle size, zeta potential, loading and release of DT and poly(I:C). 
After intradermal injection of BALB/c mice with the formulations through a hollow 
microneedle, the immunogenicity was assessed by DT-specific ELISAs. All formulations 
induced similar total IgG and IgG1 titers. However, all the liposomal groups containing both 
DT and poly(I:C) showed enhanced IgG2a titers compared to DT/poly(I:C) solution, 
indicating that the immune response was skewed towards  Th1 direction. This enhancement 
was similar for all liposomal groups that contain both DT and poly(I:C) in the formulations. 
Our results reveal that a mixture of DT encapsulated liposomes and poly(I:C) encapsulated 
liposomes have a similar effect on the antibody respon es as DT and poly(I:C) co-
encapsulated liposomes. These findings may have implications for future design of liposomal 
vaccine delivery systems.  
Keywords : Immunogenicity, diphtheria toxoid, poly(I:C), liposomes, hollow microneedle, 
intradermal vaccination 
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1. Introduction 
Vaccination has become the most effective method for preventing infectious diseases, having 
led to the eradication of smallpox and severe restriction of other devastating diseases such as 
polio and measles [1, 2]. However, there is still a need for new and better vaccines against 
emerging infectious diseases [3]. Nowadays, vaccinatio  gains increasing attention also for 
therapeutic use against established diseases such a cancer and chronic auto-immune disorders 
[4]. Most vaccines are delivered by intramuscular or subcutaneous injection. However, these 
injections need special training and can cause pain[5]. To avoid the drawbacks of the 
hypodermic needles, microneedles have been developed [6]. Microneedles are micro-sized 
needle structures with a length shorter than 1 mm and c n be used to penetrate skin barrier in 
a non-invasive and pain-free way [7-9]. Owing to the large number of antigen presenting cells 
in viable dermis and epidermis, dose-sparing may be achieved [10, 11].  
Traditional vaccines are derived from attenuated organisms or inactivated pathogens and 
toxins. Attenuated vaccines have safety concerns as they may revert back to their virulent 
form [12]. Inactivated vaccines like subunit antigens are safer but they are generally less 
immunogenic [1, 12]. To enhance and modify the immune response, immune modulators or 
nanoparticle delivery systems can be used [13]. Nanop rticles are expected to improve the 
immunogenicity of antigens by protecting the antigens from degradation, increasing their 
uptake by antigen-presenting cells and co-delivering a tigens and immune modulators [14].  
Liposomes have been studied frequently because of their excellent biocompatibility and 
biodegradability [15]. Studies have shown that co-formulating antigen and immune 
modulators in liposomes can affect the quality of immune response after intradermal 
vaccination [15-23]. One recent study showed that co-encapsulation of OVA and poly(I:C), a 
TLR3 ligand, in 1,2-dioleoyl-3-trimethylammonium-propane chloride (DOTAP)-based 
cationic liposomes significantly increased the IgG2a response (Th1 type) and the CD8+ T cell 
response compared to OVA and poly(I:C) solutions [17]. Another study in a human skin 
explant model showed that a melanoma-associated antigen and immune modulator co-
encapsulated liposomes induced a higher CD8+ T cell response compared to the co-
administration of antigen loaded liposomes and freesolution of the immune modulator [21]. 
These results are noteworthy, as nowadays there is an increasing need for potent cellular 
immune responses, e.g., for immunotherapy of cancer [14, 24, 25] and intracellular pathogens 
[26, 27]. However, it is not yet well understood whet er the antigen and immune modulator 
need to be co-encapsulated in liposomes, or they can similarly modulate the immune response 
when encapsulated individually in liposomes.  
In the present study, we aimed to study the immunoge icity of diphtheria toxoid (DT) and 
poly(I:C) loaded liposomes after intradermal delivery. DT and poly(I:C) were used as a model 
antigen and immune modulator, respectively. DT and poly(I:C) were individually 
encapsulated or co-encapsulated into DOTAP-based cationic liposomes. The prepared 
liposomal formulations were injected into mice by using hollow microneedles. The IgG1 and 
IgG2a titers, which are indications of a Th2 and a Th1 type immune response, respectively 
[18], were determined. The results revealed that the liposomal formulations skewed the 
immune response towards a Th1 direction, no matter whether DT and poly(I:C) were 
encapsulated individually or co-encapsulated in liposomes, as compared to DT/poly(I:C) 
solutions. 
2. Materials and methods 
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2.1. Materials 
DT (batch 04-44, 1 µg equal to 0.3 Lf) and diphtheria toxin were provided by Intravacc 
(Bilthoven, The Netherlands). Aluminum phosphate was purchased from Brenntag (Ballerup, 
Denmark). Egg phosphatidylcholine (EggPC), DOTAP and 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE) were ordered from Avanti Polar Lipids (Alabaster, AL). 
Polyinosinic-polycytidylic acid (poly(I:C)) (low molecular weight) and its rhodamine-labeled 
version were purchased from Invivogen (Toulouse, France). Foetal bovine serum (FBS), 
M199 medium (with Hanks’ salts and L-glutamin), bovine serum albumin (BSA) and 
hydrofluoric acid ≥48% were ordered from Sigma-Aldrich (Zwijndrecht, The Netherlands). 
Glucose solution, L-Glutamine (200 mM), penicillin-streptomycin (10000 U/ml) and 1-stepTM 
ultra 3,3',5,5'-tetramethylbenzidine (TMB) were obtained from Thermo-Fisher Scientific 
(Waltham, MA). HRP-conjugated goat anti-mouse total IgG, IgG1 and IgG2a were purchased 
from Southern Biotech (Birmingham, AL). Sulfuric acid (95-98%) was obtained from JT 
Baker (Deventer, The Netherlands). VivaSpin 2 and 500 centrifugal concentrators (PES 
membrane, MWCO 1000 kDa) were obtained from Sartorius Stedim (Nieuwegein, The 
Netherlands). Sterile phosphate buffered saline (PBS, 163.9 mM Na+, 140.3 mM Cl-, 8.7 mM 
HPO4
2-, 1.8 mM H2PO
4-, pH 7.4) was obtained from Braun (Oss, The Netherlands). 10 mM 
PB (7.7 mM Na2HPO4, 2.3 mM NaH2PO4, pH 7.4) was prepared in the laboratory. All the 
other chemicals used were of analytical grade and Milli-Q water (18 MΩ/cm, Millipore Co.) 
was used for the preparation of all solutions. 
2.2. Preparation of liposomes 
Liposomes were prepared by thin-film hydration followed by extrusion, as reported earlier 
[23]. EggPC (25 mg/ml), DOPE (25 mg/ml) and DOTAP (25 mg/ml) in chloroform were 
mixed in a molar ratio of 9:1:2.5 in a round bottom flask. The organic solvent was evaporated 
by using a rotary evaporator (Buchi rotavapor R210, Flawil, Switzerland) for 1 h at 40 °C and 
120 rpm. To prepare DT encapsulated liposomes (Lipo-DT), the lipid film was hydrated with 
0.25 mg/ml DT dissolved in 10 mM PB (pH 7.4) by vortexing for 10 s, resulting in a 12.5 
mg/ml lipid suspension. To prepare poly(I:C) encapsulated liposomes (Lipo-PIC), the lipid 
film was hydrated with 0.25 mg/ml poly(I:C) solution (containing 0.5% (w/w) rhodamine-
labeled poly(I:C)). To prepare DT and poly(I:C) co-encapsulated liposomes (Lipo-DT-PIC), 
after lipid film hydration with DT solution, 0.25 mg/ml poly(I:C) (containing 0.5% (w/w) 
rhodamine-labeled poly(I:C)) dissolved in 10 mM PB (pH 7.4) was added slowly (2 µl/min) 
into the lipid suspension by using a syringe pump (NE-300, Prosense, Oosterhout, The 
Netherlands). Next, the lipid vesicles were extruded (LIPEXTM extruder, Northern Lipids, 
Burnaby, Canada) four times through a carbonate filr with a pore size of 400 nm and 
another four times through a filter with a pore size of 200 nm (Nucleopore Millipore, 
Amsterdam, The Netherlands). To remove the DT/poly(I:C) not associated with liposomes, 
the suspension was transferred into VivaSpin 2 centrifugal concentrators (1000 kDa MWCO) 
and centrifuged (Allegra X-12R, Beckman Coulter, Indianapolis, IN) for 6 h (350 g, 22 °C). 
Finally, the liposomes were washed with 10 mM PB and kept at 4 °C in the refrigerator prior 
to use. The filtrates, containing the free DT/poly(I:C), were collected for determination of 
loading efficiency of DT and poly(I:C). 
2.3. Characterization of liposomal formulations 
2.3.1. Particle size and zeta potential measurements 
The particle size of the liposomes was measured by ynamic light scattering by using a Nano 
ZS® zetasizer (Malvern Instruments, Worcestershire, U.K.). The zeta potential of liposomes 
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was measured by the same instrument by using laser Doppler velocimetry. The liposomes 
were diluted with 10 mM PB (pH 7.4) to a concentration of 25 µg/ml for the measurements. 
The samples were measured 3 times with 10 runs for each measurement.  
2.3.2. Determination of encapsulation efficiency (E) and loading capacity (LC) of 
DT/poly(I:C) in liposomes 
To determine the EE and LC of DT and poly(I:C), theintrinsic fluorescence intensity of DT 
(λex 280 nm/ λem 320 nm) and fluorescence intensity of rhodamine lab led poly(I:C) (λex 545 
nm/ λem 576 nm) in the purification filtrates were measured by using a Tecan M1000 plate 
reader (Männedorf, Switzerland). The EE and LC were calculated by using Eq. (1) and Eq. (2) 
as below: 
EE =
 	!"! 56/' ((*:,) 
..	  56/' ((*:,)
 × 100 %                (1)                                
LC =
 	!"! 56/' ((*:,) 
71'38"34564' ((*:,)
 × 100 %          (2)                                  
Where Mloaded DT/poly(I:C) represents the mass of encapsulated DT or poly(I:C), Mtotal DT/poly(I:C) is 
the total amount of DT or poly(I:C) added to the formulations and Mliposomes+DT+poly(I:C) is the 
total weight of liposomes, DT and poly(I:C).  
2.3.3 In vitro release of DT and poly(I:C) from liposomes 
To study the in vitro release of DT and poly(I:C) from Lipo-DT, Lipo-PIC and Lipo-DT-PIC, 
the liposomes (containing about 80 µg/ml DT with or without 80 µg/ml poly(I:C)) were 
dispersed in PBS and shaken with a speed of 550 rpm at 37 ºC by using an Eppendorf 
thermomixer (Nijmegen, The Netherlands). At predetermined time points, 300 µl liposomes 
were transferred into the VivaSpin 500 concentrators and centrifuged for 30 min with a speed 
of 350 g. After the centrifugation, fresh PBS with the same volume as the filtrates was added 
back to the liposomes. The concentration of DT and poly(I:C) in the filtrates was determined 
by measuring the intrinsic fluorescence intensity of DT (λex 280 nm/λem 320 nm) and 
fluorescence intensity of rhodamine labeled poly(I:C) (λex 545 nm/λem 576 nm), respectively, 
by using a Tecan M1000 plate reader.  
2.3.4 Adsorption of free DT or poly(I:C) on liposomes loaded with the other active 
ingredient 
To investigate the adsorption of free DT to Lipo-PIC, DT was mixed with Lipo-PIC in PBS, 
resulting in a concentration of 31 µg/ml for both DT and poly(I:C). The samples were 
incubated in the Eppendorf thermomixer (Nijmegen, The Netherlands) at 37 °C with a speed 
of 300 rpm. To investigate the adsorption of free poly(I:C) to Lipo-DT, poly(I:C) was mixed 
with Lipo-DT in PBS, resulting in a concentration of 31 µg/ml for both DT and poly(I:C). 
After 4 or 24 h, the samples were transferred to VivaSpin 500 centrifugal concentrators (PES 
membrane, 1000 kDa MWCO) and centrifuged for 30 minwith a speed of 350 g. The DT or 
poly(I:C) in the filtrates was quantified by measuring the intrinsic fluorescence intensity of 
DT (λex 280 nm/ λem 320 nm) or fluorescence intensity of rhodamine labe ed poly(I:C) (λex 
545 nm/ λem 576 nm), respectively. The adsorption efficiency of DT or poly(I:C) was 
calculated according to Eq. (3) as follow: 
Adsorption efDicieny % = (1 −
56/' ((*:,) 1/ H1 .0	."3 
56/' ((*:,) ..	 
 ) × 100 %      (3)                                      
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where MDT/poly(I:C) in filtrates represents the mass of DT or poly(I:C) in filtrates after 
centrifugation, and MDT/poly(I:C) total is the total mass of DT or poly(I:C) added. 
2.4. Hollow microneedles and applicator 
The hollow microneedles were prepared by hydrofluoric acid etching of fused silica 
capillaries [28, 29]. Briefly, silica capillaries (Polymicro, Phoenix AZ, 375 μm outer diameter, 
50 μm inner diameter) were cut into 4-cm pieces and filled with silicone oil in a vacuum oven 
(100 °C) overnight. The silicone oil-filled capillaries were etched into hollow microneedles 
by immersing their ends in ≥48% hydrofluoric acid for 4 h at room temperature. Finally, the 
polyimide coating on the microneedles was removed by dipping the microneedles into hot 
sulfuric acid (250 °C) for 5 min.  
To reproducibly insert hollow microneedles into mouse skin, a hollow microneedle applicator 
developed in our lab was used [28, 29]. The system consists of a syringe pump (NE-300, 
Prosense, Oosterhout, The Netherlands) and an injector, which were used to accurately 
control the injection rate (10 µl/min), the injection volume (10 µl) and the injection depth 
(120 µm). The pump, injector and hollow microneedles were connected by using high-
pressure resistant CapTiteTM connectors and silica capillaries.  
2.5. Immunization study 
Female BALB/c (H2d) mice were ordered from Charles Rivers (Maastricht, T e Netherlands) 
and accommodated under standardized conditions in the animal facility of Leiden Academic 
Centre for Drug Research, Leiden University. The immunization study was approved by the 
ethical committee on animal experiments of Leiden University (Licence number 14166). 
The mice were 7-8 weeks old at the beginning of theexperiments. The mice were 
anesthetized by intraperitoneal injection of ketamine (60 mg/kg) and xylanize (4 mg/kg) 
before shaving of the injection site. The mice were th n injected with 10 µl of the 
formulations, containing 0.31 µg DT with or without 0.31 µg poly(I:C), into abdomen skin by 
using the hollow microneedle and the applicator, as described above. The following liposomal 
formulations were used: DT encapsulated liposomes (Lipo-DT), a mixture of DT-
encapsulated liposomes and free poly(I:C) (Lipo-DT+PIC), a mixture of free DT and 
poly(I:C)-encapsulated liposomes (DT+Lipo-PIC), a mixture of DT-encapsulated liposomes 
and poly(I:C)-encapsulated liposomes (Lipo-DT+Lipo-PIC), and DT and poly(I:C) co-
encapsulated liposomes (Lipo-DT-PIC). Control groups were injected with 0.31 µg DT with 
or without 0.31 µg poly(I:C) solution (DT/poly(I:C)). All formulations were freshly prepared 
and mixed prior to the immunization study. Subcutaneously injected 5 µg DT and 150 µg 
aluminum phosphate (DT-Alum) was used as a positive control. The mice were immunized 
on day 0, 21, 42 and sacrificed on day 56. Serum was withdrawn from the tail vein of mice on 
day 0, 21 and 42 and the sacrifice serum was taken from the femoral artery on day 56.  
2.6. Determination of DT-specific IgG antibody titers 
DT-specific antibodies were measured by using a sandwich enzyme-linked immunosorbent 
assay (ELISA) as described earlier [18]. The wells of 96-well plates were coated with 140 ng 
DT and incubated overnight at 4 °C. The plates were blocked with 1% BSA at 37 °C for 1 h. 
After blocking, appropriate three-fold serial dilutons of mouse sera were transferred into the 
plates and incubated for 2 h at 37 °C. The plates wre then incubated with horseradish 
peroxidase-conjugated goat antibodies against total IgG, IgG1 or IgG2a (1:5000 dilution) for 
1.5 h at 37 °C. Subsequently, the plates were incubated with TMB and 2 M sulfuric acid was 
Immunogenicity of diphtheria toxoid and poly(I:C) loaded cationic liposomes after hollow 
microneedle-mediated intradermal injection in mice 
87 
 
used to stop the reaction. The absorbance was measured at 450 nm by using a Tecan M1000 
plate reader. The antibody titers were expressed as log10 value of the mid-point of S-shaped 
dilution-absorbance curve of the diluted serum level.  
2.7. Determination of DT-neutralizing antibodies 
The functionality of the antibody response was determined by measuring diphtheria toxin-
neutralizing antibodies in a Vero cell test [30]. The serum samples were first diluted by M199 
medium supplemented with 5% FBS, 0.5% glucose, 0.8% L-glutamine and 1% penicillin-
streptomycin. Appropriate two-fold serial dilutions of the serum were applied to 96-well 
plates. Next, 5 × 10-5 Lf diphtheria toxin was added to each well. Subsequently, 1.25 ×104 
Vero cells were added to each well and incubated for 6 days at 37 °C in 5% CO2. Finally, the 
neutralizing antibodies were expressed as the log2 value of the highest serum dilution that 
protected the Vero cells.  
 2.8. Statistics analysis 
All the data of antibody titers were analyzed by one way ANOVA with Newman-Keuls 
Multiple post-test by using GraphPad Prism software (version 5.02). The level of significance 
was set at p<0.05. 
3. Results  
3.1. Physicochemical characteristics of the liposomes and in vitro release of DT and 
poly(I:C) 
Lipo-DT, Lipo-PIC and Lipo-DT-PIC were first characterized in terms of particle size, poly 
dispersity index (PDI) and zeta potential. As shown in Table 1, Lipo-DT and Lipo-PIC had a 
similar average size below 200 nm with a low PDI, while Lipo-DT-PIC showed a slightly 
larger size and PDI. All the liposomes had a positive zeta potential above +35 mV. Both DT 
and poly(I:C) were efficiently encapsulated into the liposomes, with a EE higher than 96%. 
Furthermore, DT and poly(I:C) had a similar LC% of about 1.7% (Table 1). 
Table 1. Physicochemical characteristics of DT/poly(I:C) encapsulated liposomes (n=3). 
Liposomes Sizea (nm) PDIb ZPc (mV) 
EEd (%) LC e (%) 
DT Poly(I:C)  DT Poly(I:C)  
Lipo-DT 182±8 0.195±0.012 +37±1 96.5±2.1 - 1.6±0.1 - 
Lipo-PIC 184±6 0.153±0.010 +37±1 - 98.5±0.8 - 1.7±0.0 
Lipo-DT-PIC  238±11 0.243±0.003 +35±1 98.0±0.8 98.9±0.5 1.7±0.0 1.7±0.0 
Data are average ± SEM of 3 independent batches.  
aSize: Z-average diameter, bPDI: poly dispersity index, cZP: zeta potential, dEE: encapsulation 
efficiency, eLC: loading capacity. 
To study the in vitro release of DT and poly(I:C), the prepared liposomes w re incubated in 
PBS for one month. As shown in Fig. 1A, there was a burst release of DT of about 25% from 
both Lipo-DT and Lipo-DT-PIC within the first day. After 3 days, almost no additional DT 
was released. On day 30, the total release of DT from Lipo-DT and Lipo-DT-PIC was about 
50% and 40%, respectively. Similarly, about 20 % of the poly(I:C) was quickly released from 
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Lipo-PIC and Lipo-DT-PIC within the first day and after day 3 almost no additional release 
was detected (Fig. 1B). On day 30, about 40% and 25% of the loaded poly(I:C) were released 
from Lipo-PIC and Lipo-DT-PIC, respectively. In summary, after incubation in PBS for one 
month, less than half of the loaded DT or poly(I:C) was released from the liposomes. 
 
Figure 1. In vitro release of DT and poly(I:C) from liposomes. A: Release of DT from Lipo-
DT (spheres) and Lipo-DT-PIC (squares). Insertion: release over a period of 1.5 days. B: 
Release of poly(I:C) from Lipo-PIC (spheres) and Lipo-DT-PIC (squares). Insertion: release 
over a period of 1.5 days. Bars represent mean ± SEM, n = 3.  
 
Figure 2. DT-specific total IgG titers on day 21 (A), 42 (B) and 56 (C). Bars represent mean 
± SEM, n = 8. *p < 0.05, **p < 0.01. 
In order to study the interaction between free DT or p ly(I:C) and the positively charged 
liposomes loaded with the other active ingredient after mixing in PBS, the adsorption of DT 
or poly(I:C) on the liposomes were determined. There were 75.9 ± 3.8% (mean ± SEM, n=3) 
and 77.4 ± 0.8% (mean ± SEM, n=3) of DT adsorbing o the surface of Lipo-PIC at 4 h or 24 
h after mixing, respectively. In case of poly(I:C), 95.9 ± 2.7% (mean ± SEM, n=3) and 95.6 ± 
1.0%  (mean ± SEM, n=3) were adsorbed on the surface of Lipo-DT at 4 or 24 h after mixing, 
respectively. In summary, most of free DT or poly(I:C) was adsorbed on the surface of 
liposomes after mixing. 
3.2. Intradermal vaccination study 
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The formulations were intradermally delivered into mice by using hollow microneedles with a 
DT dose of 0.31 µg with or without 0.31 µg poly(I:C), based on our previous dose response 
study [31]. Subcutaneously injected DT-Alum with a much higher dose (5 µg DT and 100 µg 
Alum) was used as a positive control. During the inj ction, there was no visible leakage and 
successful injection was indicated by the formation of the bleb on the abdomen area of mouse 
skin.  
 
Figure 3. DT-specific IgG1 (A, C, E) and IgG2a (B, D, F) titers on day 21 (A, B), 42 (C, D) 
and 56 (E, F). Bars represent mean ± SEM, n = 8. *p < 0.05, ***p < 0.001. 
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DT-specific total IgG and subtype titers (IgG1 and IgG2a) are presented in Fig. 2 and Fig. 3, 
respectively. As shown in Fig. 2, total IgG titers increased after each immunization. As 
expected, DT-Alum induced significantly higher total IgG responses than all other 
formulations on day 21 and 42 (p<0.05) (Fig. 2A, B). However, on day 56 the response of the 
intradermal groups increased to similar levels to that induced by DT-Alum (except DT), 
despite the 15-fold lower dose administered (Fig. 2C). The encapsulation of DT/poly(I:C) in 
liposomes did not increase the total IgG response compared to DT/poly(I:C) solutions 
(p>0.05). Furthermore, the addition of poly(I:C) did not change the total IgG response. 
Next, the IgG1 and IgG2a titers were measured. As shown in Fig. 3, the IgG1 response 
followed the total IgG response: liposomal formulation groups induced equally strong IgG1 
responses compared to DT/poly(I:C) solutions (p>0.05). However, when focusing on IgG2a 
response, clear differences were observed among the groups. On day 21 all groups except DT-
Alum developed a detectable IgG2a response (Fig. 3B). After the 1st boost (day 42), all 
groups showed an IgG2a response (Fig. 3D). Moreover, liposomal groups that contained both 
DT and poly(I:C), i.e., Lipo-DT+PIC, DT+Lipo-PIC, Lipo-DT+Lipo-PIC and Lipo-DT-PIC, 
induced a similar IgG2a response that was higher than e response induced by DT solution 
(p<0.05) and the DT and poly(I:C) mixture (Fig. 3D), although compared with the latter the 
difference is not significant (p>0.05). After the 2nd boost (day 56), the IgG2a response of all 
groups increased to a higher level, but still the liposomal groups containing both DT and 
poly(I:C) induced a distinctly higher IgG2a response than DT solution (Fig. 3F). In summary, 
the results showed that the IgG2a response was enhanced when DT/poly(I:C) was loaded in 
liposomes, no matter whether only one ingredient or b th of them were encapsulated in 
liposomes. Furthermore, DT and poly(I:C) individually encapsulated in liposomes induced a 
similar IgG2a response compared to DT and poly(I:C) co-encapsulated in liposomes. In 
contrast, DT encapsulated liposomes (Lipo-DT) did not enhance the IgG2a response 
compared to DT solution. Additionally, the DT-Alum group did not improve the IgG2a 
response in spite of a much higher dose.  
In order to study functionality of the antibody response, the neutralizing antibody titers in 
serum on day 56 were determined by a Vero cell assay. The sera of the DT-Alum group 
contained higher levels of toxin-neutralizing antibodies than all other groups (p<0.05) (Fig. 4). 
The liposomal groups containing both DT and poly(I:C) showed similar neutralizing titers 
compared to DT/poly(I:C) solutions. The Lipo-DT group seemed to have the lowest titers 
among the intradermal groups, but the difference is not significant. In summary, the 
encapsulation of DT/poly(I:C) in liposomes did not improve the protective immunity against 
diphtheria toxin. 
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Figure 4. DT-neutralizing antibody titers of mice. Results are shown for serum collected on 
day 56. Bars represent mean ± SEM, n = 8. *p < 0.05. 
4. Discussion 
Liposome-based delivery system for vaccination has been extensively investigated [15, 32]. 
When focusing on intradermal vaccination, several studies have shown that co-encapsulation 
of antigen and adjuvant in liposomes can increase IgG2a and CD8+ T cell responses [16, 17, 
21, 22, 33]. In one of our previous studies, we used hollow microneedles to examine the effect 
of nano-encapsulation of OVA and poly(I:C) on the immune response in mice after 
intradermal vaccination. In that study, four types of nanoparticles were compared and the 
results indicated that OVA- and poly(I:C)-containing cationic liposomes were more potent 
than the other nanoparticles and significantly increased the IgG2a response compared to OVA 
and poly(I:C) solutions [17]. In the present study, we used the same liposome composition to 
study whether co-encapsulation of antigen and immune modulator is the essential factor for 
increased IgG2a levels. To investigate this, we co-encapsulated DT and poly(I:C) or 
encapsulated them individually in liposomes and studied the IgG (subtype) response 
following hollow microneedle-mediated intradermal vaccination. The results showed that 
liposomal formulations containing both DT and poly(I:C), induced higher IgG2a titers than 
those induced by DT/poly(I:C) solutions, no matter whether only one ingredient or both of 
them were encapsulated in liposomes. Furthermore, DT and poly(I:C) that were both 
individually encapsulated in liposomes induced similar IgG2a titers compared to DT and 
poly(I:C) co-encapsulated in liposomes.  
The results of Lipo-DT-PIC are well in accordance with previously reported results [16, 23], 
showing that the co-encapsulation of antigen and immune modulator in liposomes can 
increase IgG2a responses and favor Th1 type immune responses after intradermal delivery by 
using a hypodermic needle. This may be caused by a liposome induced increase in the uptake 
of antigen and adjuvant by antigen presenting cells, as the size of liposomes (smaller than 200 
nm) is favorable for uptake by dendritic cells [34-6]. Burke et al. additionally showed that 
liposomes may facilitate the access of poly(I:C) to cellular cytoplasm and up-regulate TLR 
signalling molecules and NLRP3 inflammasome pathway [37]. Furthermore, cationic 
liposomes may have a stronger interaction with the negatively charged cell membrane due to 
the attractive electrostatic interaction compared to negatively charged particles, which allows 
longer retention time on the cell surface and subsequently sustained release of antigen and 
adjuvant [15, 38, 39]. Finally, several studies have indicated that the co-processing of antigen 
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and adjuvant by antigen presenting cells after being taken up may be the reason for a higher 
IgG2a response [16, 17, 21]. The delivery of antige and the triggering of TLR in the same 
dendritic cell may synergistically induce a superior antigen presentation to T cells [21, 40]. 
The results of Lipo-DT+PIC and DT+Lipo-PIC are in li e with our previous study by 
Varypataki et al, who found that the mixture of antigen-loaded liposomes and free poly(I:C) 
solution induced a similar IFN-γ-producing CD4+ T cell response (Th1) as antigen and 
adjuvant co-encapsulated liposomes after hypodermic needle-mediated intradermal delivery 
[41]. One explanation may be that the negatively charged antigen and adjuvant mixed with the 
liposome formulation adhered to the surface of positively charged liposomes after intradermal 
injection due to the electrostatic interaction. As a result, most of the antigen and adjuvant 
were co-delivered into the antigen presenting cells although they were not co-encapsulated in 
the liposomes. The adsorption study supported our hypot esis, as most of the DT or poly(I:C) 
were found to adsorb on the surface of liposomes aft r mixing in PBS.   
In case of the Lipo-DT+Lipo-PIC formulation, we expect that these two liposomes would 
repel with each other due to their strong surface charge. Indeed, the particle size and zeta 
potential of Lipo-DT+Lipo-PIC were found to remain the same within 24 h after mixing in 
PBS (data not shown). Nevertheless, Lipo-DT+Lipo-PIC induced similar IgG2a responses as 
Lipo-DT-PIC. These results indicate that the indiviually encapsulated DT and poly(I:C) are 
as efficient as the DT and poly(I:C) co-encapsulated in the liposomes for activation of 
immune system when administered intradermally. This may be explained by an efficient 
uptake of both Lipo-DT and Lipo-PIC by the same antigen presenting cells. One possible 
approach to further investigate this is to use confocal microscopy to study the fate of 
fluorescently labeled liposomes and antigen/adjuvant following administration in vivo. 
In order to produce liposomes loaded with the optimal ratio of antigen/adjuvant with a high 
loading efficiency, optimization work needs to be done. Our results clearly suggest that co-
encapsulation of antigen and adjuvant in liposomes ay not be necessary for the use in 
intradermal delivery. This might simplify the work for the development of formulations. This 
may even be particularly beneficial for developing formulations that must contain multiple 
antigens and adjuvants, e.g., for personalized therapi s of cancer patients [42]. Such 
formulations can be prepared by mixing different liposomes loaded with only antigen or only 
adjuvant. Furthermore, it may be interesting to test whether our current findings also hold true 
for other nanoparticulate vaccine delivery systems.  
Finally, the results of neutralizing antibody assay indicate that high IgG2a titers did not 
contribute to the immunity against diphtheria, which s in line with a previous study [30]. The 
high IgG2a titers may be more suitable for anti-viral mmune responses where a Th1 response 
is more desired [43].  
5. Conclusion 
Our results show that DT and poly(I:C) can be successfully encapsulated into cationic 
liposomes with a high loading efficiency. After hollow microneedle-mediated intradermal 
vaccination, the antigen and adjuvant encapsulated liposomes evoked a potent immune 
response and shifted the IgG1/IgG2a balance more to the IgG2a direction. The combination of 
DT-encapsulated and poly(I:C)-encapsulated liposomes ar  able to simulate an equally strong 
IgG2a response compared to DT and poly(I:C) co-encapsul ted liposomes. These findings 
may have implications for future design of liposomal formulations aiming for modification of 
immune response after intradermal delivery.  
Immunogenicity of diphtheria toxoid and poly(I:C) loaded cationic liposomes after hollow 
microneedle-mediated intradermal injection in mice 
93 
 
Acknowledgements  
We thank Hilde Vrieling and Amy Kogelman from Intravacc for their help with the 
neutralizing antibody assay. We thank Juha Mönkäre for the help with liposomes. 
Guangsheng Du acknowledges the support from China Scholarship Council.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5 
94 
 
References: 
[1] L.J. Peek, C.R. Middaugh, C. Berkland, Nanotechnology in vaccine delivery, Adv. Drug 
Deliv. Rev. 60 (2008) 915-928. 
[2] H. Jiang, Q. Wang, X. Sun, Lymph node targeting strategies to improve vaccination 
efficacy, J. Control. Release 267 (2017) 47-56. 
[3] R. Rappuoli, M. Pizza, G. Del Giudice, E. De Gregorio, Vaccines, new opportunities for a 
new society, Proc. Nati. Acad. USA 111 (2014) 12288-12293. 
[4] C.J. Melief, T. van Hall, R. Arens, F. Ossendorp, S.H. van der Burg, Therapeutic cancer 
vaccines J. Clin. Investi. 125 (2015) 3401-3412. 
[5] Y.C. Kim, J.H. Park, M.R. Prausnitz, Microneedls for drug and vaccine delivery, Adv. 
Drug Deliv. Reviews 64 (2012) 1547-1568. 
[6] E. Larraneta, M.T. McCrudden, A.J. Courtenay, R.F. Donnelly, Microneedles: A new 
frontier in nanomedicine delivery, Pharm. Res. 33 (2016) 1055-1073. 
[7] K. van der Maaden, W. Jiskoot, J. Bouwstra, Microneedle technologies for (trans)dermal 
drug and vaccine delivery, J. Control. Release 161 (20 2) 645-655. 
[8] J. Tu, G. Du, M. Reza Nejadnik, J. Monkare, K. van der Maaden, P.H.H. Bomans, N. 
Sommerdijk, B. Slutter, W. Jiskoot, J.A. Bouwstra, A. Kros, Mesoporous silica nanoparticle-
coated microneedle arrays for intradermal antigen dlivery, Pharm. Res. 34 (2017) 1693-
1706. 
[9] A.M. de Groot, G. Du, J. Monkare, A.C.M. Platteel, F. Broere, J.A. Bouwstra, A. Sijts, 
Hollow microneedle-mediated intradermal delivery of model vaccine antigen-loaded PLGA 
nanoparticles elicits protective T cell-mediated immunity to an intracellular bacterium, J. 
Control. Release 266 (2017) 27-35. 
[10] N. Li, L.H. Peng, X. Chen, S. Nakagawa, J.Q. Gao, Transcutaneous vaccines: novel 
advances in technology and delivery for overcoming the barriers, Vaccine 29 (2011) 6179-
6190. 
[11] M. Leone, J. Monkare, J. Bouwstra, G. Kersten, Dissolving microneedle patches for 
dermal vaccination, Pharm. Res. 34 (2017) 2223-2240. 
[12] S.G. Reed, M.T. Orr, C.B. Fox, Key roles of adjuvants in modern vaccines, Nat. Med. 19 
(2013) 1597-1608. 
[13] L. Zhao, A. Seth, N. Wibowo, C.X. Zhao, N. Mitter, C.Z. Yu, A.P.J. Middelberg, 
Nanoparticle vaccines, Vaccine 32 (2014) 327-337. 
[14] Y. Fan, J.J. Moon, Nanoparticle drug delivery s stems designed to improve cancer 
vaccines and immunotherapy, Vaccines 3 (2015) 662-685. 
[15] A.K. Giddam, M. Zaman, M. Skwarczynski, I. Toth, Liposome-based delivery system 
for vaccine candidates: constructing an effective formulation, Nanomedicine 7 (2012) 1877-
1893. 
[16] S.M. Bal, S. Hortensius, Z. Ding, W. Jiskoot, J.A. Bouwstra, Co-encapsulation of antigen 
and Toll-like receptor ligand in cationic liposomes affects the quality of the immune response 
in mice after intradermal vaccination, Vaccine 29 (011) 1045-1052. 
[17] G. Du, R.M. Hathout, M. Nasr, M.R. Nejadnik, J. Tu, R.I. Koning, A.J. Koster, B. 
Slutter, A. Kros, W. Jiskoot, J.A. Bouwstra, J. Monkare, Intradermal vaccination with hollow 
microneedles: A comparative study of various protein antigen and adjuvant encapsulated 
nanoparticles, J. Control. Release 266 (2017) 109-118. 
[18] B. Slutter, S.M. Bal, Z. Ding, W. Jiskoot, J.A. Bouwstra, Adjuvant effect of cationic 
liposomes and CpG depends on administration route, J. Control. Release 154 (2011) 123-130. 
[19] Y.Q. Qiu, L. Guo, S.H. Zhang, B. Xu, Y.H. Gao, Y. Hu, J. Hou, B.K. Bai, H.H. Shen, 
P.Y. Mao, DNA-based vaccination against hepatitis B virus using dissolving microneedle 
arrays adjuvanted by cationic liposomes and CpG ODN, rug Deliv. 23 (2016) 2391-2398. 
Immunogenicity of diphtheria toxoid and poly(I:C) loaded cationic liposomes after hollow 
microneedle-mediated intradermal injection in mice 
95 
 
[20] Y. Suzuki, D. Wakita, K. Chamoto, Y. Narita, T. suji, T. Takeshima, H. Gyobu, Y. 
Kawarada, S. Kondo, S. Akira, H. Katoh, H. Ikeda, T. Nishimura, Liposome-encapsulated 
CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity, Cancer 
Res. 64 (2004) 8754-8760. 
[21] M.A. Boks, S.C.M. Bruijns, M. Ambrosini, H. Kal y, L. van Bloois, G. Storm, T. de 
Gruijl, Y. van Kooyk, In situ delivery of tumor antigen- and adjuvant-loaded liposomes 
boosts antigen-specific T-Cell responses by human dermal dendritic cells, J. Invest. Dermatol. 
135 (2015) 2697-2704. 
[22] L. Guo, J.M. Chen, Y.Q. Qiu, S.H. Zhang, B. Xu, Y.H. Gao, Enhanced transcutaneous 
immunization via dissolving microneedle array loaded with liposome encapsulated antigen 
and adjuvant, Int. J. Pharmaceut. 447 (2013) 22-30. 
[23] E.M. Varypataki, A.L. Silva, C. Barnier-Quer, N. Collin, F. Ossendorp, W. Jiskoot, 
Synthetic long peptide-based vaccine formulations for induction of cell mediated immunity: 
A comparative study of cationic liposomes and PLGA nanoparticles, J. Control. Release 226 
(2016) 98-106. 
[24] S. Hamdy, O. Molavi, Z.S. Ma, A. Haddadi, A. Alshamsan, Z. Gobti, S. Elhasi, J. 
Samuel, A. Lavasanifar, Co-delivery of cancer-associated antigen and Toll-like receptor 4 
ligand in PLGA nanoparticles induces potent CD8(+) T cell-mediated anti-tumor immunity, 
Vaccine 26 (2008) 5046-5057. 
[25] R. Ammi, J. De Waele, Y. Willemen, I. Van Brussel, D.M. Schrijvers, E. Lion, E.L.J. 
Smits, Poly(I:C) as cancer vaccine adjuvant: Knocking on the door of medical breakthroughs, 
Pharmacol. Ther. 146 (2015) 120-131. 
[26] C.S.W. Chong, M. Cao, W.W. Wong, K.P. Fischer, W.R. Addison, G.S. Kwon, D.L. 
Tyrrell, J. Samuel, Enhancement of T helper type 1 immune responses against hepatitis B 
virus core antigen by PLGA nanoparticle vaccine delivery, J. Control. Release 102 (2005) 85-
99. 
[27] M. Zaric, O. Lyubomska, O. Touzelet, C. Poux, S. Al-Zahrani, F. Fay, L. Wallace, D. 
Terhorst, B. Malissen, S. Henri, U.F. Power, C.J. Scott, R.F. Donnelly, A. Kissenpfennig, 
Skin dendritic cell targeting via microneedle arrays laden with antigen-encapsulated poly-
D,L-lactide-co-glycolide nanoparticles induces efficient antitumor and antiviral immune 
responses, ACS Nano 7 (2013) 2042-2055. 
[28] K. van der Maaden, S.J. Trietsch, H. Kraan, E.M. Varypataki, S. Romeijn, R. Zwier, H.J. 
van der Linden, G. Kersten, T. Hankemeier, W. Jiskoot, J. Bouwstra, Novel hollow 
microneedle technology for depth-controlled microinjection-mediated dermal vaccination: a 
study with polio vaccine in rats, Pharm. Res. 31 (2014) 1846-1854. 
[29] P. Schipper, K. van der Maaden, S. Romeijn, C. Oomens, G. Kersten, W. Jiskoot, J. 
Bouwstra, Determination of depth-dependent intradermal immunogenicity of adjuvanted 
inactivated polio vaccine delivered by microinjections via hollow microneedles, Pharm. Res. 
33 (2016) 2269-2279. 
[30] Z. Ding, E. Van Riet, S. Romeijn, G.F.A. Kersten, W. Jiskoot, J.A. Bouwstra, Immune 
modulation by adjuvants combined with diphtheria toxoid administered topically in BALB/c 
mice after microneedle array pretreatment, Pharm. Res 26 (2009) 1635-1643. 
[31] P. Schipper, K. van der Maaden, V. Groeneveld, M. Ruigrok, S. Romeijn, S. Uleman, C. 
Oomens, G. Kersten, W. Jiskoot, J. Bouwstra, Diphtheria toxoid and N-trimethyl chitosan 
layer-by-layer coated pH-sensitive microneedles induce potent immune responses upon 
dermal vaccination in mice, J. Control. Release 262 ( 017) 28-36. 
[32] Y. Perrie, F. Crofts, A. Devitt, H.R. Griffiths, E. Kastner, V. Nadella, Designing 
liposomal adjuvants for the next generation of vaccines, Adv. Drug Deliv. Rev. 99 (2016) 85-
96. 
Chapter 5 
96 
 
[33] E.M. Varypataki, K. van der Maaden, J. Bouwstra, F. Ossendorp, W. Jiskoot, Cationic 
liposomes loaded with a synthetic long peptide and poly(I:C): a defined adjuvanted vaccine 
for induction of antigen-specific T cell cytotoxicity, AAPS J. 17 (2015) 216-226. 
[34] M.O. Oyewumi, A. Kumar, Z.R. Cui, Nano-microparticles as immune adjuvants: 
correlating particle sizes and the resultant immune responses, Expert Rev. Vaccines 9 (2010) 
1095-1107. 
[35] V. Manolova, A. Flace, M. Bauer, K. Schwarz, P. Saudan, M.F. Bachmann, 
Nanoparticles target distinct dendritic cell populations according to their size, Eur. J. Immunol. 
38 (2008) 1404-1413. 
[36] N. Benne, J. van Duijn, J. Kuiper, W. Jiskoot, B. Slutter, Orchestrating immune 
responses: How size, shape and rigidity affect the immunogenicity of particulate vaccines, J. 
Control. Release 234 (2016) 124-134. 
[37] M.L. Burke, M. Veer, J. Pleasance, M. Neeland, M. Elhay, P. Harrison, E. Meeusen, 
Innate immune pathways in afferent lymph following vaccination with poly(I:C)-containing 
liposomes, Innate immun. 20 (2014) 501-510. 
[38] Y.F. Ma, Y. Zhuang, X.F. Xie, C. Wang, F. Wang, D.M. Zhou, J.Q. Zeng, L.T. Cai, The 
role of surface charge density in cationic liposome-promoted dendritic cell maturation and 
vaccine-induced immune responses, Nanoscale 3 (2011) 307-2314. 
[39] C. Foged, C. Arigita, A. Sundblad, W. Jiskoot, G. Storm, S. Frokjaer, Interaction of 
dendritic cells with antigen-containing liposomes: ffect of bilayer composition, Vaccine 22 
(2004) 1903-1913. 
[40] O. Schulz, S.S. Diebold, M. Chen, T.I. Naslund, M.A. Nolte, L. Alexopoulou, Y.T. 
Azuma, R.A. Flavell, P. Liljestrom, C.R.E. Sousa, Toll-like receptor 3 promotes cross-
priming to virus-infected cells, Nature 433 (2005) 887-892. 
[41] M. Diwan, M. Tafaghodi, J. Samuel, Enhancement of immune responses by co-delivery 
of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres, J. Control. 
Release 85 (2002) 247-262. 
[42] S. Grabbe, H. Haas, M. Diken, L.M. Kranz, P. Langguth, U. Sahin, Translating 
nanoparticulate-personalized cancer vaccines into clinical applications: case study with RNA-
lipoplexes for the treatment of melanoma, Nanomedicine-Uk 11 (2016) 2723-2734. 
[43] J. Cenna, G.S. Tan, A.B. Papaneri, B. Dietzschold, M.J. Schnell, J.P. McGettigan, 
Immune modulating effect by a phosphoprotein-deleted rabies virus vaccine vector expressing 
two copies of the rabies virus glycoprotein gene, Vaccine 26 (2008) 6405-6414. 
 
 
 
 
 
 
 
 
 
Coated and hollow microneedle-mediated intradermal i munization in mice with diphtheria 
toxoid loaded mesoporous silica nanoparticles 
97 
 
 
 
 
Chapter 6 
 
Coated and hollow microneedle-mediated 
intradermal immunization in mice with 
diphtheria toxoid loaded mesoporous silica 
nanoparticles 
 
Guangsheng Du1, Laura Woythe1, Koen van der Maaden1, Mara Leone1, Stefan Romeijn1, Gideon 
Kersten1,2, Wim Jiskoot1, Joke A. Bouwstra1,*  
1Division of BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, 
The Netherlands 
2 Institute for Translational Vaccinology (Intravacc), Bilthoven, The Netherlands 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from Pharm. Res. 2018 (35):189. 
Chapter 6 
98 
 
Abstract 
The aim of this study was to examine the immunogenicity of diphtheria toxoid (DT) loaded 
mesoporous silica nanoparticles (MSNs) after coated an  hollow microneedle-mediated 
intradermal immunization in mice. DT was loaded into MSNs and the nanoparticle surface 
was coated with a lipid bilayer (LB-MSN-DT). To preare coated microneedles, alternating 
layers of negatively charged LB-MSN-DT and positively charged N-trimethyl chitosan (TMC) 
were coated onto pH-sensitive microneedle arrays via a layer-by-layer approach. Microneedle 
arrays coated with 5 or 3 layers of LB-MSN-DT were used to immunize mice and the elicited 
antibody responses were compared with those induced by hollow microneedle-injected liquid 
formulation of LB-MSN-DT. Liquid DT formulation with and without TMC (DT/TMC) 
injected by a hollow microneedle were used as controls. LB-MSN-DT had an average size of 
about 670 nm and a zeta potential of -35 mV. The encapsulation efficiency of DT in the 
nanoparticles was 77%. The amount of nano-encapsulated DT coated onto the microneedle 
array increased linearly with increasing number of the coating layers. Nano-encapsulated DT 
induced stronger immune responses than DT solution when delivered intradermally via 
hollow microneedles, but not when delivered via coated microneedles. In conclusion, both the 
nano-encapsulation of DT and the type of microneedles affect the immunogenicity of the 
antigen.  
Keywords: Coated microneedles, hollow microneedles, mesoporous silica nanoparticles, 
diphtheria toxoid, intradermal vaccination 
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1. Introduction 
Vaccination is one of the most cost-effective tools t  prevent infectious diseases in man [1]. 
Traditional vaccines are based on attenuated or inactivated pathogens. Nowadays, subunit 
vaccines containing only immunogenic parts of a pathogen are being extensively investigated 
because they are safer [2]. The disadvantage of subunit vaccines is that they are generally less 
immunogenic than traditional vaccines. To overcome this, adjuvants such as immune 
modulators and nanoparticulate delivery systems can be used [3, 4].  
Nanoparticles have been extensively studied for the delivery of vaccines, as they can improve 
the immunogenicity of antigens by enhancing the targeting of antigens to antigen-presenting 
cells (APCs) [5]. Furthermore, the immune responses can potentially be modified by tuning 
the properties of nanoparticles such as size, surface charge, and release kinetics of antigens [3, 
6, 7]. Among different types of nanoparticles, mesopor us silica nanoparticles (MSNs) have 
gained increasing attention because of their excellent biocompatibility and stability. Besides, 
the silica surface can be easily modified and functio alized and the large pores and surface 
area of MSNs enable efficient loading of antigens with a high loading capacity [8, 9]. Studies 
have shown that antigen loaded MSNs are able to increase the uptake of antigens by APCs 
and improve immune responses in mice [9-11]. 
Vaccines are mostly administered by intramuscular or subcutaneous injection, but these 
methods have disadvantages such as low acceptance by a considerable number of people and 
infection risk due to needlestick injuries or reuse of needles [12-14]. Additionally, the 
delivery of vaccines to APCs may be inefficient as these delivery sites are not rich of APCs 
[15]. To avoid the drawbacks of hypodermic needles, microneedles have been developed. 
Microneedles are micrometer-sized needle-like structu es and can be used to penetrate skin 
and deliver the antigen in a minimal invasive and pain-free way [16]. The skin contains a 
large number of APCs, and therefore microneedle-mediat  intradermal delivery of vaccines 
has potential for effective vaccination [17].  
Several types of microneedles are in development, such as coated, dissolvable and hollow 
microneedles [16]. On the one hand, coated and dissolvable microneedles are used to 
administer dry-state vaccine formulations [18], which offer the potential advantage of 
improving antigen stability [16, 19]. Previously, silicon microneedle arrays with a pH-
sensitive surface were developed to bind negatively charged vaccines at slightly acidic 
conditions (pH 5.8) and release the coated material at physiological pH (7.4) [20]. Several 
studies have shown that the antigen coated microneedles induced a similar immune response 
as subcutaneously or intramuscularly injected antige  solution [21-23]. On the other hand, 
hollow microneedles are used to inject liquid formulations and the dose can be precisely 
controlled. We previously showed that hollow microneedles together with an applicator can 
be used to deliver antigen-loaded nanoparticles intradermally [24]. 
In this study, we aimed to examine the immunogenicity of intradermally delivered DT loaded 
MSNs by using either coated microneedle arrays or a single hollow microneedle. The 
microneedle arrays were coated with DT loaded in MSNs by using a layer-by-layer coating 
approach after which the delivered dose into ex vivo human skin were examined. In an 
subsequent immunization study, the antibody response i duced by LB-MSN-DT coated 
microneedles was compared with that obtained after inj ction of a suspension of LB-MSN-
DT by hollow microneedles into mouse skin.  
2. Materials and methods 
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2.1. Materials 
DT (batch 04-44, 1 µg equal to 0.3 Lf) and diphtheria toxin were provided by Intravacc 
(Bilthoven, The Netherlands). (3-aminopropyl)triethoxysilane (APTES, 99%), 4-
pyridinecarboxaldehyde (97%), sodium cyanoborohydride (NaBH3CN, 95%), cholesterol 
(≥99%), fetal bovine serum (FBS), M199 medium (with Hank’s salts and L-glutamine) and 
bovine serum albumin (BSA) were obtained from Sigma-Aldrich (Zwijndrecht, The 
Netherlands). 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) and 1,2-dioleoyl-sn-
glycero-3-[phospho-L-serine](sodium salt) (DOPS) were purchased from Avanti Polar Lipids 
Inc (Alabaster, AL). Hydrogen peroxide (30%) was purchased from Fluka (Steinheim, 
Germany). Toluene (≥99.7%) was obtained from Biosolve (Valkenswaard, The Netherlands). 
N-trimethyl chitosan (TMC) and rhodamine labeled TMC (TMC-Rho) were prepared as 
reported previously [23, 25]. Glucose solution, L-glutamine (200 nM), penicillin-
streptomycin (10000 U/mL) and 1-stepTM ultra 3,3',5,5'-tetramethylbenzidine (TMB) were 
purchased from Thermo-Fisher Scientific (Waltham, MA). IRDye 800CW protein labeling kit 
(low molecular weight) was ordered from LI-COR (Lincoln, NE). HRP-conjugated goat anti-
mouse total IgG, IgG1 and IgG2a were ordered from Southern Biotech (Birmingham, AL). 
Sulfuric acid (95-98%) was obtained from JT Baker (Deventer, The Netherlands). Sterile 
phosphate buffered saline (PBS, 163.9 mM Na+, 140.3 mM Cl-, 8.7 mM HPO4
2-, 1.8 mM 
H2PO
4-, pH 7.4) was ordered from B. Braun (Oss, The Netherlands). 1 mM phosphate buffer 
(PB) with a pH of 7.4 or 5.8 was prepared in the lab. Milli-Q water (18 MΩ/cm, Millipore Co.) 
was used for the preparation of all solutions. All the other chemicals used were of analytical 
grade.  
2.2. Preparation of DT encapsulated and lipid fused MSNs (LB-MSN-DT) 
Plain MSNs with a particle size of about 200 nm andlarge pores (about 10 nm in diameter) 
were prepared and modified with amino groups to generate a positively charged surface, as 
described earlier [11, 26]. To improve the colloidal st bility of MSNs, liposomes were coated 
onto the surface of MSNs by using a method as previously described [11]. These liposomes 
were prepared by lipid film hydration followed by sonication. Briefly, DOPC, DOPS and 
cholesterol with a molar ratio of 7:1:2 were dissolved in chloroform in a round bottom flask. 
The organic solvent was evaporated by using a rotary evaporator (Buchi rotavapor R210, 
Flawil, Switzerland) for 30 min. Subsequently, the lipid film was hydrated with 1 mM PB (pH 
7.4) and vortexed for 10 s to form a lipid vesicle suspension. The suspension was sonicated in 
a Branson 2510 water bath (Danbury, CT) for 10 min. The obtained liposomes were stored at 
4 °C in the refrigerator for further use.  
To prepare LB-MSN-DT, 0.5 mL MSNs (2 mg/mL) and 0.5mL DT (0.5 mg/mL) were mixed 
in 1 mM PB (pH 7.4), followed by addition of 0.5 mL liposomes (2 mg/mL) in 1 mM PB (pH 
7.4). To prepare LB-MSN-DT loaded with Alexa488 or IRDye 800CW labeled DT, plain DT 
was replaced with fluorescently labeled DT according the need of experiments. The mixture 
was incubated in an Eppendorf thermomixer (Nijmegen, The Netherlands) for 1.5 h at 25 °C 
with a speed of 300 rpm. To remove the excess DT and liposomes, the suspension was 
centrifuged by using a Sigma 1-15 centrifuge (Osterod , Germany) for 5 min with a speed of 
10,000 g. The resultant pellet was washed and re-dispersed in 1 mM PB (pH 7.4) for further 
use.  
2.3. Characterization of LB-MSN-DT 
2.3.1. Measurement of size and zeta potential of LB-MSN-DT 
Coated and hollow microneedle-mediated intradermal i munization in mice with diphtheria 
toxoid loaded mesoporous silica nanoparticles 
101 
 
The size and zeta potential of LB-MSN-DT were determined by using dynamic light 
scattering (DLS) and laser Doppler velocimetry, respectively, with a Nano ZS® zetasizer 
(Malvern Instruments, Worcestershire, U.K.). The samples were diluted in 1 mM PB (pH 7.4) 
to a concentration of 25 µg/mL (expressed based on the concentration of MSNs) and 
measured 3 times with 10 runs for each measurement. 
2.3.2. Determination of encapsulation efficiency (E) and loading capacity (LC) of DT in 
LB-MSN-DT 
The loading efficiency of DT was determined by measuring the intrinsic fluorescence 
intensity of DT ((λex 280 nm/λem 320 nm) in the supernatant before and after encapsul tion by 
using a Tecan M1000 plate reader (Männedorf, Switzerland). The EE and LC were calculated 
using the equations below:  
EE =
 	!"! 56 
..	  56
 × 100 %                                                   
LC =
 	!"! 56 
IJK3
 × 100 %                                                                                       
Where Mloaded DT represents the mass of encapsulated DT, Mtotal DT is the total amount of DT 
added to the formulation and MMSNs is the weight of MSNs.  
2.3.3. In vitro release of DT from LB-MSN-DT 
To study the release of DT, 1 mL nanoparticle suspen ion with a concentration of 1 mg/mL 
(expressed based on the concentration of MSNs, corresponding to about 0.2 mg/mL DT) in 
PBS was incubated for one month at 37 °C by using an Eppendorf thermomixer (Nijmegen, 
The Netherlands) set at a speed of 550 rpm. At predetermined time points, the samples were 
centrifuged for 5 min with a speed of 10,000 g. 600 µL sample from the supernatant was 
collected and the amount of DT was measured by intrinsic fluorescence intensity of DT. Fresh 
PBS with the same volume of the collected supernatant w s added back to the suspension. 
The release percentage of DT was calculated by dividing the released amount of DT by the 
total amount of DT initially loaded in LB-MSN-DT. 
2.4. Coating of LB-MSN-DT on microneedle arrays and release of LB-MSN-DT in ex 
vivo human skin 
2.4.1 Modification of microneedle arrays to achieve a pH-sensitive surface  
Silicon microneedle arrays with 576 microneedles per array on a back plate of 5 × 5 mm2 with 
a microneedle length of 200 µm were kindly provided by Robert Bosch GmbH (Stuttgart, 
Germany). To obtain pH-sensitive microneedles, the surface was modified with pyridine 
groups as previously reported [20]. In brief, the microneedle surface was first cleaned by 
piranha solution (70% sulfuric acid and 30% hydrogen p roxide) at 120 °C for 2 h. Caution: 
piranha is strongly acidic and oxidizing. Piranha reacts violently with organic compounds, 
and it should not be stored in closed containers. Subsequently, the microneedles were 
extensively washed with MilliQ water followed by washing with acetone and methanol. Next, 
the microneedles were incubated in 2% APTES in toluene overnight to obtain an amine-
modified surface and thereafter incubated with 4-pyridinecarboxaldehyde (100 mM) in 
anhydrous isopropanol containing 1% acetic acid overnight. Finally, the formed imine bonds 
were reduced to secondary amines by incubating the microneedles with NaBH3CN (50 mM) 
in isopropanol for 2 h. After cleaning the microneedl s were stored under vacuum at 50 °C 
until further use. 
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2.4.2 Multilayer coating of LB-MSN-DT on the surface of microneedle arrays 
LB-MSN-DT and TMC were alternately coated onto the surface of microneedle arrays by 
using a layer-by-layer approach. The pH-sensitive microneedle arrays were transferred into 
Greiner Cellstar® 48 well plates. 50 µL negatively charged LB-MSN-DT (0.5 mg/mL) in 1 
mM PB (pH 5.8) was added onto the top of each microneedle array and the arrays were 
incubated for 30 min. The excess nanoparticles were ashed by adding 450 µL 1 mM PB (pH 
5.8). Next, the microneedle arrays were dried under pr ssurized nitrogen flow for 10 min. 
After the first coating layer of LB-MSN-DT, 50 µL positively charged TMC (40 µg/mL) in 1 
mM PB (pH 5.8) was added onto the top of each microneedle array and the arrays were 
incubated with TMC for another 30 min. The concentration of LB-MSN and TMC in the 
coating solutions based on prior studies [11, 23]. The excess TMC was removed by washing 
the microneedle arrays with 450 µL 1 mM PB (pH 5.8). Subsequently, the microneedle arrays 
were dried under nitrogen flow as described above. This procedure was repeated until the 
desired number of coating layers of LB-MSN-DT was reached. After the last layer of LB-
MSN-DT, no more TMC was coated onto the microneedle surface. In order to study the dose 
effect of DT using coated microneedles, the microneedle arrays were coated with either 5 or 3 
layers of LB-MSN-DT and 4 or 2 alternate layers of TMC, respectively. 
To determine the coating efficiency of DT on microneedles, the amount of nano-encapsulated 
DT in the supernatant after washing was determined by measuring the intrinsic fluorescence 
of DT. The coating efficiency was calculated by divi ing the amount of coated DT by the 
total amount of DT initially added to the coating solution. 
2.4.3 Insertion of microneedle arrays into ex vivo human skin 
 Ex vivo human skin was obtained from a local hospital according to Helsinki principles. A 
written informed patient consent was obtained. To reproducibly insert the microneedles into 
the skin, an in-house developed impact-insertion injector together with a uPRAX applicator 
controller (Delft, The Netherlands) was used by using either a single insertion mode or 
multiple insertion mode [27, 28]. In case of a single insertion, the microneedle arrays were 
inserted into the skin with an average velocity of 0.5 m/s and kept in the skin for 30 min by 
applying a force of 5 N on top of the microneedle array. In case of multiple insertion mode, 
the microneedle arrays were 10 times inserted into the skin within 10 s with an average 
velocity of 0.5 m/s. After the last penetration, the microneedles were removed from the skin.  
2.4.4 Visualization of the coated microneedles before and after penetration of ex vivo 
human skin by scanning electronic microscopy (SEM)  
The 5-layer LB-MSN-DT coated microneedles were visualized with a Nova NanoSEM 
(Eindhoven, The Netherlands) operated with a voltage of 15 kV before and after removal 
from the skin. To increase the surface conductivity, the microneedle arrays were coated with a 
layer of platina/palladium before visualization.  
2.4.5 Release of LB-MSN-DT from microneedle arrays into ex vivo human skin 
To visualize the release of LB-MSN-DT from microneedle arrays into the skin, the 5-layer 
LB-MSN-DT coated microneedle arrays and the released nanoparticles in the skin were 
visualized by using a Nikon D-Eclipse C1 CLSM (Toky, Japan). For this purpose, DT-
Alexa488 and TMC-Rho were used. The coated microneedles and the skin area penetrated by 
coated microneedles were scanned with a depth resolution of 5 µm/step by using a 10 × and 4 
× Plan Apo objective, respectively. An argon laser (488 nm) with a 530/55 emission filter and 
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a diode-pumped solid-state laser (561 nm) with a 590/55 emission filter were used for 
visualization of DT-Alexa488 and TMC-Rho, respectively.  
The released amount of DT in the ex vivo human skin was quantified by using a Perkin-Elmer 
IVIS Lumina Series III in vivo imaging system (Waltham, MA, USA). For this purpose, DT 
was labeled with IRDye 800 CW (DT-IRDye800) by using a IRDye 800CW protein labeling 
kit (low molecular weight) according to the manufacturer's instruction. The LB-MSN-DT-
IRDye800 coated microneedles were inserted into human skin by using either the single or 
multiple insertion mode as described above. A calibr t on curve was prepared by injecting 
different amounts of LB-MSN-DT-IRDye800 in the skin by using a hollow microneedle (see 
below). To determine the amount of DT released from the coated microneedles, the 
fluorescence intensity of DT-IRDye800 in the skin was measured by using the in vivo 
imaging system with a 745 nm excitation wavelength and an ICG emission filter. By using the 
calibration curve the amount of delivered DT was calcul ted.    
2.5. Hollow microneedles and applicator 
The hollow microneedles were prepared by etching of fused silica capillaries with 
hydrofluoric acid, as previously described [29]. In brief, silica capillaries (375 µm outer 
diameter, 50 µm inner diameter) were cut into 4-cm pieces and filled with silicone oil in a 
vacuum oven (100 ºC) overnight. The tips of capillaries were etched in ≥48% hydrofluoric 
acid for 4 h. Subsequently, the polyimide coating was removed by dipping the microneedle 
tips into hot sulfuric acid (250 ºC) for 5 min. The applicator for hollow microneedles consists 
of a syringe pump and an injector for precise control of injection depth, rate and volume. The 
hollow microneedles, injector and pump were connected by silica capillaries and high-
pressure resistant CapTiteTM connectors [24]. 
2.6. Immunization studies in mice 
Female BALB/c mice of 7-8 weeks old (Charles River, Maastricht, The Netherlands) at the 
start of the experiments were used for the immunization study. The animals were housed 
under standardized conditions in the animal facility of Leiden Academic Centre for Drug 
Research. The study was approved by the ethical committee on animal experiments of Leiden 
University (Licence number 14166).  
Mice were first anesthetized by intraperitoneal injection of ketamine (60 mg/kg) and xylanize 
(4 mg/kg) before shaving the abdomen area. In case of coated microneedles, the LB-MSN-DT 
coated microneedle arrays were inserted into the abdomen of mice by using the multiple 
insertion mode as described above for the studies in ex vivo human skin. Each mouse was 
immunized with one microneedle array coated with eier 5 or 3 layers of LB-MSN-DT. In 
case of hollow microneedles the following groups were included: a) 10 µL suspension of LB-
MSN-DT, b) 10 µL DT solution and c) 10 µL DT and TMC solution. All formulations of 
hollow microneedle groups contained 0.31 µg DT. Thesame amount of TMC was included in 
the DT and TMC group. The formulation was injected into the skin of the abdomen of mice 
with a rate of 10 µL/min at a depth of 120 µm. Subcutaneously injected 5 µg DT formulated 
with 150 µg colloidal aluminum phosphate (DT-Alum) in PBS with a volume of 100 µL was 
used as a positive control. The mice were immunized on day 0 (prime), 21 (1st boost), 42 
(2nd boost) and sacrificed on day 56. The serum was ithdrawn from the tail veins of the 
mice on day 0, 21 and 42 prior to the immunization. O  day 56 the serum was collected from 
thoracic vein and the mice were sacrificed by cervical dislocation.  
2.7. Measurement of DT-specific antibody titers 
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The total IgG and subtype IgG1 and IgG2a titers in the serum were measured by using ELISA 
as previously reported [30]. Briefly, the wells of 96-well plates were first coated with 140 ng 
DT overnight at 4 °C. Next, the plates were blocked with 1% BSA and appropriate 3-fold 
serial diluted serum samples were applied to the plates and incubated for 2 h at 37 °C. 
Subsequently, HRP-conjugated goat anti-mouse total IgG, IgG1 and IgG2a were added into 
the wells and incubated for 1.5 h. Finally, TMB was added to the plates and 2 M sulfuric acid 
was added to stop the reaction. The absorbance was me ured at 450 nm by using a Tecan 
M1000 plate reader. The antibody titers were expressed as the 10log value where the 
corresponding absorbance is located in the middle of the S-shaped dilution-absorbance curve. 
2.8. Measurement of DT-neutralizing antibody titers  
To check the functionality of the antibodies, diphtheria toxin neutralizing antibody titers in 
the serum of the mice at day 56 were checked by using a Vero-cell assay [31]. Briefly, 
appropriate 2-fold serial diluted serum was first applied to 96-well plates. 5 × 10-5 Lf 
diphtheria toxin was added to each well and incubated for 2 h at 37°C in a stove with 5% CO2. 
Subsequently, 1.25 × 104 Vero cells were added to each well and incubated for 6 days at 37°C 
in the stove with 5% CO2. Finally, the neutralizing antibodies were shown as the 
2log value of 
the highest dilution times of serum that protected the Vero cells. 
2.9. Statistics analysis 
All the data of antibody titers were analyzed by one way ANOVA with Newman-Keuls 
Multiple post-test by using GraphPad Prism software (version 5.02). The level of significance 
was set at *p < 0.05, **p < 0.01, ***p < 0.001. 
3. Results  
3.1. Physicochemical characteristics of LB-MSN-DT 
The physicochemical characteristics of LB-MSN-DT are shown in Table 1. The size of LB-
MSN-DT was approximately 700 nm with a polydispersity index (PDI) slightly larger than 
0.3. The nanoparticles showed a high negative zeta potential. DT was efficiently encapsulated 
into the nanoparticles with a high EE and LC.  
Table 1. Physicochemical characteristics of LB-MSN-DT (n=3). 
Nanoparticles Sizea (nm) PDIb ZPc (mV) EE%d  LC% e  
LB-MSN-DT 676 ± 7 0.322 ± 0.016 -35 ± 1 77.1 ± 6.4 19.3 ± 1.6 
Data are average ± SEM of 3 independent batches.  
aSize: Z-average in diameter, bPDI: polydispersity index, cZP: zeta potential, dEE: 
encapsulation efficiency, eLC: loading capacity. 
3.2. In vitro release of DT from LB-MSN-DT 
The in vitro release of DT was investigated by suspending LB-MSN-DT in PBS for one 
month. As shown in Fig. 1, there was a moderate burst release of DT of about 20% within the 
first day, followed by a sustained release, reaching a total release percentage of about 70% on 
day 30. These results indicate that the LB-MSN-DT may serve as a reservoir and allow the 
sustained release of DT, but at the same time retain sufficient DT for a prolonged period of 
time to deliver it as nanoparticulate antigen to APCs.  
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Figure 1. In vitro release of DT from LB-MSN-DT in PBS at 37 ˚C as a function of time. 
Bars represent mean ± SEM, n = 3. 
 
3.3. Coating of LB-MSN-DT on microneedle arrays and release of LB-MSN-DT in ex 
vivo human skin 
3.3.1 Quantification of coated amount of nano-encapsulated DT on microneedle arrays 
As shown in Fig. 2A, the amount of nano-encapsulated DT that was coated onto the 
microneedles increased linearly with increasing number of layer coatings. About 0.4 µg DT 
was coated onto the microneedles of one microneedle array per layer. The coating efficiency 
was similar for each layer and was about 20-26% (Fig. 2B). As shown in Table 2, the 
cumulative amount of nano-encapsulated DT coated on the microneedle surfaces of one 
microneedle array was about 1.9 µg and 1.1 µg, corresponding to 9.7 µg and 5.7 µg LB-
MSN-DT (based on the mass of MSNs) for a 5-layer and 3-layer coating, respectively.  
 
 
Figure 2. Cumulative amount of nano-encapsulated DT (A) that was coated on the 
microneedles of one microneedle array and coating efficiency (B) as a function of the number 
of layers. Data is represented as average ± SEM of 3 independent microneedle arrays. 
 
 
Chapter 6 
106 
 
Table 2. Coated and released amount of DT/LB-MSN-DT from the microneedles of a single 
1microneedle array (n=3). 
Microneedles Coated DT (µg) 
a Coated 
LB-MSN-
DT (µg) 
b Delivered DT (µg) 
c Delivered percentage 
(%) 
Multiple 
insertion 
mode 
Single    
insertion 
mode 
Multiple 
insertion 
mode 
Single 
insertion 
mode 
5-layer 
coated 
1.9±0.1 9.7±0.2 0.814±0.008 0.341±0.083 42.8±0.1% 17.9±0.8% 
3-layer 
coated 
1.1±0.1 5.7±0.2 0.256±0.001 - 23.2±0.0% - 
Data are average ± SEM of 3 independent microneedle arrays.  
a The coated amount of LB-MSN-DT is expressed as the mass of MSNs and was calculated by 
using the coated amount of DT and loading capacity of DT in LB-MSN-DT. 
b The delivered dose of DT was measured in ex vivo human skin. 
c Delivered percentage was calculated by dividing the delivered amount of DT in ex vivo 
human skin by the coated amount of DT on the microneedles. 
3.3.2 Visualization of coated microneedles before and after penetrating ex vivo human 
skin by SEM 
The 5-layer LB-MSN-DT coated microneedles were visualized by SEM. The uncoated pH-
sensitive microneedles showed a smooth surface (Fig. 3A, B1-B2). On the surface of LB-
MSN-DT coated microneedles (Fig. 3C1-C2), single nanoparticles or clusters of 
nanoparticles were observed. After insertion of the microneedles into and removal from the 
skin, the nanoparticle density was reduced on the microneedle surface (Fig. 3D1-D2). 
3.3.3 Visualization of the released LB-MSN-DT in ex vivo human skin  
After observation of the reduction of the number of nanoparticles on the microneedle surface 
after penetration in and withdrawal from human skin, CLSM was used to visualize the 
released LB-MSN-DT in the skin. To this end, the 5-layer LB-MSN-DT coated microneedles 
before penetration of the skin were first visualized (Fig. 4). The green color from DT-
Alexa488 (Fig. 4A) and red color from TMC-Rho (Fig. 4B) were observed and they 
colocalized on the surface of the microneedles (Fig. 4C). These results support the SEM 
images of LB-MSN-DT coated microneedles (Fig. 3C1-C2), further revealing that LB-MSN-
DT were successfully coated onto the surface of the microneedles.  
Next, the released LB-MSN-DT in the skin was visualized by CLSM. After a single insertion, 
the fluorescence of the released DT-Alexa488 and TMC-Rho were clearly observed (Fig. 4D-
F). The green color from DT-Alexa488 (Fig. 4D) and red color from TMC-Rho (Fig. 4E) co-
localized in the micro-channels induced by the microneedles (Fig. 4F). After the 
microneedles were inserted in and withdrawn from the skin by using the multiple insertion 
mode, clearly more micro-channels were observed as indicated by the fluorescence of DT-
Alexa488 and TMC-Rho (Fig. 4G-I). These results together with the SEM images of the 
coated microneedles after penetration of the skin indicate that LB-MSN-DT were successfully 
released into skin.  
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Figure 3. Scanning electron microscopy (SEM) images of uncoated pH-sensitive 
microneedles (A, B1-B2), microneedles coated with 5 layers of LB-MSN-DT/TMC (C1-C2), 
and the microneedles after insertion into and removal (multiple insertion mode) from ex vivo 
human skin (D1-D2).  
 
Figure 4. Confocal laser scanning microscopy (CLSM) images of 5-layer LB-MSN-DT 
coated microneedles (A: DT-Alexa488; B: TMC-Rho; C: merged), and ex vivo human skin 
after insertion and removal of microneedle arrays (5-layer coated) by using single (D: DT-
Alexa488; E: TMC-Rho; F: merged) or multiple insertion mode (G: DT-Alexa488; H: TMC-
Rho; I: merged).  
3.3.4 Quantification of the released amount of DT from microneedles into ex vivo human 
skin  
As shown in Table 2, after insertion of the 5-layer coated microneedle arrays into ex vivo 
human skin, the delivery efficiency from the microneedles by using the multiple insertion 
mode (42.8%) was more than twice as high compared to that in single insertion mode (17.9%). 
Based on this observation, the multiple insertion mode was chosen for subsequent penetration 
Chapter 6 
108 
 
studies. Next, the released amounts of DT from microneedles coated with 5 and 3 layers of 
LB-MSN-DT were compared. The amount of delivered DTin the skin from one 5-layer 
coated microneedle array (0.814 µg) was about 3-fold higher than that from a 3-layer coated 
microneedle array (0.256 µg) (Table 2).  
3.4. IgG antibody titers after intradermal vaccination 
 
Figure 5. DT-specific total IgG antibody titers on day 21 (A), 42 (B) and 56 (C). Bars 
represent mean ± SEM, n = 8. *p < 0.05, **p < 0.01, ***p < 0.001. 
Total IgG titers are shown in Fig. 5. On day 21 all groups showed detectable total IgG titers 
(Fig. 5A). On day 42, the responses of all groups increased compared to those on day 21. 
Responses of hollow microneedle injected LB-MSN-DT were significantly higher than those 
induced by DT/TMC solution and LB-MSN-DT coated microneedle groups (Fig. 5B) 
(p<0.05). On day 21 and 42, DT-Alum induced higher total IgG responses than other groups, 
probably due to the much higher dose used (p<0.01). On day 56, the responses of hollow 
microneedle injected LB-MSN-DT and 5-layer LB-MSN-DT coated microneedles increased 
to similar IgG levels as those induced by DT-Alum, despite the ca. 15-fold lower dose, while 
DT/TMC solution elicited significantly lower levels than DT-Alum.  
In all these three immunizations, the addition of TMC did not improve the total IgG response. 
Additionally, 5-layer LB-MSN-DT coated microneedles seemed to induce a stronger total IgG 
response than 3-layer coated microneedles, although the difference was not significant 
(p˃0.05). In summary, LB-MSN-DT delivered by both coated and hollow microneedles 
successfully induced DT-specific total IgG responses. LB-MSN-DT induced superior total 
IgG responses as compared to DT/TMC solution when administered by hollow microneedles 
(after 1st boost), but not when using coated microneedles. 
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Figure 6. DT-specific IgG1 (A, C, E) and IgG2a (B, D, F) antibody titers on day 21 (A, B), 
42 (C, D) and 56 (E, F). Bars represent mean ± SEM, n = 8. *p < 0.05, **p < 0.01, *** p < 
0.001.  
 
Besides total IgG, we measured the subtype IgG1 and IgG2a titers. As shown in Fig. 6, IgG1 
followed the trend of total IgG (Fig. 6A, C, E). Hollow microneedle injected LB-MSN-DT 
induced stronger responses than DT/TMC solution (after 1st boost). However, this advantage 
of using LB-MSN-DT disappeared when LB-MSN-DT were delivered by coated 
microneedles. In case of IgG2a titers, on day 21 all groups except coated microneedles 
induced detectable IgG2a titers (Fig. 6B). On day 42, DT-Alum induced significantly higher 
titers than other groups (Fig. 6D) (p˂0.05). Although not significant, hollow microneedle 
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injected LB-MSN-DT seemed to induce a higher IgG2a response compared to DT solution 
(p=0.10) and coated microneedles (p=0.12). On day 56, hollow microneedle injected LB-
MSN-DT and DT solution showed significantly higher IgG2a titers than 3-layer LB-MSN-DT 
coated microneedle group (p˂0.01), but this was not significant compared to 5-layer LB-
MSN-DT coated microneedles (Fig. 6F) (p=0.15). Furthermore, the IgG2a titers induced by 
hollow microneedle injected LB-MSN-DT reached a level similar to those induced by DT-
Alum. In summary, hollow microneedle injected LB-MSN-DT induced stronger IgG1 and 
IgG2a titers than LB-MSN-DT coated microneedles. 
The functionality of the antibody response was determined by measuring the DT-neutralizing 
antibodies from serum taken on day 56. As expected, the subcutaneously injected DT-Alum 
with a high dose induced high neutralizing antibody titers (Fig. 7). Hollow microneedle-
injected LB-MSN-DT showed a significant higher neutralizing response than a mixture of DT 
and TMC solution and coated microneedle groups.  
 
Figure 7. DT-neutralizing antibody titers of mice. Results are shown for serum collected on 
day 56. Bars represent mean ± SEM, n = 8. *p < 0.05, *** p < 0.001.  
 
4. Discussion 
Microneedle technologies for the intradermal delivery of drugs, including vaccines, have been 
extensively investigated during the past twenty years [32]. As the skin contains a large 
number of APCs, such as epidermal Langerhans cells and dermal dendritic cells, 
microneedles have gained particular attention as attractive delivery systems for intradermal 
vaccination [33]. In this study, we investigated the immunogenicity of DT encapsulated 
MSNs after coated microneedle- and hollow microneedle-mediated intradermal immunization 
in mice. We showed that LB-MSN-DT delivered by both coated and hollow microneedles 
induced DT-specific antibody titers. Both the nano-encapsulation of DT and the type of 
microneedles were found to affect the immune respones.   
Nanoparticulate vaccines have been reported to enhance the immunogenicity of antigens by 
increasing their uptake by APCs [3, 34]. In this study, MSNs were chosen for the loading of 
DT as they have large pores which allow for efficient loading of antigen [11]. In a previous 
study it was shown that ovalbumin (OVA) loaded MSNs were able to elicit antibody 
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responses with a reduced antigen dose compared to OVA solution adjuvanted with QuilA [9]. 
In another study, MSNs loaded with a virus related antigen induced 10-fold higher antibody 
responses than the mixture of the antigen and an immune modulator [10]. Our findings are in 
line with these results, as we showed that hollow microneedle injected LB-MSN-DT induced 
distinctly higher total IgG and IgG1 titers as compared to a solution of plain DT.   
When coating LB-MSN-DT onto the microneedle arrays, the coated amount of DT per layer 
on one microneedle array (about 500 ng) was higher than that reported in a previous study 
(about 300 ng) where plain DT was coated onto the same type of microneedle arrays [23]. The 
high loading capacity of DT in LB-MSN-DT together with the high surface charge of LB-
MSN-DT may synergistically lead to this higher coating amount. Additionally, the multilayer 
coating approach used in the current study can further increase the coated amount of antigen 
by increasing the number of coating layers. By adjusting the number of coating layers, the 
coated amount of nanoparticles/antigen can be tailored. 
Besides the successful coating of antigen on microneedles, it is important to have a fast 
release of the coating after the microneedles were p netrated into skin. Here we showed that 
by using a multiple insertion mode (10 penetrations within 10 s), the released amount of 
antigen was increased by 2.5-fold as compared to a single insertion mode. The amount of DT 
released into the skin was also increased compared to that released from the 5 layer coatings 
of plain DT using a single penetration [23]. Therefo , the combination of multiple insertions 
with nanoparticle coatings may require less coating layers, which will facilitate the production 
process of coated microneedles. When using multiple ins rtions, the application time was 
much shorter than that used in single penetration mode. The improvement of release 
efficiency may be due to the friction force between the microneedles and the skin tissue when 
the microneedles were inserted in and removed from the skin. The short wearing time of 
microneedles by using the multiple insertion mode might help improving the acceptance by 
vaccinees. 
While hollow microneedle injected LB-MSN-DT induced a stronger immune response as 
compared to plain DT, LB-MSN-DT delivered by coated microneedles induced a comparable 
response as DT/TMC solution. The results of coated microneedles are in contrast with those 
reported in a recent study, which showed that nanoprticulate vaccine coated microneedles 
induced superior immune responses as compared to antigen solution intradermally delivered 
by a hypodermic needle [35]. One explanation is that the dose delivered by coated 
microneedles may be lower than that delivered by hollow microneedles. However, there are at 
least two arguments against this hypothesis. Firstly, the coated microneedles delivered a two-
fold higher (5-layer coated) or comparable (3-layer coated) dose in ex vivo human skin, 
respectively, compared to that delivered by hollow microneedles. Secondly, a previous study 
showed that the delivery amount of antigen from coated microneedles into ex vivo human skin 
was similar as that delivered in ex vivo mouse skin [23]. Therefore, the lower than expected 
responses of coated microneedle delivered LB-MSN-DT was not likely caused by lower dose 
of DT delivered.  
Although the LB-MSN-DT coated microneedles induced similar total IgG and IgG1 
responses as compared to hollow microneedle injected LB-MSN-DT on day 56 (p>0.05), they 
induced distinctly lower IgG2a responses. At the same time, it has been reported that nano-
encapsulation of antigen can increase IgG2a responses [24, 36]. These results suggest that the 
advantage of using nanoparticles is abrogated when they are delivered by coated microneedles. 
One possible explanation for the lower response induce  by coated microneedles is that the 
nanoparticles were not released from the nanoparticle/TMC layers after their deposition in the 
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skin. As a result, the nanoparticles may be not effici ntly taken up by APCs or drained to 
lymph nodes. In the hollow microneedle groups, the addition of TMC did not improve the 
immune responses either. An adjuvant effect of TMC has been reported for hypodermic 
needle-mediated intradermal vaccination [37]. This inconsistency may be caused by the much 
lower dose of TMC used in our study.  
Previous studies have shown that IgG1 titers may be mainly responsible for the neutralizing 
titers against diphtheria toxin [31]. However, our results showed that although hollow 
microneedle and coated microneedle groups induced IgG1 responses close to those induced 
by DT-Alum, they still induced much lower neutralizing antibodies. These results indicate 
that the IgG1 titers may need to reach a certain threshold in order to achieve protection 
against diphtheria toxin. 
5. Conclusion 
In this study, we showed that DT loaded MSNs can be successfully delivered into mice by 
using coated and hollow microneedles, and evoke DT specific antibody responses. When 
inserting coated microneedles into skin, the multiple insertion mode of the applicator 
significantly increased the release efficiency of the coating compared to the single insertion 
mode. DT encapsulated in MSNs induced a stronger antibody response than antigen solution 
when delivered by hollow microneedles (after 1st boost), but not by coated microneedles. Our 
results revealed that both the nano-encapsulation of DT and the type of microneedles affect 
the immunogenicity of the antigen.  
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Introduction 
Microneedles have been extensively investigated for intradermal delivery of vaccines during 
the last two decades. They are, as the name suggests, n edle-like structures with a length 
shorter than 1 mm. The microneedles can be used to effectively pierce stratum corneum, 
which is the upper-most layer and the main barrier of skin, thereby facilitating the delivery of 
vaccines into the skin [1, 2]. As the microneedles do not reach nerves and blood vessels, the 
application of microneedles is minimally invasive and pain free. This will minimize the stress 
caused by traditional hypodermic needles and thus may i prove the compliance of vaccinees. 
Furthermore, as the skin contains a large number of antigen-presenting cells (APCs), such as 
epidermal Langerhans cells and dermal dendritic cells, microneede-mediated intradermal 
delivery of vaccines has high potential for effective vaccination [3]. 
Different types of microneedles have been developed for vaccine delivery. Initially, solid 
microneedles were used to pierce the skin, after which vaccine formulations were applied 
topically onto the penetrated skin after removal of the microneedles [4]. However, an 
important drawback of this method is that the delivery efficiency of vaccines is low as the 
diffusion through the conduits is limited because of the small diameter of the conduits. To 
increase the delivery efficiency, coated, dissolvable and hollow microneedles are now being 
investigated. Coated microneedles are prepared from solid microneedle arrays by coating the 
microneedle surface with vaccines. After the microneedle arrays are inserted, the coating is 
deposited in the skin. Dissolvable microneedles are made of soluble polymers, biodegradable 
polymers or sugars and the vaccines are loaded in the matrix of microneedles. After insertion 
of microneedles in the skin, the matrix starts to dissolve or degrade, thereby releasing the 
vaccine. Hollow microneedles contain a conduit through which the vaccine formulation can 
be injected into the skin. The preparation methods f these different types of microneedles 
have been extensively reviewed [1-3, 5]. 
Nanoparticulate vaccines are antigen loaded nanoparticles with a diameter less than 1000 nm 
[6]. Nanoparticles are capable of protecting the antige  from degradation and increasing the 
uptake of antigen by APCs. Additionally, nanoparticles allow the co-delivery of antigen and 
adjuvant, which has been reported to be crucial for improving immune responses [7, 8]. 
Besides, it has been reported that the immune responses can be modified or enhanced by 
tuning the physicochemical characteristics of nanoprticulate vaccines, such as size, surface 
charge and release kinetics of antigen and adjuvant [9, 10]. Various types of nanoparticles 
have been investigated as vaccine delivery systems, such as polymeric nanoparticles, 
liposomes, inorganic nanoparticles, et al [6]. 
Nowadays, an increasing number of studies are focusing on the use of microneedles for 
intradermal delivery of nanoparticulate vaccines, aiming to combine the advantages of both 
microneedles and nanoparticulate vaccines. A previous study showed that microneedles 
coated with antigen loaded lipid nanocapsules result d in a higher IgG2a response than plain 
antigen coated microneedles [11]. Other studies showed that dissolvable microneedles loaded 
with antigen containing PLGA nanoparticles induced stronger Th1/CD8+ responses than 
antigen solution [12, 13]. Besides, hollow microneedl  injected toxoid-loaded chitosan 
nanoparticles induced a higher IgG2a response and stronger expression of Th1 cytokines than 
a commercial vaccine of tetanus toxoid [14]. All of these studies showed the advantages of 
using microneedles for intradermal delivery of nanoparticulate vaccines.  
The aim of this thesis was to determine 1) whether mic oneedles can be used and optimized to 
effectively deliver nanoparticulate vaccines intradermally and 2) whether the physicochemical 
characteristics of nanoparticulate vaccines have an ffect on the immunogenicity of antigens 
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after microneedle-mediated intradermal vaccination. In this thesis, we focused on the use of 
coated and hollow microneedles for the delivery of nanoparticulate vaccines. In case of coated 
microneedles, silicon microneedle arrays were modifie  with pyridine groups to obtain a pH-
sensitive surface. These microneedles are capable of binding negatively charged antigens at 
acidic conditions and releasing the coating at neutral pH [15, 16]. In case of hollow 
microneedles, the microneedles were prepared by etching fused silica capillaries with 
hydrofluoric acid [17]. These microneedles can be used to inject liquid formulations 
intradermally into the skin. Microscopy images of the microneedle array and hollow 
microneedle are shown in Fig. 1. 
In the studies described in this thesis, the coated nd hollow microneedles were developed and 
combined with nanoparticles with various physicochemical characteristics. The efficacy of 
these antigen loaded nanoparticles with and without co-encapsulation of an immune 
modulator on improving or modulating the immune responses was investigated. 
 
Figure 1. Microscopy images of microneedles. A: scanning electron microscopy (SEM) 
image of a pH-sensitive microneedle array, B: bright-field microscopy image of a hollow 
microneedle. 
Summary of the results 
In Chapter 1, a short introduction to the use of microneedles and nanoparticles for vaccine 
delivery via the skin is given. Next, the progress of using microneedles for intradermal 
delivery of nanoparticulate vaccines is briefly described. Finally, the aim and the outline of 
the thesis are provided.  
In Chapter 2, a study is described in which a new type of mesoporous silica nanoparticles 
(MSNs) with large pores (about 10 nm) was successfully developed. The synthesized 
nanoparticles showed an efficient loading of ovalbumin (OVA) with a maximum loading 
capacity of about 34%. The colloidal stability of the MSNs was enhanced by coating the 
surface of antigen loaded MSNs with a negatively charged lipid bilayer (LB-MSN-OVA). To 
examine whether the MSNs could enhance antigen uptake by dendritic cells, the uptake of 
OVA loaded in LB-MSN-OVA by bone marrow derived denritic cells (BMDCs) was 
examined. Indeed, LB-MSN-OVA showed a higher uptake than free OVA. In the next step, 
nanoparticles were coated onto pyridine-modified microneedle arrays. The coating process 
was based on the electrostatic interaction between th  positively charged microneedles and 
the negatively charged nanoparticles. Scanning electron microscopy (SEM) and confocal laser 
scanning microscopy (CLSM) showed that LB-MSN-OVA were successfully coated onto the 
microneedle surface. About 1.5 μg of encapsulated OVA was coated onto one microneedle 
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array. Finally, a release study showed that LB-MSN-OVA were successfully released from 
the microneedles upon piercing ex vivo human skin.  
The studies described in Chapter 3 focus on poly(lactic-co-glycolic acid) (PLGA) 
nanoparticles. OVA loaded PLGA nanoparticles with a positive or negative zeta potential and 
OVA and poly(I:C) co-encapsulated PLGA nanoparticles (with a negative zeta potential) were 
prepared  The effect of encapsulation of OVA with or without poly(I:C) on T cell responses 
was investigated after hollow microneedle mediated intradermal immunization in mice. 
Firstly, the capacity of OVA-loaded PLGA nanoparticles to induce T cell responses in OVA-
specific T cell (OT-I and OT-II cells) transferred mice was studied. It was shown that OVA-
loaded PLGA nanoparticles with a positive or negative zeta potential induced similar 
proliferations of the adoptively transferred OVA-specific CD8+ and CD4+ T cells, which were 
both significantly higher than those induced by OVA solution. Next, the capacity of PLGA 
nanoparticles loaded with OVA with and without poly(I:C) to induce endogenous T cell 
responses in wild type mice was studied. The OVA-loaded PLGA nanoparticles (both cationic 
and anionic), and OVA and poly(I:C) co-encapsulated nanoparticles were found to be able to 
induce endogenous OVA-specific CD8+ T cell responses in the wild type mice. The addition 
of poly(I:C) (either mixed with OVA solution or co-encapsulated with OVA in PLGA 
nanoparticles) enhanced CD8+ T cell responses. Furthermore, OVA loaded PLGA 
nanoparticles with a positive zeta potential induced stronger endogenous CD8+ T cell 
responses than anionic PLGA nanoparticles. Finally, it was studied whether the elicited 
endogenous T cell responses were able to protect th wild type mice from infection with 
OVA-secreting intracellular bacterium Listeria monocytogenes. It was shown that OVA and 
poly(I:C) co-encapsulated PLGA nanoparticles provided a full protection against the 
bacterium. In summary, in this study it was shown that PLGA nanoparticle formulations are 
excellent systems for delivery of protein antigen into the skin to induce protective cellular 
immune responses by using hollow microneedles for intradermal immunization. 
The results of Chapter 2 and 3 demonstrate the advantages of using nanoparticulate vaccines 
for improving the immunogenicity of antigen. In Chapter 4, studies are reported in which 
hollow microneedles were used to further investigate the effect of nano-encapsulation of 
antigen and adjuvant on the immune responses. OVA and poly(I:C) loaded PLGA 
nanoparticles, liposomes, MSNs and gelatin nanoparticles (GNPs), covering a broad range of 
physicochemical particle characteristics, were compared. PLGA nanoparticles and liposomes 
showed a smaller particle size (below 200 nm) and slower release of OVA/poly(I:C) than 
MSNs and GNPs (mean particle size of both particles was about 500-700 nm). The 
vaccination studies revealed that the encapsulation of OVA and co-encapsulation of OVA and 
poly(I:C) in the various types of nanoparticles induced similar total IgG and IgG1 responses, 
but higher IgG2a antibody responses as compared to OVA/poly(I:C) solution. The type of 
nanoparticles had a major effect on the IgG2a response: PLGA nanoparticles and cationic 
liposomes induced higher responses than MSNs and GNPs, correlating with a smaller 
nanoparticle size and a slower release of antigen and adjuvant. When studying cell mediated 
immune responses, the antigen and adjuvant loaded cationic liposomes induced the strongest 
proliferation of adoptively transferred CD8+ and CD4+ T cells, suggesting their superiority for 
intradermal vaccination over the other nanoparticles. The studies described in this chapter 
demonstrate that the in-house developed hollow microneedles can be used to screen different 
nanoparticulate vaccine formulations for intradermal vaccination. 
After the observation of the superior immune respones of antigen and adjuvant co-
encapsulated liposomes as compared to other nanoparticles, the aim of the next series of 
studies was to examine whether the co-encapsulation of a tigen and adjuvant in liposomes is 
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a crucial factor for the higher IgG2a responses. These studies have been described in Chapter 
5, using the same type of cationic liposomes as in the studies reported in Chapter 4. 
Diphtheria toxoid (DT) and poly(I:C) were used as a model antigen and adjuvant, 
respectively. DT and poly(I:C) were either individually encapsulated or co-encapsulated in 
the liposomes with high loading efficiencies of more than 90%. After hollow microneedle-
mediated intradermal immunization, the antigen- anddjuvant-containing liposomes evoked 
potent antibody responses and shifted the IgG1/IgG2a balance to a IgG2a response, no matter 
whether DT and poly(I:C) were individually encapsulated or co-encapsulated in the 
liposomes. These results indicate that the combinatio  of DT and poly(I:C) individually 
encapsulated liposomes are as efficient as DT and poly(I:C) co-encapsulated liposomes for 
the modulation of the immune response.  
In Chapter 6 studies are reported in which DT loaded and lipid bilayer coated MSNs (LB-
MSN-DT) were coated onto pH-sensitive microneedle arrays. Additionally, the antibody 
response elicited by coated microneedles was compared to that elicited by hollow 
microneedle-delivered LB-MSN-DT. By using the same pr paration method as described for 
OVA loaded MSNs in Chapter 2, DT was successfully loaded into MSNs followed by fusion 
of a negatively charged lipid bilayer onto the surface of MSNs. The synthesized nanoparticles 
showed a high loading capacity of DT of about 20%. The LB-MSN-DT and N-trimethyl 
chitosan (TMC) were alternately coated onto the pH sensitive surface of the pyridine-
modified microneedle arrays by using a layer-by-layer coating approach. SEM and CLSM 
images demonstrated that LB-MSN-DT were successfully coated onto the microneedle 
surfaces. It was shown that the cumulative coated amount of nano-encapsulated DT for a 5-
layer and 3-layer coating on the microneedle surface of one microneedle array was about 1.9 
µg and 1.1 µg, respectively, corresponding to 9.7 µg and 5.7 µg LB-MSN-DT (expressed as 
the weight of MSNs). A release study in ex vivo human skin showed that 0.814 µg and 0.256 
µg of the encapsulated DT were released from a 5-layer nd 3-layer coated microneedle array, 
respectively. An in vivo study in mice showed that LB-MSN-DT delivered by both coated and 
hollow microneedles successfully induced DT-specific antibody responses. The nano-
encapsulated DT induced stronger antibody responses than DT solution when delivered by 
hollow microneedles (after 1st boost immunization), but induced only comparable responses 
as DT solution when delivered by coated microneedles. The results of the research described 
in this chapter demonstrate that both the encapsulation of antigen and the type of 
microneedles can affect the immunogenicity of antigen, and that the coated microneedle 
system may need to be improved in order to obtain optimal immune responses. 
In summary, the collective results described in this esis show that nanoparticulate vaccines 
can be delivered intradermally by coated and hollow microneedles and evoke antigen-specific 
immune responses. The choice of both the nanoparticles and the microneedle(s) could have 
important influences on the immune responses. Microneedle arrays coated with antigen 
loaded and lipid bilayer fused MSNs could be a promising system for convenient and fast 
intradermal delivery of protein antigen, although our results indicate that the system needs to 
be improved in order to obtain optimal immune responses. Moreover, antigen and adjuvant 
loaded nanoparticles can increase IgG2a (Th1) and CD8+ responses after intradermal delivery 
by hollow microneedles. This effect depends on the ype and the physicochemical 
characteristics of the nanoparticles, in which smaller size and controlled release properties of 
antigen and adjuvant were found to correlate with the stronger effect. Finally, the combination 
of separate antigen loaded and adjuvant loaded nanoparticles may be as efficient as the 
antigen and adjuvant co-encapsulated nanoparticles for modification of the immune responses 
following intradermal immunization.  
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Discussion and prospects 
MSN coated microneedle arrays for intradermal delivery of protein antigen 
One main goal of the work described in this thesis wa  to optimize coated microneedles for 
intradermal delivery of nanoparticulate vaccines. For coated microneedles, one limiting factor 
is the relatively small coating amount of antigen due to the small surface area of 
microneedles. In the studies described in this thesis, MSNs with large pores (10 nm in 
diameter) were synthesized to allow for efficient loading of antigens. Indeed, it was shown 
that the synthesized MSNs had a high loading capacity of OVA and DT,which was about 20% 
for both antigens. The high loading capacity of antigens in MSNs together with the strong 
surface charge of MSNs may synergistically have led to the higher coating amounts of antigen 
onto the microneedle array surfaces (about 500 ng per layer) as compared to our previous 
study (about 300 ng per layer), in which plain DT was coated onto the same type of 
microneedle arrays [18]. Previously, a layer-by-layer coating approach was used for the 
coating of antigen onto the pH-sensitive microneedl arrays, in which the coating amount of 
antigen could be tailored by adjusting the number of coating layers [18, 19]. In Chapter 6 it 
was shown that this multilayer coating method can also be used for the coating of antigen 
loaded MSNs.  
Besides an adequate coating amount of antigen, it is important that the coated antigen can be 
released fast into the skin. We showed that by using a multiple insertion mode (10 times 
penetration in 10 s) of the microneedles, the releas  efficiency of the coated antigen was 
significantly increased and the required wearing time of the microneedles was significantly 
decreased. The shorter wearing time of microneedles may help improving the compliance of 
vaccinees. However, a disadvantage of using the multiple insertion mode is that an expensive 
applicator needs to be used. If the applicator is put onto the medical market in the future, the 
scale production may help decreasing the cost per applic tor.  
The immunization studies in mice showed that DT encapsulated MSNs induced stronger 
immune responses than DT solution when delivered by hollow microneedles, but only 
induced comparable responses as DT solution when delivered by coated microneedles. The 
results of coated microneedles are contradictory to the results reported in a previous study, in 
which microneedles coated with OVA loaded lipid nanocapsules enhanced immune responses 
compared to those induced by plain OVA coated microneedles [11]. In that study, the lipid 
nanocapsules and a hydrolytically degradable poly(β-amino ester) were alternately coated 
onto microneedles by using a layer-by-layer coating approach. The results showed that the 
multilayers were successfully released into the skin and completely broke down within 24 h, 
thereby allowing uptake of the nanocapsules by APCs. A possible reason for the lower 
responses of the coated microneedles in the study described in Chapter 6 is that the individual 
LB-MSN-DT nanoparticles cannot escape from the multiple nanoparticle/TMC layer 
deposited in the skin. As a result, the nanoparticles may not be efficiently taken up by APCs. 
It would therefore be interesting to study the use of polymers which are easier to degrade (for 
example, poly(β-amino ester)) or less viscous (for example, TMC with a lower molecular 
weight).  
Hollow microneedle mediated intradermal delivery of nanoparticulate vaccines 
In the studies described in this thesis, hollow microneedles are used as a tool to investigate the 
effect of the physicochemical characteristics of nanoparticulate vaccines on the immune 
responses. Previously, it has been shown that antigen and immune modulator co-encapsulated 
nanoparticles were able to enhance IgG2a and CD8+ T cell responses after traditional 
hypodermic needle mediated intradermal vaccination [8, 20, 21]. Our results showed that this 
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trend remains in hollow microneedle-mediated intrade mal vaccination. The results showed 
that the co-delivery of antigen and adjuvant by using nanoparticles significantly increased 
IgG2a titers. Co-encapsulation of antigen and adjuvant (poly(I:C) may allow the delivery of 
antigen and adjuvant in the same antigen presenting cells, which may increase the 
presentation of antigen to T cells [20, 22]. Furthermore, nanoparticles with a smaller size and 
slower release of antigen and adjuvant induced stronger IgG2a titers. The smaller size of 
nanoparticles may enhance the uptake of antigen and adjuvant by antigen presenting cells [9, 
23]. These results demonstrate that the quality and type of immune responses can be modified 
to desired direction by using nanoparticles with appro riate physicochemical properties.  
The results described in the thesis further showed that individual encapsulation of antigen and 
adjuvant is as efficient as co-encapsulation of antige  and adjuvant in liposomes for the 
induction of higher IgG2a titers, indicating that co-encapsulation of antigen and adjuvant may 
not be necessary for the use of intradermal delivery. This might help simplifying the work for 
development of liposomal formulations. The formulations can be made by simply mixing 
antigen loaded liposomes and adjuvant loaded liposome . It will be interesting to test whether 
these findings remain when other types of TLR ligands are used. Overall, the results described 
in the thesis indicate that the optimal nanoparticles for intradermal use should be encapsulated 
with antigen and adjuvant (either individually encapsulated or co-encapsulated), have a small 
particle size (below 200 nm) and a sustained releas of antigen and adjuvant.  
In the research described in this thesis, it was also shown that co-encapsulation of antigen and 
adjuvant in 1,2-dioleoyl-3-trimethylammonium-propane chloride (DOTAP)-based cationic 
liposomes induced potent Th1/CD8+ T cell responses. Furthermore, the liposomes induce  the 
strongest T cell responses among four types of the nanoparticles. Some recent studies also 
reported that peptide-loaded cationic liposomes were able to induce effective T cell responses 
for the prevention of tumor growth [24] and clearance of established tumors [25]. These 
results demonstrate the potential of cationic liposomes for inducing high T-cell responses, 
which are important for treatment of tumors and combat against intracellular bacteria. In the 
future, it would be important to test whether the effectiveness of cationic liposome 
formulations holds true for other tumor models.  
Prospects of the use of microneedles for intradermal delivery of nanoparticulate vaccines 
In case of hollow microneedles, the antigen and adjuvant loaded nanoparticles are suspended 
in buffer before the injection and the physicochemical properties of the nanoparticulate 
vaccines probably do not change during the injection by hollow microneedles. As a result, by 
using hollow microneedles it is convenient to study the effect of the physicochemical 
characteristics of nanoparticles on the immune respon es. Furthermore, by using hollow 
microneedles, the influence of injection depth on the immune responses can be easily studied 
[26]. Instead, in case of coated and dissolvable microneedles, the nanoparticles suspended in 
buffer are first coated onto or loaded into the microneedles. The nanoparticles are dried during 
the fabrication of microneedles and released from the microneedles after the penetration of the 
skin. During this process, it is possible that the properties of nanoparticles and the 
encapsulated antigen are impacted. For example, the nanoparticles may aggregate and the 
antigen may lose some activity. Therefore, hollow microneedles may be more suitable for 
preliminary research, such as screening of nanoparticulate vaccines for intradermal 
vaccination and study of the effect of physicochemical characteristics of nanoparticles on 
immune responses. After the screening, the selected nanoparticulate vaccines can be used for 
the development of coated or dissolvable microneedles.  
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Although the results in this thesis showed that the coated and hollow microneedles can be 
used to intradermally deliver the nanoparticulate vaccines and evoke antigen specific immune 
responses, further research is needed to develop and optimize the two technologies. The 
interest in combining microneedle and nanoparticulate vaccine technologies will continue to 
grow with the emergence of new types of nanoparticles and fabrication methods of 
microneedles. Finally, the largest challenge is to translate the research to products which can 
finally benefit patients. This will need continuous and joint efforts from academia and the 
pharmaceutical industry.  
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Nederlandse samenvatting 
Inleiding 
Gedurende de laatste twee decennia is veel onderzoek verricht naar micronaalden met als 
voornaamste toepassing intradermale vaccinatie. Dit zijn, zoals de naam al doet vermoeden, 
naaldachtige structuren met een lengte van minder dan 1 mm. De micronaalden kunnen 
worden gebruikt om het stratum corneum (de opperhuid), de bovenste laag en de belangrijkste 
barrière van de huid, effectief te doorboren, waardoo  het eenvoudiger is om vaccins via de 
huid toe te dienen [1, 2]. Aangezien micronaalden zo kort zijn dat ze geen zenuwen en 
bloedvaten bereiken, is de toediening van micronaalden minimaal invasief en pijnvrij. Dit 
beperkt de stress voor gevaccineerden en kan zo bijdragen aan een hogere vaccinatiegraad. 
Bovendien kan intradermale toediening van vaccins door middel van micronaalden de 
effectiviteit van vaccinatie verbeteren, omdat de huid een hoge concentratie aan antigeen 
presenterende cellen (APC's) bevat, zoals epidermal Langerhanscellen en dermale 
dendritische cellen [3]. 
Verschillende soorten micronaalden zijn ontwikkeld voor de toediening van vaccins. 
Aanvankelijk werden massieve micronaalden gebruikt om de huid te doorboren, waarna na 
verwijdering van de micronaalden vaccinformuleringe op de huid werden aangebracht [4]. 
Een belangrijk nadeel van deze methode is dat slecht  en klein deel van het vaccin in de huid 
terechtkomt, aangezien de diffusie door de aangebrachte gaatjes beperkt is vanwege de kleine 
diameter daarvan. Om dit probleem te omzeilen worden nu gecoate, oplosbare en holle 
micronaalden ontwikkeld. Gecoate micronaalden worden gemaakt uit massieve 
micronaaldenarrays, waarbij het oppervlak van de micronaalden bedekt is met het antigeen 
(de “werkzame stof” in een vaccin). Nadat de micronaalden in de huid ingebracht zijn, wordt 
de coating in de huid afgegeven. Oplosbare micronaalden zijn gemaakt van oplosbare 
polymeren, biologisch afbreekbare polymeren of suikers. Het antigeen wordt in de matrix van 
micronaalden geladen. Na het inbrengen van micronaalden in de huid begint de matrix op te 
lossen of af te breken, waardoor het antigeen vrijkomt. Holle micronaalden bevatten een 
kanaal waardoor de vaccinformulering in de huid kanworden geïnjecteerd. Een overzicht van 
de bereidingsmethoden voor deze verschillende soorten micronaaldjes is uitgebreid besproken 
in de literatuur [1-3, 5]. 
 
Op nanodeeltjes gebaseerde vaccins (hieronder nanodeeltjes-vaccins genoemd) bevatten 
nanodeeltjes met een diameter kleiner dan 1000 nm die beladen zijn met antigeen [6]. 
Nanodeeltjes zijn in staat om het antigeen te beschermen tegen afbraak en de opname van 
antigeen door APC's te vergroten. Bovendien is het mogelijk door middel van nanodeeltjes 
het antigeen en adjuvans (een hulpstof ter bevordering van de immuunrespons) gezamenlijk 
toe te dienen. Dit zou de immuunrespons kunnen verbet en [7, 8]. Daarnaast kan de 
immuunrespons worden gemodificeerd of versterkt door e fysisch-chemische eigenschappen 
van nanodeeltjes te optimaliseren, zoals grootte en oppervlaktelading van de deeltjes alsmede 
de afgiftekinetiek van antigeen en adjuvans [9, 10]. Verschillende soorten nanodeeltjes zijn 
onderzocht als antigeen-afgiftesystemen, zoals o.a. polymere nanodeeltjes, liposomen en 
anorganische nanodeeltjes [6]. 
 
Tegenwoordig wordt steeds meer onderzoek verricht naar het gebruik van micronaalden voor 
intradermale toediening van nanodeeltjes-vaccins. Dit heeft als doel om de voordelen van 
micronaalden en nanodeeltjes te combineren. Uit eenrdere studie is gebleken dat 
micronaalden gecoat met antigeen beladen nanodeeltjes bestaande uit lipiden leidden tot een 
hogere IgG2a respons dan micronaalden met alleen het antigeen [11]. Uit andere studies bleek 
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dat oplosbare micronaalden beladen met antigeen bevattende PLGA-nanodeeltjes leidde tot 
hogere Th1 en CD8+ T-celresponsen in vergelijking met een oplossing van rij antigeen [12, 
13]. Tevens bleek dat met holle micronaalden geïnjecteerde tetanustoxoïde beladen chitosan-
nanodeeltjes een hogere IgG2a-respons en hogere expssie van Th1-cytokines leidden dan 
een commercieel tetanustoxoïdevaccin [14]. Uit deze onderzoeken blijkt dat het gebruik van 
micronaalden voor intradermale toediening van nanodeeltjes-vaccins voordelen kan bieden. 
 
Gebaseerd op deze bevindingen is het doel van het onderzoek beschreven in dit proefschrift 
om 1) micronaalden te gebruiken en te optimaliseren om intradermaal nanodeeltjes-vaccins 
toe te dienen en 2) te onderzoeken of de fysisch-chemische eigenschappen van nanodeeltjes-
vaccins de immuunrespons tegen het antigeen beïnvloden na intradermale toediening met 
micronaalden. In het onderzoek beschreven in dit proefschrift hebben we ons gericht op het 
gebruik van gecoate en holle micronaalden. Gecoate micronaalden waren gebaseerd op 
micronaald-arrays gemaakt van silicium waarbij het oppervlakte gemodificeerd was met 
pyridinegroepen, waardoor de lading van het oppervlakte pH-gevoelig was. Deze 
micronaalden zijn in staat om negatief geladen antige en te binden in een zure omgeving en 
de coating af te geven bij neutrale pH zoals aanwezig in de huid [15, 16]. In het geval van 
holle micronaalden werden de micronaalden gemaakt uit silica capillairen die geëtst werden 
met fluorwaterstofzuur [17]. Deze micronaalden kunnen worden gebruikt om vloeibare 
formuleringen intradermaal in de huid te injecteren. Microscopische afbeeldingen van een 
micronaaldenarray en een holle micronaald zijn weerg geven in Fig. 1. 
 
 
 
Figuur 1. Microscopische opnamen van micronaalden. A: scanning electronen 
microscopische afbeelding van een pH-gevoelige micronaaldenarray, B: microscopische 
opname van een holle micronaald. 
 
Samenvatting van de resultaten  
In hoofdstuk 1 wordt een korte inleiding gegeven over het gebruik van micronaalden en 
nanodeeltjes voor vaccintoediening via de huid. 
 
In hoofdstuk 2 wordt een nieuw type mesoporeuze silica-nanodeeltjes (MSN's) met grote 
poriën geïntroduceerd. Deze silica-nanodeeltjes werden beladen met ovalbumine (OVA). De 
maximale beladingscapaciteit was ongeveer 34%. De colloïdale stabiliteit van de MSN's werd 
verhoogd door het oppervlak van de MSN's te bekleden met een negatief geladen 
lipidenmembraan (LB-MSN-OVA). Vervolgens werd onderzocht of de MSN's de 
antigeenopname door dendritische cellen verbeterde. Daartoe werd de opname van LB-MSN-
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OVA door dendritische cellen onderzocht en vergeleken met die van een OVA-oplossing. 
Inderdaad leidde het gebruik van LB-MSN-OVA tot een hogere opname in dendritische 
cellen dan OVA-oplossing. Vervolgens werden met pyridine gemodificeerde 
micronaaldenarrays gecoat met LB-MSN-OVA. Het coatingproces vond plaats onder zure 
omstandigheden (pH 5,8). Het coatingsproces was gebase rd op de elektrostatische interactie 
tussen het positief geladen micronaaldenoppervlak en de negatief geladen nanodeeltjes. Uit 
scanning-elektronenmicroscopie (SEM) en confocale lser-scanningmicroscopie (CLSM) 
opnamen bleek dat LB-MSN-OVA met succes op het oppervlak van de micronaalden werd 
gecoat. In  totaal kon 1,5 μg OVA in LB-MSN-OVA gecoat worden op één 
micronaaldenarray. Tenslotte bleek uit afgiftestudies dat de gecoate micronaaldenarrays na 
penetratie in de menselijke ex-vivo huid de LB-MSN-OVA afgaven. 
 
De studies beschreven in Hoofdstuk 3 zijn uitgevoerd met een ander type nanodeeltje, 
namelijk poly(melkzuur-co-glycolzuur) (PLGA-)nanodeeltjes. OVA bevattende PLGA-
nanodeeltjes werden gemaakt met een positieve of negatieve oppervlaktelading en PLGA-
nanodeeltjes die zowel OVA als poly(I:C), een adjuvans, bevatten. Het effect van inkapseling 
van OVA met of zonder poly(I:C) in PLGA nanodeeltjes op T-celresponsen werd onderzocht. 
Hiertoe werden de formuleringen met een holle micronaald intradermaal geïnjecteerd in 
muizen. Er werden verschillende experimenten uitgevoerd. Ten eerste werd onderzocht of 
OVA bevattende PLGA-nanodeeltjes tot een hogere T-celrespons leidden dan een OVA-
oplossing. Het bleek dat OVA bevattende PLGA-nanodeeltjes met een positieve of negatieve 
oppervlaktelading tot een vergelijkbare verhoging van het aantal OVA-specifieke (niet 
endogene) CD8+ en CD4+ T-cellen leidden. Het aantal T-cellen was aanzienlijk hoger dan 
geïnduceerd door een OVA oplossing. Omdat dit een heel positief resultaat was, werd in een 
tweede stap uitgezocht of OVA bevattende PLGA-nanodeeltjes met en zonder poly(I:C) ook 
leiden tot een verhoging van endogene T-cellen. Toediening van OVA bevattende PLGA-
nanodeeltjes (met een positieve of negatieve oppervlakte lading) en PLGA-nanodeeltjes die 
zowel OVA als poly (I: C) bevatten leidde tot een verhoging van het aantal endogene OVA-
specifieke CD8+ T-cellen. Poly(I:C) in de formulering (hetzij gemengd met OVA-oplossing 
hetzij met OVA ingebouwd in de PLGA-nanodeeltjes) verhoogde de CD8+ T-celresponsen. 
Bovendien bleek dat OVA-bevattende PLGA-nanodeeltjes met een positieve 
oppervlaktelading een sterkere endogene CD8+ T-celrespons opwekten dan OVA bevattende 
PLGA-nanodeeltjes met een negatieve oppervlakte lading. Ten slotte werd onderzocht of de 
opgewekte endogene T-celresponsen ook in staat waren de muizen te beschermen tegen een 
infectie met de intracellulaire bacterie Listeria monocytogenes. Het bleek dat OVA en 
poly(I:C) bevattende PLGA-nanodeeltjes leiden tot een volledige bescherming tegen de 
bacterie. Samengevat, uit deze studie blijkt dat PLGA-nanodeeltjes uitstekende formuleringen 
zijn voor de intradermale toediening van een eiwitant geen, en dat deze formulering resulteert 
in een beschermende cellulaire immuunrespons. 
 
Uit de resultaten beschreven in hoofdstuk 2 en 3 blijkt dat antigeen bevattende nanodeeltjes 
de immuunrespons drastisch kunnen verbeteren. Daarom is het interessant om de effectiviteit 
van verschillen typen OVA bevattende nanodeeltjes mt elkaar te vergelijken. Dit onderzoek 
wordt beschreven in Hoofdstuk 4. In dit hoofdstuk werden verschillende OVA bevattende 
nanodeeltjes met of zonder adjuvans, poly(I:C), metelkaar vergeleken. Holle micronaalden 
werden weer gebruikt om de formuleringen intradermaal toe te dienen. OVA en poly(I:C) 
bevattende negatief geladen PLGA-nanodeeltjes, positief geladen liposomen, negatief geladen 
MSN's en positief geladen gelatine-nanodeeltjes (GNP's) werden met elkaar vergeleken. De 
nanodeeltjes verschilden verder in gemiddelde grootte en in afgifteprofiel. PLGA-
nanodeeltjes en liposomen hadden een gemiddelde deeltjesgrootte van ongeveer 150 nm. 
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Tevens was de afgiftesnelheid van OVA en poly(I:C) laag. De deeltjesgrootte van MSN's en 
GNP's was tussen de 500-700 nm en de afgiftesnelheid van OVA en poly(I:C) was veel 
sneller. Uit immunisatiestudies in muizen bleek dat OVA bevattende nanodeeltjes en OVA en 
poly(I:C) bevattende nanodeeltjes in vergelijking met OVA en poly(I:C) in een buffer 
oplossing tot vergelijkbare IgG- en IgG1-responsen leidden.  Echter er was wel een belangrijk 
verschil in IgG2a-responsen in vergelijking met een OVA / poly(I:C) oplossing. Het type 
nanodeeltje had invloed op de hoogte van de IgG2a respons: Negatief geladen PLGA-
nanodeeltjes en positief geladen liposomen veroorzaakten hogere IgG2a-responsen dan de 
negatief geladen MSN's en de postief geladen GNP's. Dit geeft aan dat een kleine 
nanodeeltjesgrootte en/of een langzame afgifte van antigeen en adjuvans leidt tot een hogere 
IgG2a-respons. Omdat IgG2a vaak gerelateerd is aan cellulaire responsen, werd besloten ook 
deze te onderzoeken. Het bleek dat OVA en poly(I:C) bevattende positief geladen liposomen 
de sterkste verhoging van het aantal CD8+ en CD4+ T-cellen teweegbrachten en dus superieur 
zijn ten opzichte van de andere onderzochte deeltjes. Ook blijkt uit deze studies dat de in 
eigen huis ontwikkelde holle micronaalden met applicator uitstekend gebruikt kunnen worden 
voor het screenen van verschillende vaccinformulering n. 
 
De volgende vraag in het onderzoek was of het cruciaal is om antigen en adjuvans beiden in 
dezelfde nanodeeltjes te verpakken, of dat ze ieder apa t in de nanodeeltjes verpakt kunnen 
worden met behoud van de immunogeniciteit. De studies om deze vraag te beantwoorden zijn 
beschreven in hoofdstuk 5. In dit onderzoek werd hetzelfde type positief geladen liposomen 
gebruikt, waarin DT en poly(I:C) ofwel samen in dezelfde liposomen (DT/poly(I:C)-
liposomen) of afzonderlijk in de liposomen (DT-liposomen en poly(I:C)-liposomen) 
ingebouwd werden. Intradermale vaccinatie werd uitgevoerd met de holle micronaalden met 
de volgende formuleringen: i) DT in buffer, ii) DT gemengd met poly(I:C) in buffer, iii) DT-
liposomen, iv) een mengsel van DT-liposomen en poly(I:C)-liposomen en v) DT/poly(I:C)-
liposomen. De antigeen- en adjuvans-bevattende liposomen wekten sterke responsen op, 
waarbij de IgG2a-respons hoger was in vergelijking met DT in buffer, ongeacht of DT en 
poly(I:C) individueel of beiden in dezelfde liposomen waren geïncorporeerd. Deze resultaten 
laten zien dat een intradermaal toegediende formulering met een mengsel van DT-liposomen 
en poly(I:C)-liposomen even immunogeen is als een formulering met DT/poly(I:C)-
liposomen. 
 
In Hoofdstuk 6 worden studies beschreven waarin met een fosfolipidenmembraan omhulde 
MSN’s waarin DT is geïncorporeerd (LB-MSN-DT) zijn gecoat op pH-gevoelige 
micronaaldenarrays. Met dezelfde bereidingsmethode als beschreven voor OVA in hoofdstuk 
2, werd DT geïncorporeerd in MSN’s. Vervolgens werd een negatief geladen 
fosfolipidenmembraan op het oppervlak van de MSN's aangebracht. De nanodeeltjes hadden 
een hoge beladingscapaciteit van DT, namelijk ongeveer 20%. De negatief geladen LB-MSN-
DT nanodeeltjes en het positief geladen N-trimethylc itosan (TMC) werden afwisselend 
gecoat op het pH-gevoelige oppervlak van de met pyridine gemodificeerde 
micronaaldenarrays. Uit SEM- en CLSM-afbeeldingen bleek dat de nanodeeltjes met succes 
op het oppervlak van de micronaalden waren gecoat. De cumulatieve gecoate hoeveelheid DT 
in LB-MSN-DT voor een 5-laagse en 3-laagse coating was respectievelijk ongeveer 1,9 μg en 
1,1 μg DT, overeenkomend met ca. 9,7 μg en 5,7 μg LB-MSN-DT (uitgedrukt als het gewicht 
van MSN's). Uit een afgiftestudie in de ex vivo mens lijke huid bleek dat 0,814 μg en 0,256 
μg van de geïncorporeerde DT werd afgegeven aan de hui  met respectievelijk een 5-laagse 
en 3-laagse gecoate micronaaldenarray. Deze gecoate micronaalden arrays werden vervolgens 
gebruikt voor een intradermale immunisatiestudie. D immuunrespons werd vergeleken met 
dezelfde dosis LB-MSN-DT toegediend via een holle micronaald. LB-MSN-DT induceerde 
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sterkere antilichaamresponsen dan een DT-oplossing bij toediening via een holle micronaald, 
maar induceerde slechts een vergelijkbare respons als een DT-oplossing wanneer toegediend 
door gecoate micronaalden. De resultaten van het in di hoofdstuk beschreven onderzoek laten 
zien dat zowel de incorporatie van het antigeen in ee  nanodeeltje als de keuze van het type 
micronaalden de immuunrespons tegen het antigeen kan beïnvloeden, en dat het gecoate 
micronaaldsysteem mogelijk moet worden verbeterd om een optimale immuunrespons op te 
wekken. 
 
Samengevat tonen de in dit proefschrift beschreven r sultaten aan dat antigenen in 
nanodeeltjes intradermaal kunnen worden toegediend door gebruikmaking van gecoate en 
holle micronaalden, waarmee vervolgens antigeen-specifieke antistof- en T-celresponsen 
opgewekt kunnen worden. De keuze van zowel de nanodeeltjes als de micronaald(en) kan een 
belangrijke invloed hebben op de effectiviteit van de vaccinatie. Micronaaldenarrays gecoat 
met antigeen-geladen MSN's zouden een veelbelovend systeem kunnen zijn voor 
gemakkelijke en snelle intradermale toediening van een eiwit antigeen, hoewel onze 
resultaten aangeven dat het systeem nog moet worden verbeterd om een optimale 
immuunrespons te verkrijgen. Bovendien kunnen met antigeen en adjuvans beladen 
nanodeeltjes IgG2a en vooral CD8+ T-celresponsen verhogen na intradermale toediening door 
een holle micronaald. Dit effect hangt af van de fysisch-chemische eigenschappen van de 
nanodeeltjes, waarbij bleek dat de kleinere nanodeeltjes en/of een langzame afgifte van het 
antigeen en adjuvans uit de deeltjes de respons verterken. Ten slotte kan, wanneer 
intradermaal toegediend via een holle micronaald, de combinatie van afzonderlijke met 
antigeen en adjuvans geladen nanodeeltjes even effecti  zijn als een formulering met het 
antigeen en adjuvans samen geïncorporeerd in dezelf nanodeeltjes. 
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